

Survival, Durable Tumor Remission, and Long-Term Safety in Melanoma Receiving Nivolumab

Journal of Clinical Oncology

32, 1020-1030

DOI: 10.1200/jco.2013.53.0105

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 357.	0.7	60
2	New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy. <i>Drug, Healthcare and Patient Safety</i> , 2014, 6, 77.	2.5	32
3	Pathways and therapeutic targets in melanoma. <i>Oncotarget</i> , 2014, 5, 1701-1752.	1.8	202
4	Regulation of T-cell Tolerance by Lymphatic Endothelial Cells. <i>Journal of Clinical & Cellular Immunology</i> , 2014, 05, .	1.5	40
5	Adding fuel to the fire: Immunogenic intensification. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3306-3312.	3.3	4
6	The Use of Anti-CD40 mAb in Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2014, 405, 165-207.	1.1	21
7	PD-1 and PD-L1 antibodies for melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3111-3116.	3.3	54
8	Biomarkers in melanoma: where are we now?. <i>Melanoma Management</i> , 2014, 1, 139-150.	0.5	1
9	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. , 2014, 2, 40.		50
10	Operative Management of Metastatic Melanoma in Bone May Require En Bloc Resection of Disease. <i>Clinical Orthopaedics and Related Research</i> , 2014, 472, 3196-3203.	1.5	12
11	New antibody approaches to lymphoma therapy. <i>Journal of Hematology and Oncology</i> , 2014, 7, 58.	17.0	50
12	Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma. <i>Journal of Hematology and Oncology</i> , 2014, 7, 91.	17.0	22
14	The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade. <i>Clinical Cancer Research</i> , 2014, 20, 4982-4984.	7.0	80
15	Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 351.	2.8	15
16	The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. <i>Frontiers in Pharmacology</i> , 2014, 5, 235.	3.5	280
17	Is vaccine research still relevant for metastatic melanoma?. <i>Melanoma Management</i> , 2014, 1, 91-94.	0.5	5
18	The MEK inhibitor trametinib for the treatment of advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 1341-1349.	0.8	0
19	Immune checkpoints in cancer clinical trials. <i>Chinese Journal of Cancer</i> , 2014, 33, 434-444.	4.9	96

#	ARTICLE	IF	CITATIONS
20	Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. <i>Frontiers in Pharmacology</i> , 2014, 5, 252.	3.5	34
21	Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. <i>Oncolmunology</i> , 2014, 3, e954956.	4.6	19
23	Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2965-2970.	2.5	432
24	Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer. <i>Cancer Discovery</i> , 2014, 4, 1377-1386.	9.4	76
25	PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature</i> , 2014, 515, 568-571.	27.8	5,429
26	Cosmic triangles and black-hole masses. <i>Nature</i> , 2014, 515, 498-499.	27.8	0
27	Antitumour immunity gets a boost. <i>Nature</i> , 2014, 515, 496-498.	27.8	90
28	The Immunological Synapse. <i>Cancer Immunology Research</i> , 2014, 2, 1023-1033.	3.4	330
29	Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies. <i>Drugs</i> , 2014, 74, 1993-2013.	10.9	96
30	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. , 2014, 2, 42.		186
31	Perspectives for immunotherapy in glioblastoma treatment. <i>Current Opinion in Oncology</i> , 2014, 26, 608-614.	2.4	26
32	Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 290-295.	2.0	32
33	Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. <i>Frontiers in Immunology</i> , 2014, 5, 206.	4.8	108
34	Novel immune checkpoint blocker approved for the treatment of advanced melanoma. <i>Oncolmunology</i> , 2014, 3, e967147.	4.6	27
35	Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. <i>Oncolmunology</i> , 2014, 3, e29244.	4.6	83
36	Blockade of the B7-H1/PD-1 Pathway as a Basis for Combination Anticancer Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 290-295.	2.0	32
37	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1-14.	3.4	38
38	How To Train Your Oncolytic Virus: the Immunological Sequel. <i>Molecular Therapy</i> , 2014, 22, 1881-1884.	8.2	6

#	ARTICLE	IF	CITATIONS
39	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clinical and Translational Immunology, 2014, 3, e22.	3.8	64
40	Recent developments in the medical and surgical treatment of melanoma. Ca-A Cancer Journal for Clinicians, 2014, 64, 171-185.	329.8	56
41	The translation of cancer genomics: time for a revolution in clinical cancer care. Genome Medicine, 2014, 6, 22.	8.2	13
42	Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects. Clinical Cancer Research, 2014, 20, 6258-6268.	7.0	88
43	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, The, 2014, 384, 1109-1117.	13.7	1,588
44	Ipilimumab in the treatment of advanced melanoma – a clinical update. Expert Opinion on Biological Therapy, 2014, 14, 1709-1718.	3.1	8
45	Clinical cancer research: the past, present and the future. Nature Reviews Clinical Oncology, 2014, 11, 663-669.	27.6	29
46	Management of melanoma. British Medical Bulletin, 2014, 111, 149-162.	6.9	61
47	Nivolumab: A Review of Its Use in Patients with Malignant Melanoma. Drugs, 2014, 74, 1233-1239.	10.9	72
48	The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity. Journal of Immunology, 2014, 193, 3835-3841.	0.8	178
49	Opportunistic infections in patients treated with immunotherapy for cancer. , 2014, 2, 19.		98
50	Treatment of unresectable stage IV metastatic melanoma with avelumab after anti-neoplastic treatment failure: a phase II, multi-centre study. , 2014, 2, 27.		7
51	Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations. Journal of Clinical Oncology, 2014, 32, 986-988.	1.6	50
52	Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. Cancer Research, 2014, 74, 5458-5468.	0.9	1,014
53	Indications and Options for Systemic Therapy in Melanoma. Surgical Clinics of North America, 2014, 94, 1049-1058.	1.5	12
55	American association for cancer research – AACR congress 2014. Oncologie, 2014, 16, 341-366.	0.7	0
56	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS</i> and <i>RAF</i> Mutations. Clinical Cancer Research, 2014, 20, 4251-4261.	7.0	60
57	What have we learned from cancer immunotherapy in the last 3 years?. Journal of Translational Medicine, 2014, 12, 141.	4.4	28

#	ARTICLE	IF	CITATIONS
58	<i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates. <i>Cancer Immunology Research</i> , 2014, 2, 846-856.	3.4	514
59	Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review). <i>Oncology Reports</i> , 2014, 32, 875-886.	2.6	37
60	The role of chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , 2014, 1, 173-184.	0.5	8
61	Advances in targeted therapy for melanoma: a focus on MEK inhibition. <i>Clinical Investigation</i> , 2014, 4, 903-913.	0.0	0
62	Agents Make "Preferred List" in Metastatic Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 785-787.	4.9	0
63	Targeting immune checkpoints in melanoma: an update. <i>Melanoma Management</i> , 2015, 2, 339-352.	0.5	2
64	Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery. <i>Oncology Letters</i> , 2015, 10, 1079-1086.	1.8	14
65	Safety and immunologic correlates of Melanoma CVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. <i>Journal of Translational Medicine</i> , 2015, 13, 214.	4.4	84
66	New clinical advances in immunotherapy for the treatment of solid tumours. <i>Immunology</i> , 2015, 145, 182-201.	4.4	35
67	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. <i>Cancer Science</i> , 2015, 106, 945-950.	3.9	78
68	Long-term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma. <i>Annals of Surgery</i> , 2015, 262, 456-464.	4.2	26
69	Development of 1-N-11C-Methyl-L- and -D-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan. <i>Scientific Reports</i> , 2015, 5, 16417.	3.3	15
70	Present, Emerging and Possible Future Biomarkers in Castration Resistant Prostate Cancer (CRPC). <i>Current Cancer Drug Targets</i> , 2015, 15, 243-255.	1.6	15
71	Understanding Immune Checkpoint Inhibitors for Effective Patient Care. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 709-717.	0.6	17
72	Essential Role of the "A...C" Motif in the TCR-CD4 Complex. <i>Nature Digest</i> , 2015, 12, 30-32.	0.0	0
73	Novel melanoma therapy. <i>Experimental Hematology and Oncology</i> , 2015, 5, 23.	5.0	8
74	Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. , 2015, 3, 27.		17
75	Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma. <i>Melanoma Research</i> , 2015, 25, 239-245.	1.2	23

#	ARTICLE	IF	CITATIONS
76	From personalized to patient-specific treatment of metastatic melanoma. Melanoma Management, 2015, 2, 193-197.	0.5	0
77	Update on checkpoint blockade therapy for lymphoma. , 2015, 3, 33.		11
78	Inhibitory receptors as targets for cancer immunotherapy. European Journal of Immunology, 2015, 45, 1892-1905.	2.9	116
79	Treatment for metastatic melanoma: a new and evolving era. International Journal of Clinical Practice, 2015, 69, 273-280.	1.7	2
80	Nivolumab: Immunotherapy in Malignant Melanoma. Clinical Journal of Oncology Nursing, 2015, 19, 430-432.	0.6	8
81	Case of respiratory discomfort due to myositis after administration of nivolumab. Journal of Dermatology, 2015, 42, 1008-1009.	1.2	61
82	Pembrolizumab in the management of metastatic melanoma. Melanoma Management, 2015, 2, 315-325.	0.5	4
83	Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer, 2015, 121, 4007-4015.	4.1	56
84	Systemic therapy of metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2015, 13, 1223-1237.	0.8	12
85	Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. Internal Medicine Journal, 2015, 45, 696-701.	0.8	28
86	Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents. Journal of Immunotherapy, 2015, 38, 259-266.	2.4	9
87	Liver resection and ablation for metastatic melanoma: A single center experience. Journal of Surgical Oncology, 2015, 111, 962-968.	1.7	19
88	Systemtherapie des metastasierten malignen Melanoms. JDDG - Journal of the German Society of Dermatology, 2015, 13, 1223-1238.	0.8	7
89	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Current Opinion in Oncology, 2015, 27, 384-391.	2.4	18
90	The end of the beginning: PD-1 inhibition as the new standard of care first-line immunotherapy in metastatic melanoma. Melanoma Management, 2015, 2, 305-309.	0.5	1
91	Comparative healthcare costs in patients with metastatic melanoma in the USA. Melanoma Research, 2015, 25, 312-320.	1.2	22
92	Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. Pharmacotherapy, 2015, 35, 963-976.	2.6	183
93	Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. Current Opinion in Oncology, 2015, 27, 482-488.	2.4	31

#	ARTICLE	IF	CITATIONS
94	Immunotherapies for bladder cancer. Current Opinion in Urology, 2015, 25, 586-596.	1.8	17
95	Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1. Aids, 2015, 29, 1911-1915.	2.2	14
96	Targeted and Immunotherapeutic Approaches in Brain Metastases. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 67-74.	3.8	16
97	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. Journal of Clinical Investigation, 2015, 125, 3384-3391.	8.2	1,112
98	Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?. Cancer Management and Research, 2015, 7, 93.	1.9	10
99	Nivolumab in the treatment of malignant melanoma: review of the literature. OncoTargets and Therapy, 2015, 8, 2045.	2.0	21
100	PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRP α axis in HPV negative head and neck squamous cell carcinoma. Oncotarget, 2015, 6, 42067-42080.	1.8	95
101	The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β 2 and interferon γ 3 in metastatic lymph nodes in malignant melanoma. Polish Journal of Pathology, 2015, 4, 376-382.	0.3	14
102	New developments in the management of advanced melanoma – role of pembrolizumab. OncoTargets and Therapy, 2015, 8, 2535.	2.0	16
103	From dismal prognosis to rising star: melanoma leads the way with new generation cancer therapies. Medical Journal of Australia, 2015, 202, 115-116.	1.7	2
105	Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?. Viruses, 2015, 7, 6291-6312.	3.3	48
106	Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?. Frontiers in Immunology, 2015, 6, 258.	4.8	16
107	Inhibitory Receptors Beyond T Cell Exhaustion. Frontiers in Immunology, 2015, 6, 310.	4.8	188
108	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. Frontiers in Oncology, 2015, 5, 152.	2.8	26
109	Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. OncoTargets and Therapy, 2015, 8, 929.	2.0	27
110	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget, 2015, 6, 4704-4716.	1.8	127
111	TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. Journal of Clinical Investigation, 2015, 125, 2046-2058.	8.2	603
112	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. Forum on Immunopathological Diseases and Therapeutics, 2015, 6, 7-17.	0.1	82

#	ARTICLE	IF	CITATIONS
113	Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. PLoS ONE, 2015, 10, e0118564.	2.5	197
114	Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF- κ B. PLoS ONE, 2015, 10, e0123410.	2.5	181
115	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS ONE, 2015, 10, e0130142.	2.5	390
116	Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. Journal of Immunology Research, 2015, 2015, 1-7.	2.2	49
117	Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment. BioMed Research International, 2015, 2015, 1-12.	1.9	59
118	Clinical Development of Immune Checkpoint Inhibitors. BioMed Research International, 2015, 2015, 1-12.	1.9	51
119	Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. BioMed Research International, 2015, 2015, 1-8.	1.9	43
120	Immunotherapy in Tumors. Deutsches Ärztblatt International, 2015, 112, 809-15.	0.9	31
121	Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. BioMed Research International, 2015, 2015, 1-13.	1.9	59
122	Human Tumor Antigens and Cancer Immunotherapy. BioMed Research International, 2015, 2015, 1-17.	1.9	173
123	Patient-Specific Therapeutic Vaccines for Metastatic Melanoma. Oncology Issues, 2015, 30, 48-57.	0.1	3
124	Recent Clinical Advances in the Treatment of Cutaneous Melanoma. Clinical Cancer Drugs, 2015, 2, 16-28.	0.3	0
125	Managing Immune Checkpoint-Blocking Antibody Side Effects. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 76-83.	3.8	344
126	Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget, 2015, 6, 15772-15787.	1.8	265
127	New Insights in Cutaneous Melanoma Immune-Therapy â€” Tackling Immune-Suppression and Specific Anti-Tumoral Response. , 0, , .		2
128	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520.	27.0	7,696
129	Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapyâ€™s smart bombs. Cancer Gene Therapy, 2015, 22, 63-63.	4.6	5
130	Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. Future Oncology, 2015, 11, 997-1009.	2.4	2

#	ARTICLE	IF	CITATIONS
131	Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology. <i>Annals of Pharmacotherapy</i> , 2015, 49, 907-937.	1.9	155
132	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 107-121.	3.2	8
133	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. <i>Clinical Therapeutics</i> , 2015, 37, 764-782.	2.5	469
134	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. <i>Lung Cancer</i> , 2015, 88, 117-123.	2.0	49
135	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. <i>Future Oncology</i> , 2015, 11, 133-140.	2.4	9
136	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. <i>Cancer Research</i> , 2015, 75, 2928-2936.	0.9	193
137	Does It Make a Difference? Understanding Immune Effects of Targeted Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3102-3104.	7.0	27
138	Transcriptional repression of IFN- γ by ATF2 confers melanoma resistance to therapy. <i>Oncogene</i> , 2015, 34, 5739-5748.	5.9	23
139	Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma. <i>JAMA Dermatology</i> , 2015, 151, 797.	4.1	88
140	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1148-1157.	3.4	391
141	Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma. <i>Neurosurgical Focus</i> , 2015, 38, E6.	2.3	20
142	New Strategies in Melanoma: Entering the Era of Combinatorial Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 2424-2435.	7.0	29
144	Checkpoint blockade in lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 69-73.	2.5	11
145	Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 501-519.	3.3	3
146	Pseudoprogression and Immune-Related Response in Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3541-3543.	1.6	720
147	Immunotherapy of Melanoma. <i>Progress in Tumor Research</i> , 2015, 42, 22-29.	0.1	14
148	Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 4286-4293.	7.0	627
149	The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 353-366.	0.5	1

#	ARTICLE	IF	CITATIONS
150	Current and Emerging Perspectives on Immunotherapy for Melanoma. <i>Seminars in Oncology</i> , 2015, 42, S3-S11.	2.2	19
151	Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma. <i>Lung Cancer Management</i> , 2015, 4, 249-259.	1.5	0
152	PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 326-332.	3.4	310
153	Circulating Biomarkers in Malignant Melanoma. <i>Advances in Clinical Chemistry</i> , 2015, 69, 47-89.	3.7	34
154	Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies. <i>Seminars in Oncology</i> , 2015, 42, 429-435.	2.2	68
155	Thrombocytopenia due to low-dose colchicine therapy: A possible drug interaction with nivolumab and implications for supportive care. <i>Acta Oncologica</i> , 2015, 54, 1235-1237.	1.8	10
156	Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 221-228.	1.5	256
157	PD-L1 expression in small cell neuroendocrine carcinomas. <i>European Journal of Cancer</i> , 2015, 51, 421-426.	2.8	209
158	PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. <i>European Journal of Cancer</i> , 2015, 51, 359-366.	2.8	21
160	Immunotherapy for the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2015, 17, 5.	4.0	59
161	CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. <i>Cancer Medicine</i> , 2015, 4, 661-672.	2.8	100
162	Targeting drivers of melanoma with synthetic small molecules and phytochemicals. <i>Cancer Letters</i> , 2015, 359, 20-35.	7.2	67
163	Construction, expression, purification, and characterization of a dual-targeting PD-1/VEGF-A fusion protein (P-V). <i>Protein Expression and Purification</i> , 2015, 109, 1-6.	1.3	2
164	The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. <i>Current Opinion in Immunology</i> , 2015, 33, 23-35.	5.5	298
165	Immune Checkpoint Blockade in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 1974-1982.	1.6	2,220
166	PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. <i>Cancer Treatment Reviews</i> , 2015, 41, 114-121.	7.7	161
167	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , The, 2015, 16, 15-17.	10.7	10
168	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 12-21.	3.2	22

#	ARTICLE	IF	CITATIONS
169	Standing on the shoulders of giants: a scientific journey from Singapore to stem cells. <i>Journal of Pediatric Surgery</i> , 2015, 50, 15-22.	1.6	5
170	Immunotherapy of melanoma: Present options and future promises. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 115-128.	5.9	59
171	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	27.0	4,795
172	Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo. <i>Journal of Immunology</i> , 2015, 194, 950-959.	0.8	362
173	Current challenges in designing GBM trials for immunotherapy. <i>Journal of Neuro-Oncology</i> , 2015, 123, 331-337.	2.9	34
175	Nivolumab in melanoma: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 97-106.	3.2	124
176	Nivolumab and Olaparib. <i>Hospital Pharmacy</i> , 2015, 50, 356-366.	1.0	4
177	Evolving Concepts: Immunity in Oncology from Targets to Treatments. <i>Journal of Oncology</i> , 2015, 2015, 1-15.	1.3	23
178	Nivolumab: targeting PD-1 to bolster antitumor immunity. <i>Future Oncology</i> , 2015, 11, 1307-1326.	2.4	158
179	A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2015, 26, 1824-1829.	1.2	184
181	Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2086-2094.	2.8	45
182	Therapeutic Advances and Treatment Options in Metastatic Melanoma. <i>JAMA Oncology</i> , 2015, 1, 380.	7.1	66
183	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 ^{-/-} /IL2R ³ null Immunodeficient Mice. <i>Cancer Research</i> , 2015, 75, 3466-3478.	0.9	137
184	Pembrolizumab for the treatment of melanoma. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 515-527.	3.1	2
185	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. <i>Immunotherapy</i> , 2015, 7, 499-512.	2.0	18
186	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>OncoImmunology</i> , 2015, 4, e1008814.	4.6	102
187	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. <i>OncoTargets and Therapy</i> , 2015, 8, 157.	2.0	134
188	New immunotherapies targeting the PD-1 pathway. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 587-595.	8.7	158

#	ARTICLE	IF	CITATIONS
189	Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1873-1877.	1.6	9
190	Efficacy and Safety of Nivolumab in Patients With <i>BRAF</i> V600 Mutant and <i>BRAF</i> Wild-Type Advanced Melanoma. <i>JAMA Oncology</i> , 2015, 1, 433.	7.1	201
191	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472.	28.4	576
192	Cost-effectiveness of therapies for melanoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 229-242.	1.4	9
193	Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. <i>Cancer Research</i> , 2015, 75, 3747-3759.	0.9	93
194	Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. <i>Trends in Molecular Medicine</i> , 2015, 21, 482-491.	6.7	146
195	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. <i>Seminars in Oncology</i> , 2015, 42, 601-616.	2.2	139
196	In-situ tumor vaccination: Bringing the fight to the tumor. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1901-1909.	3.3	60
197	The pharmacology of second-generation chimeric antigen receptors. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 499-509.	46.4	411
198	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015, 42, 587-600.	2.2	259
199	Dabrafenib in the treatment of metastatic or unresectable melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 265-276.	2.4	7
200	Mechanisms of action of therapeutic antibodies for cancer. <i>Molecular Immunology</i> , 2015, 67, 28-45.	2.2	136
201	Immuno-regulatory antibodies for the treatment of cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 787-801.	3.1	40
202	Toxicities of Immunotherapy for the Practitioner. <i>Journal of Clinical Oncology</i> , 2015, 33, 2092-2099.	1.6	521
203	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015, 33, 2013-2020.	1.6	385
204	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3140-3148.	7.0	120
205	T cell metabolic fitness in antitumor immunity. <i>Trends in Immunology</i> , 2015, 36, 257-264.	6.8	237
206	Esophageal malignant melanoma: analysis of 134 cases collected by the Japan Esophageal Society. <i>Esophagus</i> , 2015, 12, 158-169.	1.9	18

#	ARTICLE	IF	CITATIONS
207	Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience. <i>Investigational New Drugs</i> , 2015, 33, 664-670.	2.6	3
208	Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. <i>Journal of Neuro-Oncology</i> , 2015, 123, 339-346.	2.9	10
209	Treatment of NRAS-Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 15.	3.0	110
210	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	27.0	4,838
211	Melanoma Treatments: Advances and Mechanisms. <i>Journal of Cellular Physiology</i> , 2015, 230, 2626-2633.	4.1	40
212	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. <i>Drugs</i> , 2015, 75, 563-575.	10.9	18
213	Immune checkpoint blockade in hematologic malignancies. <i>Blood</i> , 2015, 125, 3393-3400.	1.4	208
214	Clinically feasible approaches to potentiating cancer cell-based immunotherapies. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 851-869.	3.3	67
215	Classifying Cancers Based on T-cell Infiltration and PD-L1. <i>Cancer Research</i> , 2015, 75, 2139-2145.	0.9	1,167
216	Overcoming T cell exhaustion in infection and cancer. <i>Trends in Immunology</i> , 2015, 36, 265-276.	6.8	856
217	PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-L1 clinical trials. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 245-253.	3.3	356
218	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. <i>Science Translational Medicine</i> , 2015, 7, 280sr1.	12.4	134
219	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. <i>Clinical Cancer Research</i> , 2015, 21, 3052-3060.	7.0	198
220	Role for Radiation Therapy in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 323-335.	1.5	13
221	Metastasectomy for Stage IV Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 279-298.	1.5	23
222	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 375-384.	10.7	2,353
223	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. <i>Molecular Immunology</i> , 2015, 67, 4-17.	2.2	180
224	Repurposing Drugs in Oncology (ReDO) – clarithromycin as an anti-cancer agent. <i>Ecancermedicalscience</i> , 2015, 9, 513.	1.1	62

#	ARTICLE	IF	CITATIONS
225	Melanoma-intrinsic β -catenin signalling prevents anti-tumour immunity. Nature, 2015, 523, 231-235.	27.8	2,130
226	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB / 1.6 1,035 Clinical Oncology, 2015, 33, 2004-2012.	1.6	1,035
227	Molecular Biology and Immunology of Head and Neck Cancer. Surgical Oncology Clinics of North America, 2015, 24, 397-407.	1.5	32
228	Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. Clinical Cancer Research, 2015, 21, 2892-2897.	7.0	31
229	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. , 2015, 3, 15.		57
230	Safety of pembrolizumab for the treatment of melanoma. Expert Opinion on Drug Safety, 2015, 14, 957-964.	2.4	27
231	Identification and Characterization of MEDI4736, an Antagonistic Anti-Programmed Death 1 Monoclonal Antibody. Cancer Immunology Research, 2015, 3, 1052-1062.	3.4	314
232	Melanoma. Nature Reviews Disease Primers, 2015, 1, 15003.	30.5	417
233	Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors. Journal of Thoracic Oncology, 2015, 10, 500-508.	1.1	129
234	Surgical management of metastatic melanoma in the era of targeted systemic therapies. Melanoma Research, 2015, 25, 1-8.	1.2	5
235	Anti-Programmed Death 1 Therapy in Melanoma. Seminars in Oncology, 2015, 42, 466-473.	2.2	41
236	Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. British Journal of Cancer, 2015, 112, 1421-1427.	6.4	215
237	Toxicity Patterns With Immunomodulating Antibodies and Their Combinations. Seminars in Oncology, 2015, 42, 423-428.	2.2	55
238	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. European Journal of Radiology, 2015, 84, 1259-1268.	2.6	105
239	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 2015, 27, 450-461.	16.8	3,266
240	TGF β 2 Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Research, 2015, 75, 2232-2242.	0.9	429
241	Cancer Vaccines: Can They Improve Survival?. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 147-151.	1.0	6
242	Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncology, The, 2015, 16, e498-e509.	10.7	660

#	ARTICLE	IF	CITATIONS
243	Predictive biomarkers in precision medicine and drug development against lung cancer. Chinese Journal of Cancer, 2015, 34, 295-309.	4.9	34
244	Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Review of Anticancer Therapy, 2015, 15, 1135-1141.	2.4	22
245	Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. Cancer Biology and Therapy, 2021, 22, 513-526.	3.4	24
246	PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. Cancer Immunology Research, 2015, 3, 110-115.	3.4	45
247	Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterology Report, 2015, 3, gov053.	1.3	80
248	Immunosuppressive mechanisms in glioblastoma: Fig. 1.. Neuro-Oncology, 2015, 17, vii9-vii14.	1.2	275
249	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, The, 2015, 16, e534-e542.	10.7	582
250	Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma. Cancer Immunology Research, 2015, 3, 1299-1302.	3.4	68
251	Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences, 2015, 36, 822-846.	8.7	242
252	Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology, 2015, 4, e1026530.	4.6	82
253	Practical Approaches to Immunotherapy in the Clinic. Seminars in Oncology, 2015, 42, S20-S27.	2.2	10
255	Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunology Research, 2015, 3, 1185-1192.	3.4	227
256	Nivolumab: A Review in Advanced Melanoma. Drugs, 2015, 75, 1413-1424.	10.9	44
257	Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Review of Anticancer Therapy, 2015, 15, 981-993.	2.4	59
258	Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma”An exclamation sign with a question mark. Oncoimmunology, 2015, 4, e1058037.	4.6	27
259	Frequent PD-L1 expression in testicular germ cell tumors. British Journal of Cancer, 2015, 113, 411-413.	6.4	126
260	Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. Future Oncology, 2015, 11, 2299-2306.	2.4	20
261	Epigenetic and Immune Regulation of Colorectal Cancer Stem Cells. Current Colorectal Cancer Reports, 2015, 11, 414-421.	0.5	5

#	ARTICLE	IF	CITATIONS
262	Case 31-2015. New England Journal of Medicine, 2015, 373, 1458-1467.	27.0	4
263	Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. Lancet Oncology, The, 2015, 16, e522-e526.	10.7	20
264	Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Seminars in Oncology, 2015, 42, S11-S18.	2.2	55
265	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. Drugs and Aging, 2015, 32, 821-834.	2.7	12
266	ImmunogÃ©nitÃ© de la chimiothÃ©rapie. Oncologie, 2015, 17, 345-353.	0.7	0
267	Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. Bioconjugate Chemistry, 2015, 26, 2062-2069.	3.6	139
268	Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages. OncoImmunology, 2015, 4, e1047584.	4.6	57
269	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunology Research, 2015, 3, 1375-1385.	3.4	342
271	Anti-â€œPD-1â€ Related Pneumonitis during Cancer Immunotherapy. New England Journal of Medicine, 2015, 373, 288-290.	27.0	339
272	Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 187-194.	1.0	20
273	Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma. Human Vaccines and Immunotherapeutics, 2015, 11, 1201-1208.	3.3	11
274	PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. OncoImmunology, 2015, 4, e1029701.	4.6	53
275	Immune checkpoint inhibitors in melanoma. Melanoma Management, 2015, 2, 267-284.	0.5	6
276	Immune Checkpoint Inhibitors. Progress in Tumor Research, 2015, 42, 55-66.	0.1	151
277	Immunopharmacogenomics. , 2015, , .		3
278	FcÎ³Rs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis. Cancer Cell, 2015, 28, 285-295.	16.8	291
279	Emerging immune checkpoints for cancer therapy. Acta OncolÃ³gica, 2015, 54, 1706-1713.	1.8	40
280	Management of melanoma brain metastases. Melanoma Management, 2015, 2, 225-239.	0.5	2

#	ARTICLE	IF	CITATIONS
281	Landscape of Tumor Antigens in T Cell Immunotherapy. Journal of Immunology, 2015, 195, 5117-5122.	0.8	124
282	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Molecular Oncology, 2015, 9, 1936-1965.	4.6	64
283	Tremelimumab for the treatment of malignant mesothelioma. Expert Opinion on Biological Therapy, 2015, 15, 1819-1829.	3.1	23
284	Microenvironmental regulation of therapeutic response in cancer. Trends in Cell Biology, 2015, 25, 198-213.	7.9	604
285	Clinical blockade of PD1 and LAG3 – potential mechanisms of action. Nature Reviews Immunology, 2015, 15, 45-56.	22.7	524
286	The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. , 2015, 148, 132-153.		50
287	Oral health in oncology: impact of immunotherapy. Supportive Care in Cancer, 2015, 23, 1-3.	2.2	39
288	Structural genomic alterations in primary mediastinal large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 2239-2250.	1.3	18
289	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. International Immunology, 2015, 27, 39-46.	4.0	286
290	The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints. Cancer Discovery, 2015, 5, 43-51.	9.4	1,180
291	The development of potential antibody-based therapies for myeloma. Blood Reviews, 2015, 29, 81-91.	5.7	33
292	Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy. Blood Reviews, 2015, 29, 25-32.	5.7	38
293	PD-1+ and Foxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight, 2016, 1, .	5.0	60
295	Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. OncoTargets and Therapy, 2016, Volume 9, 6075-6082.	2.0	47
296	Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope. Reviews on Recent Clinical Trials, 2016, 11, 87-92.	0.8	3
297	Immune Checkpoint Blockade Therapy: Merits and Demerits. Journal of Clinical & Experimental Dermatology Research, 2016, 7, .	0.1	0
298	Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy. Immune Network, 2016, 16, 134.	3.6	8
299	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. Journal of Gastrointestinal Oncology, 2016, 7, 771-788.	1.4	84

#	ARTICLE	IF	CITATIONS
300	Management of Melanoma Therapy-Associated Toxicities. , 2016, , 299-319.		1
301	Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e132-e139.	3.8	13
302	Beyond RAS and BRAF: a target rich disease that is ripe for picking. Journal of Gastrointestinal Oncology, 2016, 7, 705-712.	1.4	2
303	Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination. Mediators of Inflammation, 2016, 2016, 1-12.	3.0	25
304	Targeted Nanoparticles for Drug Delivery to Melanoma. , 2016, , 203-215.		3
305	PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight, 2016, 1, .	5.0	128
306	Clinical utility of nivolumab in the treatment of advanced melanoma. Therapeutics and Clinical Risk Management, 2016, 12, 313.	2.0	16
307	The emerging role of immunotherapy in colorectal cancer. Annals of Translational Medicine, 2016, 4, 305-305.	1.7	63
308	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology, 2016, 7, 550.	4.8	409
309	Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. Frontiers in Immunology, 2016, 7, 610.	4.8	111
310	Cytokine-Induced Modulation of Colorectal Cancer. Frontiers in Oncology, 2016, 6, 96.	2.8	181
311	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. Frontiers in Oncology, 2016, 6, 256.	2.8	39
312	Updates in Therapy for Advanced Melanoma. Cancers, 2016, 8, 17.	3.7	37
313	Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS ONE, 2016, 11, e0160221.	2.5	373
314	PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. PLoS Pathogens, 2016, 12, e1005642.	4.7	87
315	Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. PLoS Medicine, 2016, 13, e1002136.	8.4	28
316	Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines, 2016, 4, 28.	4.4	372
317	The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials. OncoTargets and Therapy, 2016, 9, 1571.	2.0	7

#	ARTICLE	IF	CITATIONS
318	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 215-215.	1.7	13
320	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. <i>Oncotarget</i> , 2016, 7, 10215-10227.	1.8	158
321	Prognostic Factors for Survival in Melanoma Patients with Brain Metastases. , 2016, , 267-297.		11
322	Immune Checkpoint Therapy in Head and Neck Cancers. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 108-116.	2.0	12
323	Immune Checkpoint Therapy in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 73-80.	2.0	10
324	Safety of immune checkpoint inhibitors in Chinese patients with melanoma. <i>Melanoma Research</i> , 2016, 26, 284-289.	1.2	21
325	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. <i>Immunotherapy</i> , 2016, 8, 907-921.	2.0	20
326	Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration. <i>MAbs</i> , 2016, 8, 1371-1385.	5.2	7
327	Novel Immunotherapies for B-Cell Lymphomas and Leukemias. <i>American Journal of Therapeutics</i> , 2016, 23, e1157-e1181.	0.9	3
328	Managing Adverse Events With Immune Checkpoint Agents. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 121-129.	2.0	42
329	Targeted Therapies Combined With Immune Checkpoint Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 138-146.	2.0	36
330	Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas. <i>Melanoma Research</i> , 2016, 26, 524-527.	1.2	7
331	Immune-mediated respiratory adverse events of checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 269-277.	2.4	39
332	Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2016, 2, 1346.	7.1	667
333	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2980-2987.	1.6	444
334	Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. <i>Lung Cancer</i> , 2016, 99, 123-126.	2.0	46
335	Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 875-878.	1.3	70
336	Contact immunotherapy enhances the therapeutic effects of nivolumab in treating intralesional melanoma: Two cases reports. <i>Journal of Dermatology</i> , 2016, 43, 686-689.	1.2	23

#	ARTICLE	IF	CITATIONS
337	Major Changes in Systemic Therapy for Advanced Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 638-640.	4.9	8
338	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care, 2016, 11, 385-390.	1.4	20,872
339	Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma. Oncology Nursing Forum, 2016, 43, 219-226.	1.2	18
340	Overview and management of toxicities of immune checkpoint-blocking drugs. Forum of Clinical Oncology, 2016, 7, 28-37.	0.2	1
341	A New VISTA on combination therapy for negative checkpoint regulator blockade. , 2016, 4, 86.		36
342	A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. Signal Transduction and Targeted Therapy, 2016, 1, 16025.	17.1	35
343	PD-L1 is upregulated by EBV-driven LMP1 through NF- κ B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. Journal of Hematology and Oncology, 2016, 9, 109.	17.0	217
344	Renal effects of immune checkpoint inhibitors. Nephrology Dialysis Transplantation, 2017, 32, gfw382.	0.7	67
345	Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. Immunotherapy, 2016, 8, 1393-1404.	2.0	8
346	Challenges in the Delivery of Therapies to Melanoma Brain Metastases. Current Pharmacology Reports, 2016, 2, 309-325.	3.0	18
347	Malignant Melanoma: Beyond the Basics. Plastic and Reconstructive Surgery, 2016, 138, 330e-340e.	1.4	121
348	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. , 2016, 4, 84.		94
350	Polyfunctional Melan-A-specific tumor-reactive CD8 ⁺ T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. OncoImmunology, 2016, 5, e1114203.	4.6	25
351	Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. Expert Opinion on Pharmacotherapy, 2016, 17, 1031-1038.	1.8	28
352	Ipilimumab and Bevacizumab in Glioblastoma. Clinical Oncology, 2016, 28, 622-626.	1.4	64
353	How to report toxicity associated with targeted therapies?. Annals of Oncology, 2016, 27, 1633-1638.	1.2	12
354	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. Journal of Hematology and Oncology, 2016, 9, 47.	17.0	271
355	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs, 2016, 76, 925-945.	10.9	123

#	ARTICLE	IF	CITATIONS
356	Treatment of murine lupus with PD-Llg. <i>Clinical Immunology</i> , 2016, 162, 1-8.	3.2	16
357	Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?. <i>European Journal of Cancer</i> , 2016, 62, 76-85.	2.8	178
358	Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia. <i>Cancer Immunology Research</i> , 2016, 4, 644-649.	3.4	23
359	Novel immunotherapies for the treatment of melanoma. <i>Immunotherapy</i> , 2016, 8, 613-632.	2.0	5
360	Emerging molecular classifications and therapeutic implications for gastric cancer. <i>Chinese Journal of Cancer</i> , 2016, 35, 49.	4.9	35
361	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 31.	3.0	57
362	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. <i>Current Oncology Reports</i> , 2016, 18, 42.	4.0	54
364	Targeting T Cell Co-receptors for Cancer Therapy. <i>Immunity</i> , 2016, 44, 1069-1078.	14.3	418
365	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2016, 2, 1179.	7.1	154
366	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. <i>Eur Urol</i> 2015;68:542-3. <i>European Urology</i> , 2016, 70, e69-e70.	1.9	0
367	PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. <i>Modern Pathology</i> , 2016, 29, 1104-1112.	5.5	210
368	PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. <i>Immunotherapy</i> , 2016, 8, 733-746.	2.0	28
369	PD-1 Blockade Boosts Radiofrequency Ablation-Induced Adaptive Immune Responses against Tumor. <i>Clinical Cancer Research</i> , 2016, 22, 1173-1184.	7.0	207
370	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 275-287.	28.4	2,133
371	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 210-225.	2.8	490
372	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 190-209.	2.8	546
373	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. <i>Tumor Biology</i> , 2016, 37, 7507-7514.	1.8	40
374	The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma. <i>Medicine (United States)</i> , 2016, 95, e3134.	1.0	13

#	ARTICLE	IF	CITATIONS
375	Advances in immunotherapy for melanoma. BMC Medicine, 2016, 14, 20.	5.5	111
376	Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer. Expert Opinion on Drug Delivery, 2016, 13, 999-1013.	5.0	6
377	Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Review of Clinical Immunology, 2016, 12, 879-893.	3.0	8
378	From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discovery Today, 2016, 21, 1027-1036.	6.4	137
379	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA - Journal of the American Medical Association, 2016, 315, 1600.	7.4	857
380	Nivolumab-induced thyroid dysfunction. Japanese Journal of Clinical Oncology, 2016, 46, 575-579.	1.3	44
381	Immune checkpoint inhibition in ovarian cancer. International Immunology, 2016, 28, 339-348.	4.0	122
382	Surgical Oncology Manual. , 2016, , .		1
383	Future Medicine 2: Cancer Vaccines. , 2016, , 249-284.		0
384	Cancer immunotherapy: the beginning of the end of cancer?. BMC Medicine, 2016, 14, 73.	5.5	908
385	Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. British Journal of Cancer, 2016, 114, 1084-1089.	6.4	113
386	Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncology Letters, 2016, 11, 1581-1585.	1.8	34
387	High co-expression of PD-L1 and HIF-1 α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. European Journal of Cancer, 2016, 60, 125-135.	2.8	91
388	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, 2016, 13, 473-486.	27.6	831
389	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Human Vaccines and Immunotherapeutics, 2016, 12, 2219-2231.	3.3	49
390	Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma. JAMA Dermatology, 2016, 152, 590.	4.1	55
391	Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. Cancer Discovery, 2016, 6, 703-713.	9.4	92
392	Roles of regulatory T cells in cancer immunity. International Immunology, 2016, 28, 401-409.	4.0	412

#	ARTICLE	IF	CITATIONS
393	The integration of radiation therapy and immunotherapy in melanoma management. Journal of Radiation Oncology, 2016, 5, 131-142.	0.7	2
394	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 5461-5471.	7.0	234
395	Genetics of Melanoma. , 2016, , .		3
396	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. Journal of Histochemistry and Cytochemistry, 2016, 64, 587-600.	2.5	30
397	Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. Journal of Virology, 2016, 90, 8934-8946.	3.4	69
398	Inmunoterapia del melanoma. Piel, 2016, 31, 649-656.	0.0	0
399	Immunotherapy for malignant mesothelioma: reality check. Expert Review of Anticancer Therapy, 2016, 16, 1167-1176.	2.4	10
400	PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. OncoImmunology, 2016, 5, e1235107.	4.6	104
401	Anti-PD1-Induced Pneumonitis: Capturing the Hidden Enemy. Clinical Cancer Research, 2016, 22, 5956-5958.	7.0	12
402	Plasma Cell Dyscrasias. Cancer Treatment and Research, 2016, , .	0.5	3
403	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. Haematologica, 2016, 101, 1144-1158.	3.5	6
404	Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 207-225.	0.5	20
405	Coming-of-Age of Antibodies in Cancer Therapeutics. Trends in Pharmacological Sciences, 2016, 37, 1009-1028.	8.7	89
406	Approaches for targeting cancer stem cells drug resistance. Expert Opinion on Drug Discovery, 2016, 11, 1201-1212.	5.0	38
407	Checkpoint-Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms. JDDG - Journal of the German Society of Dermatology, 2016, 14, 685-697.	0.8	6
408	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 1533-1544.	4.2	89
409	Molecular Imaging of Immunotherapy Targets in Cancer. Journal of Nuclear Medicine, 2016, 57, 1487-1492.	5.0	77
410	Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma. Clinical Cancer Research, 2016, 22, 5480-5486.	7.0	84

#	ARTICLE	IF	CITATIONS
411	Oncolytic viruses—immunotherapeutics on the rise. <i>Journal of Molecular Medicine</i> , 2016, 94, 979-991.	3.9	43
412	The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 48.	3.0	36
413	Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. <i>Cancer Medicine</i> , 2016, 5, 1481-1491.	2.8	86
414	Inflammation and Metastasis. , 2016, , .		4
415	Malignant melanoma showing a rapid response to nivolumab. <i>Australasian Journal of Dermatology</i> , 2016, 57, 61-63.	0.7	3
416	PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. <i>Pharmacotherapy</i> , 2016, 36, 317-334.	2.6	82
417	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. <i>Cancer Science</i> , 2016, 107, 107-115.	3.9	28
418	Biomarkers in melanoma. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S104-S112.	1.2	8
419	Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. , 2016, 4, 50.		413
420	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1255-1261.	3.3	12
421	Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. <i>Journal of Immunology</i> , 2016, 197, 2532-2540.	0.8	110
422	The efficacy of anti-PD-1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016, 122, 3354-3362.	4.1	236
423	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016, 22, 6051-6060.	7.0	393
424	Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer. <i>JAMA Oncology</i> , 2016, 2, 1607.	7.1	600
425	Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes. <i>Tohoku Journal of Experimental Medicine</i> , 2016, 239, 155-158.	1.2	80
426	Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. <i>International Journal of Oncology</i> , 2016, 49, 1099-1107.	3.3	17
427	Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. <i>Annals of Oncology</i> , 2016, 27, 2288-2294.	1.2	117
428	Advances in immunotherapy for melanoma management. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2501-2511.	3.3	15

#	ARTICLE	IF	CITATIONS
429	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. Immunotherapy, 2016, 8, 775-784.	2.0	24
430	Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer, 2016, 99, 117-119.	2.0	88
431	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology, 2016, 29, 1433-1442.	5.5	144
432	Immune checkpoint inhibitors: a milestone in the treatment of melanoma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 685-695.	0.8	15
433	Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2016, 14, 662-681.	0.8	63
434	Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD-1-Antikörper beim metastasierten Melanom. JDDG - Journal of the German Society of Dermatology, 2016, 14, 662-683.	0.8	47
435	Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab. Oral Oncology, 2016, 63, e1-e3.	1.5	11
436	Talimogene laherparepvec: overview, combination therapy and current practices. Melanoma Management, 2016, 3, 267-272.	0.5	8
437	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4.	12.4	1,844
438	Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients. Oncoimmunology, 2016, 5, e1248327.	4.6	60
439	Nivolumab in melanoma. Expert Review of Anticancer Therapy, 2016, 16, 1247-1261.	2.4	20
440	Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. Trends in Molecular Medicine, 2016, 22, 1000-1011.	6.7	60
441	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein and Cell, 2016, 7, 866-877.	11.0	44
442	Drug Combinations as the New Standard for Melanoma Treatment. Current Treatment Options in Oncology, 2016, 17, 61.	3.0	16
443	Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. Therapeutic Advances in Gastroenterology, 2016, 9, 853-860.	3.2	13
445	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. , 2016, 4, 52.		37
446	Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy. Journal of Immunotherapy, 2016, 39, 306-315.	2.4	10
447	Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials. BMC Cancer, 2016, 16, 889.	2.6	2

#	ARTICLE	IF	CITATIONS
448	Programmed cell death-1 pathway inhibitors in genitourinary malignancies. Current Opinion in Urology, 2016, 26, 548-555.	1.8	9
449	Big Data and Pharmacovigilance: The Role of Oncology Nurses. Clinical Journal of Oncology Nursing, 2016, 20, 478-480.	0.6	3
450	Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clinical Endocrinology, 2016, 85, 331-339.	2.4	177
451	Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, , .	1.6	6
452	Cancer therapy-related complications in the bowel and mesentery: an imaging perspective. Abdominal Radiology, 2016, 41, 2031-2047.	2.1	12
453	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunology Research, 2016, 4, 669-678.	3.4	117
454	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. Oncoimmunology, 2016, 5, e1201625.	4.6	21
455	Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy. Cancer Research, 2016, 76, 4931-4940.	0.9	132
456	Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist, 2016, 21, 804-816.	3.7	208
457	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Medical Oncology, 2016, 33, 80.	2.5	32
458	Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma. Melanoma Research, 2016, 26, 125-137.	1.2	18
459	Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. Breast Care, 2016, 11, 102-107.	1.4	35
460	Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncology and Therapy, 2016, 4, 17-33.	2.6	19
462	Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. Cancer Research, 2016, 76, 4347-4358.	0.9	63
463	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discovery, 2016, 6, 827-837.	9.4	785
464	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39.		0
466	Upregulation of granzyme B and interferon- γ mRNA in responding lesions by treatment with nivolumab for metastatic melanoma: a case report. Journal of the European Academy of Dermatology and Venereology, 2016, 30, e231-e232.	2.4	9
467	Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity. Cancer Research, 2016, 76, 548-560.	0.9	75

#	ARTICLE	IF	CITATIONS
468	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. <i>Annals of Surgical Oncology</i> , 2016, 23, 4169-4177.	1.5	236
469	Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab. <i>Journal of Dermatology</i> , 2016, 43, 210-214.	1.2	49
470	Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600E Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878.	1.6	266
471	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>European Journal of Cancer</i> , 2016, 54, 139-148.	2.8	1,687
472	Doubling the blockade for melanoma immunotherapy. <i>OncolImmunology</i> , 2016, 5, e1106127.	4.6	9
473	Synthetic ROR γ t Agonists Enhance Protective Immunity. <i>ACS Chemical Biology</i> , 2016, 11, 1012-1018.	3.4	48
474	Current status of immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 191-203.	1.3	52
475	Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic Melanoma. <i>Mayo Clinic Proceedings</i> , 2016, 91, 288-296.	3.0	17
476	Modulation of tumor immunity: a patent evaluation of WO2015026684A1. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 417-425.	5.0	8
477	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 389-396.	3.1	35
478	Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. <i>Cancer Research</i> , 2016, 76, 1381-1390.	0.9	451
479	New insights into the anti-PD-L1 and anti-PD-1 reagents in cancer therapy. <i>European Journal of Inflammation</i> , 2016, 14, 61-65.	0.5	0
480	PD-1 Blockade Expands Intratumoral Memory T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 194-203.	3.4	321
481	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 46.	7.1	693
482	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 57-75.	3.3	46
483	Single versus combination immunotherapy drug treatment in melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 433-441.	3.1	16
484	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv362.	6.3	71
485	Checkpoint Blockade for the Treatment of Advanced Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 231-250.	0.5	36

#	ARTICLE	IF	CITATIONS
486	CTLA-4 and PD-1 Pathways. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 98-106.	1.3	1,644
487	Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. Nano Letters, 2016, 16, 2334-2340.	9.1	609
488	Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice. Cancer Immunology, Immunotherapy, 2016, 65, 601-611.	4.2	13
489	Principles of immunotherapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 163-181.	1.8	12
490	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. International Immunology, 2016, 28, 383-391.	4.0	223
491	New Translational Research in the Medical Management of Orbital Melanoma. Seminars in Ophthalmology, 2016, 31, 53-58.	1.6	4
492	Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature. Cancer Treatment Reviews, 2016, 45, 120-128.	7.7	8
493	Checkpoint inhibitors in Hodgkin's lymphoma. European Journal of Haematology, 2016, 96, 335-343.	2.2	14
494	Novel therapies for advanced squamous cell carcinoma of the lung. Future Oncology, 2016, 12, 659-667.	2.4	11
495	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. Expert Opinion on Biological Therapy, 2016, 16, 655-674.	3.1	21
496	Variation in Cancer Incidence among Patients with ESRD during Kidney Function and Nonfunction Intervals. Journal of the American Society of Nephrology: JASN, 2016, 27, 1495-1504.	6.1	91
497	Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunology Research, 2016, 4, 345-353.	3.4	214
498	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Targeted Oncology, 2016, 11, 469-477.	3.6	34
499	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nature Medicine, 2016, 22, 433-438.	30.7	721
500	Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Human Vaccines and Immunotherapeutics, 2016, 12, 1092-1101.	3.3	37
501	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treatment Reviews, 2016, 45, 7-18.	7.7	354
502	Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology, 2016, 5, e1145332.	4.6	13
503	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology, 2016, 5, e1136044.	4.6	55

#	ARTICLE	IF	CITATIONS
504	Management of toxicities of immune checkpoint inhibitors. <i>Cancer Treatment Reviews</i> , 2016, 44, 51-60.	7.7	706
505	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. <i>Nature Communications</i> , 2016, 7, 10391.	12.8	784
508	Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 193-201.	1.0	75
509	Strategies in functional proteomics: Unveiling the pathways to precision oncology. <i>Cancer Letters</i> , 2016, 382, 86-94.	7.2	7
510	Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 635-641.	2.3	14
511	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. <i>International Journal of Clinical Oncology</i> , 2016, 21, 462-473.	2.2	255
512	Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S9-S14.	2.0	0
513	High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 813-819.	4.2	53
514	Immunotherapy of Cancer. , 2016, , .		3
515	Anti-PD-1 and Anti-PD-L1 mAbs. , 2016, , 283-294.		1
516	Medical Management of Meningiomas. <i>Neurosurgery Clinics of North America</i> , 2016, 27, 249-260.	1.7	36
517	MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. <i>Immunity</i> , 2016, 44, 609-621.	14.3	566
518	Genetic and Epigenetic Regulation of PD-1 Expression. <i>Journal of Immunology</i> , 2016, 196, 2431-2437.	0.8	181
519	Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 289-293.	3.4	135
520	Ocular toxicities of MEK inhibitors and other targeted therapies. <i>Annals of Oncology</i> , 2016, 27, 998-1005.	1.2	72
521	Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4023-4029.	7.0	160
522	Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 259-268.	7.2	30
523	Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. <i>Journal of Controlled Release</i> , 2016, 231, 17-28.	9.9	171

#	ARTICLE	IF	CITATIONS
524	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 4-31.	3.2	40
525	Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities. Future Oncology, 2016, 12, 95-106.	2.4	15
526	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. European Journal of Cancer, 2016, 53, 125-134.	2.8	137
527	Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Annals of Oncology, 2016, 27, 434-441.	1.2	213
528	Reprogramming away from the exhausted T cell state. Seminars in Immunology, 2016, 28, 35-44.	5.6	25
529	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Seminars in Immunology, 2016, 28, 64-72.	5.6	52
530	Mucosal Melanoma: Epidemiology, Biology and Treatment. Cancer Treatment and Research, 2016, 167, 295-320.	0.5	89
531	Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. Pediatric Research, 2016, 79, 371-377.	2.3	12
532	PD-1 expression conditions T cell avidity within an antigen-specific repertoire. OncoImmunology, 2016, 5, e1104448.	4.6	47
533	PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF- κ B. Cancer Research, 2016, 76, 239-250.	0.9	84
534	Combination cancer immunotherapies tailored to the tumour microenvironment. Nature Reviews Clinical Oncology, 2016, 13, 143-158.	27.6	753
535	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Annals of Oncology, 2016, 27, 214-224.	1.2	86
536	Novel Treatments in Development for Melanoma. Cancer Treatment and Research, 2016, 167, 371-416.	0.5	15
537	Immune checkpoint inhibitors: a new frontier in bladder cancer. World Journal of Urology, 2016, 34, 49-55.	2.2	15
538	Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biology of Blood and Marrow Transplantation, 2016, 22, 17-22.	2.0	16
539	Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. Clinical Cancer Research, 2016, 22, 886-894.	7.0	705
540	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2016, 22, 470-478.	7.0	168
541	Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology, 2016, 150, 48-63.	1.3	90

#	ARTICLE	IF	CITATIONS
543	PD-L1 expression and prognostic impact in glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 195-205.	1.2	463
544	The role of regional chemotherapy in the management of extremity soft tissue malignancies. <i>European Journal of Surgical Oncology</i> , 2016, 42, 7-17.	1.0	15
545	Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 421-430.	3.3	18
546	Studying cancer metastasis: Existing models, challenges and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 107-117.	4.4	36
547	Clinical significance of CD70 expression on T cells in human T-lymphotropic virus type-1 carriers and adult T cell leukemia/ lymphoma patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 685-691.	1.3	4
548	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 115-128.	27.6	95
549	Case of hypophysitis caused by nivolumab. <i>Journal of Dermatology</i> , 2017, 44, 109-110.	1.2	34
550	Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies. <i>Nature Reviews Endocrinology</i> , 2017, 13, 195-207.	9.6	515
551	Inverse lichenoid drug eruption associated with nivolumab. <i>JAAD Case Reports</i> , 2017, 3, 7-9.	0.8	13
552	Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor- α is a biomarker of nivolumab reactivity. <i>Journal of Dermatological Science</i> , 2017, 86, 71-73.	1.9	105
553	A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet. <i>Clinical and Translational Medicine</i> , 2017, 6, 3.	4.0	58
554	Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. <i>European Journal of Cancer</i> , 2017, 73, 1-8.	2.8	397
555	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	1.6	458
556	Therapeutic Cancer Vaccines. , 2017, , 47-78.		2
557	Novel immune check point inhibiting antibodies in cancer therapy – Opportunities and challenges. <i>Drug Resistance Updates</i> , 2017, 30, 39-47.	14.4	98
558	Regression of intracranial meningioma following treatment with nivolumab: Case report and review of the literature. <i>Journal of Clinical Neuroscience</i> , 2017, 37, 51-53.	1.5	23
559	Radiotherapy and immunotherapy: a beneficial liaison?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 365-379.	27.6	760
560	Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now287.	1.2	128

#	ARTICLE	IF	CITATIONS
561	Rationale for stimulator of interferon genesâ€‘targeted cancer immunotherapy. <i>European Journal of Cancer</i> , 2017, 75, 86-97.	2.8	47
562	Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligandâ1 expression in bone marrow stromal cells. <i>Molecular Oncology</i> , 2017, 11, 358-372.	4.6	43
563	A first reported case of metastatic anorectal amelanotic melanoma with a marked response to anti-PD-1 antibody nivolumab: A case report. <i>International Journal of Surgery Case Reports</i> , 2017, 31, 188-192.	0.6	21
564	The chronicles of T-cell exhaustion. <i>Nature</i> , 2017, 543, 190-191.	27.8	24
565	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 387-394.	2.4	128
566	Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition. <i>Cells Tissues Organs</i> , 2017, 203, 128-138.	2.3	20
567	Emerging role of checkpoint blockade therapy in lymphoma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 81-90.	2.5	32
568	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2017, 25, 1713-1739.	2.2	125
569	The biology of uveal melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 109-140.	5.9	160
570	ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. <i>Journal of Hepatology</i> , 2017, 66, 942-951.	3.7	53
572	PD-1 and PD-L1 antibodies in cancer: current status and future directions. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 551-564.	4.2	253
573	Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. <i>Revue De Medecine Interne</i> , 2017, 38, 513-525.	1.0	36
574	Immunosenescence and cancer. <i>Biogerontology</i> , 2017, 18, 717-721.	3.9	120
575	Characterization of the Antiâ€‘PD-1 Antibody REGN2810 and Its Antitumor Activity in Human<i>PD-1</i> Knock-In Mice. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 861-870.	4.1	92
576	Mechanisms of Drug Resistance in Melanoma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 91-108.	1.8	63
577	Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. <i>International Journal of Infectious Diseases</i> , 2017, 56, 221-228.	3.3	112
578	High expression of PD-1 ligands is associated with <i>kataegis</i> mutational signature and APOBEC3 alterations. <i>Oncotimmunology</i> , 2017, 6, e1284719.	4.6	64
579	Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. <i>American Journal of Nephrology</i> , 2017, 45, 160-169.	3.1	10,656

#	ARTICLE	IF	CITATIONS
580	Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. <i>Journal of Hematology and Oncology</i> , 2017, 10, 64.	17.0	30
581	Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. <i>Molecular Imaging and Biology</i> , 2017, 19, 903-914.	2.6	91
582	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. <i>Neurotherapeutics</i> , 2017, 14, 1049-1065.	4.4	20
583	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 344-351.	0.8	143
584	Clinical Features of Acquired Resistance to Anti-“PD-1 Therapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2017, 5, 357-362.	3.4	40
585	Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1766-1773.	0.7	20
587	PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. <i>Clinical Cancer Research</i> , 2017, 23, 4938-4944.	7.0	120
588	Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. <i>Journal of Controlled Release</i> , 2017, 256, 26-45.	9.9	41
589	Increasing the safety and efficacy of chimeric antigen receptor T cell therapy. <i>Protein and Cell</i> , 2017, 8, 573-589.	11.0	67
590	Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2698-2706.	1.5	24
591	Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism. <i>Cytokine and Growth Factor Reviews</i> , 2017, 35, 15-25.	7.2	33
592	Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. <i>Radiology</i> , 2017, 283, 314-340.	7.3	19
593	Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. <i>Cell Death and Disease</i> , 2017, 8, e2779-e2779.	6.3	114
594	Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. <i>Journal of Neuro-Oncology</i> , 2017, 133, 561-569.	2.9	43
595	Epigenetics and immunotherapy: The current state of play. <i>Molecular Immunology</i> , 2017, 87, 227-239.	2.2	167
596	Focus on cutaneous and uveal melanoma specificities. <i>Genes and Development</i> , 2017, 31, 724-743.	5.9	75
597	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1113-1121.	4.2	29
598	Cutaneous T-Cell Lymphoma. , 2017, , 715-740.		1

#	ARTICLE	IF	CITATIONS
599	Immunobiology and Immune Based Therapies of Melanoma. , 2017, , 871-890.		0
600	Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. Advanced Drug Delivery Reviews, 2017, 114, 33-42.	13.7	81
601	Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient. Journal of Thoracic Oncology, 2017, 12, e51-e55.	1.1	3
602	Signaling by Antibodies: Recent Progress. Annual Review of Immunology, 2017, 35, 285-311.	21.8	167
604	The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series. Cancer Immunology, Immunotherapy, 2017, 66, 1153-1162.	4.2	34
605	Conserved Region C Functions To Regulate PD-1 Expression and Subsequent CD8 T Cell Memory. Journal of Immunology, 2017, 198, 205-217.	0.8	24
606	High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Research, 2017, 27, 24-31.	1.2	15
607	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clinical Cancer Research, 2017, 23, 3158-3167.	7.0	426
608	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. Annals of the American Thoracic Society, 2017, 14, 1248-1260.	3.2	15
609	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. European Journal of Cancer, 2017, 81, 116-129.	2.8	443
610	PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature, 2017, 545, 495-499.	27.8	1,489
611	Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist, 2017, 22, 709-718.	3.7	221
612	Imaging Studies in Immunotherapy. , 2017, , 149-179.		1
613	Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. Clinics in Chest Medicine, 2017, 38, 223-232.	2.1	36
614	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer, 2017, 116, 1558-1563.	6.4	91
615	The HLA-DR mediated signalling increases the migration and invasion of melanoma cells, the expression and lipid raft recruitment of adhesion receptors, PD-L1 and signal transduction proteins. Cellular Signalling, 2017, 36, 189-203.	3.6	26
616	Immunogenomics: using genomics to personalize cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 209-219.	2.8	7
617	Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology, 2017, 153, 1107-1119.e10.	1.3	309

#	ARTICLE	IF	CITATIONS
618	Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy. <i>Molecular Therapy</i> , 2017, 25, 1917-1932.	8.2	50
619	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017, 357, 409-413.	12.6	4,945
620	Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. <i>Clinical Cancer Research</i> , 2017, 23, 4671-4679.	7.0	110
621	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. <i>Clinical Cancer Research</i> , 2017, 23, 5202-5209.	7.0	99
622	Interaction of molecular alterations with immune response in melanoma. <i>Cancer</i> , 2017, 123, 2130-2142.	4.1	24
623	Acquired IFN γ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. <i>Nature Communications</i> , 2017, 8, 15440.	12.8	195
624	Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. <i>Cancer Science</i> , 2017, 108, 1022-1031.	3.9	100
625	Primary malignant melanoma of esophagus following chemoradiotherapy for esophageal squamous cell carcinoma: report of a case. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 336-341.	0.8	8
626	Complete response to anti-PD-1 nivolumab in massive skin metastasis from melanoma. <i>Anti-Cancer Drugs</i> , 2017, 28, 808-810.	1.4	6
627	Epigenetic modulation in cancer immunotherapy. <i>Current Opinion in Pharmacology</i> , 2017, 35, 48-56.	3.5	50
628	Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. <i>Oncogene</i> , 2017, 36, 5829-5839.	5.9	249
629	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2017, 28, 1988-1995.	1.2	326
630	Addressing the quality of the ESMO-MCBS. <i>Annals of Oncology</i> , 2017, 28, 1406.	1.2	8
631	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	27.6	945
632	Mechanistic and pharmacologic insights on immune checkpoint inhibitors. <i>Pharmacological Research</i> , 2017, 120, 1-9.	7.1	46
633	Immunotherapy in malignant melanoma: recent approaches and new perspectives. <i>Melanoma Management</i> , 2017, 4, 39-48.	0.5	7
634	Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan. <i>Journal of Dermatology</i> , 2017, 44, 932-938.	1.2	45
635	Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient. <i>Annals of Oncology</i> , 2017, 28, 1405-1406.	1.2	13

#	ARTICLE	IF	CITATIONS
636	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	10.7	428
637	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 573-585.	2.4	21
638	Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point ¹⁸ F-FDG PET/CT Imaging in Patients with Advanced Melanoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1421-1428.	5.0	209
639	Recognizing and managing on toxicities in cancer immunotherapy. <i>Tumor Biology</i> , 2017, 39, 101042831769454.	1.8	27
640	Immune Checkpoint Inhibitors in Gliomas. <i>Current Oncology Reports</i> , 2017, 19, 23.	4.0	27
641	Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. <i>Cancer Research</i> , 2017, 77, 2952-2963.	0.9	86
642	The Role of Targeted Therapy in the Management of Sinonasal Malignancies. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 443-455.	1.1	12
643	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. <i>Biomarker Research</i> , 2017, 5, 12.	6.8	149
644	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. <i>Investigational New Drugs</i> , 2017, 35, 529-536.	2.6	128
645	T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. <i>International Journal of Cancer</i> , 2017, 140, 2535-2544.	5.1	42
646	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 583-589.	1.2	510
647	Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 40-48.	2.5	71
648	Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. <i>Neuro-Oncology</i> , 2017, 19, i1-i24.	1.2	171
649	PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. <i>Blood</i> , 2017, 129, 1039-1041.	1.4	393
650	Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 129-132.	2.6	2
651	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 31-41.e4.	1.9	31
652	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 43-50.	0.9	317
653	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 785-792.	1.6	930

#	ARTICLE	IF	CITATIONS
654	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 17-28.	3.4	130
655	Innate immune signaling and regulation in cancer immunotherapy. <i>Cell Research</i> , 2017, 27, 96-108.	12.0	291
656	Metastatic melanoma imaging using a novel Tc-99m-labeled lactam-cyclized alpha-MSH peptide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4952-4955.	2.2	5
657	Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma. <i>Scientific Reports</i> , 2017, 7, 14049.	3.3	37
658	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017, 18, e653-e706.	10.7	153
659	A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry. <i>Future Science OA</i> , 2017, 3, FSO244.	1.9	24
660	Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management (Review). <i>Oncology Letters</i> , 2017, 14, 5671-5680.	1.8	54
661	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. <i>Immunotherapy</i> , 2017, 9, 995-1004.	2.0	14
662	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7263-7275.	7.0	41
663	Cutting the Brakes: Immunotherapy With PD-1 Inhibitors. <i>Clinical Skin Cancer</i> , 2017, 2, 24-31.	0.1	2
664	PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. <i>Cancer Cytopathology</i> , 2017, 125, 896-907.	2.4	164
665	Endocrine side effects of cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, T331-T347.	3.1	131
666	Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy. <i>Journal of Neuroimmunology</i> , 2017, 313, 118-122.	2.3	34
667	Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. <i>Journal of Immunotherapy</i> , 2017, 40, 334-340.	2.4	16
668	Inactivated Sendai virus particle upregulates cancer cell expression of intercellular adhesion molecule-1 and enhances natural killer cell sensitivity on cancer cells. <i>Cancer Science</i> , 2017, 108, 2333-2341.	3.9	9
669	Checkpoint immunotherapy in head and neck cancers. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 475-489.	5.9	33
670	Optimizing tumor immune response through combination of radiation and immunotherapy. <i>Medical Oncology</i> , 2017, 34, 165.	2.5	14
671	Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. <i>European Journal of Cancer</i> , 2017, 83, 247-257.	2.8	236

#	ARTICLE	IF	CITATIONS
672	Should we be combining local tumor therapies with immunotherapies as standard?. <i>Future Oncology</i> , 2017, 13, 1573-1575.	2.4	3
673	De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. <i>Nature Immunology</i> , 2017, 18, 1207-1217.	14.5	190
674	Gastric cancer: Basic aspects. <i>Helicobacter</i> , 2017, 22, e12412.	3.5	29
675	Immunotherapy in managing metastatic melanoma: which treatment when?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1523-1538.	3.1	13
676	Interprofessional Collaboration with Immune Checkpoint Inhibitor Therapy: the Roles of Gastroenterology, Endocrinology and Neurology. <i>Seminars in Oncology Nursing</i> , 2017, 33, 402-414.	1.5	5
677	Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. <i>Oncol Immunology</i> , 2017, 6, e1356153.	4.6	89
679	Nivolumab-induced autoimmune diabetes. <i>Journal of Pharmacy Practice and Research</i> , 2017, 47, 136-139.	0.8	5
680	Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?. <i>Clinical Skin Cancer</i> , 2017, 2, 10-17.	0.1	1
681	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 59, 71-78.	7.7	88
682	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	9.4	160
683	Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. <i>Journal of Dermatological Science</i> , 2017, 88, 225-231.	1.9	67
684	Melanoma subtypes demonstrate distinct PD-L1 expression profiles. <i>Laboratory Investigation</i> , 2017, 97, 1063-1071.	3.7	156
685	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1202-1210.	10.7	211
686	Precision Medicine and PET/Computed Tomography in Melanoma. <i>PET Clinics</i> , 2017, 12, 449-458.	3.0	11
687	Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology. <i>Methods</i> , 2017, 130, 23-35.	3.8	28
688	Dermoscopic features of dermatofibroma with overlying sebaceous hyperplasia. <i>Journal of Dermatology</i> , 2017, 44, 548-549.	1.2	0
689	Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1733-1736.	1.1	2
691	Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 63-67.	2.0	8

#	ARTICLE	IF	CITATIONS
692	Challenges in Conducting Clinical Research on Patients With Advanced Melanoma. Cancer Journal (Sudbury, Mass.), 2017, 23, 75-78.	2.0	2
693	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2310-2325.	6.4	46
694	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. Cell Death and Disease, 2017, 8, e2982-e2982.	6.3	17
695	Advances in the Management of Melanoma. Current Dermatology Reports, 2017, 6, 288-296.	2.1	1
696	The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. Future Oncology, 2017, 13, 2583-2592.	2.4	113
697	Human CD26 ^{high} T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nature Communications, 2017, 8, 1961.	12.8	67
698	Quality matters: immunotherapy and the evolving landscape of advanced cancer care. Expert Review of Quality of Life in Cancer Care, 2017, 2, 235-244.	0.6	2
699	An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report. Lancet Oncology, The, 2017, 18, e720-e730.	10.7	220
700	In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?. European Journal of Cancer, 2017, 87, 65-74.	2.8	19
701	32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC) Tj ETQq1 1 0.784314,rgBT /Ove	2.3	23
702	Very early response of circulating tumourâ€‘derived DNA in plasma predicts efficacy of nivolumab treatment in patients with nonâ€‘small cell lung cancer. European Journal of Cancer, 2017, 86, 349-357.	2.8	82
703	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	4.5	186
705	The new paradigm of systemic therapies for metastatic melanoma. Journal of the American Academy of Dermatology, 2017, 77, 356-368.	1.2	34
706	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2017, 28, iv119-iv142.	1.2	1,744
707	Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2017, 76, 697-708.	1.7	16
708	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 2017, 404, 62-69.	7.2	98
709	The safety of nivolumab for the treatment of metastatic melanoma. Expert Opinion on Drug Safety, 2017, 16, 955-961.	2.4	7
710	Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days. Respiratory Medicine Case Reports, 2017, 22, 31-33.	0.4	6

#	ARTICLE	IF	CITATIONS
711	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
712	Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. Oncologist, 2017, 22, 1232-1237.	3.7	109
713	Genomic profiling of colorectal cancers and the future of personalized treatment. Colorectal Cancer, 2017, 6, 11-22.	0.8	1
714	Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma. Medicine (United States), 2017, 96, e7325.	1.0	80
715	Endocrine dysfunction following immune checkpoint inhibitor therapy. Current Opinion in Endocrinology, Diabetes and Obesity, 2017, 24, 337-347.	2.3	18
716	PD-1/PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nature Reviews Clinical Oncology, 2017, 14, 203-220.	27.6	358
717	A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer. Annals of Oncology, 2017, 28, 298-304.	1.2	37
718	The safety of anti PD-1 therapeutics for the treatment of melanoma. Expert Opinion on Drug Safety, 2017, 16, 41-53.	2.4	17
719	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. Journal of Cutaneous Pathology, 2017, 44, 158-176.	1.3	186
720	Immunotherapy for Lung Malignancies. Chest, 2017, 151, 891-897.	0.8	17
721	Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered, 2017, 8, 367-373.	3.2	7
722	Immunotherapy in melanoma: Recent advances and future directions. European Journal of Surgical Oncology, 2017, 43, 604-611.	1.0	216
723	Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials. International Journal of Cancer, 2017, 140, 948-958.	5.1	42
724	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunology, Immunotherapy, 2017, 66, 45-50.	4.2	55
725	Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?. Human Vaccines and Immunotherapeutics, 2017, 13, 528-532.	3.3	30
726	TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy. Immunological Investigations, 2017, 46, 172-182.	2.0	40
727	Immunotherapy of melanoma. European Journal of Surgical Oncology, 2017, 43, 594-603.	1.0	21
728	Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clinical Cancer Research, 2017, 23, 149-158.	7.0	77

#	ARTICLE	IF	CITATIONS
729	Dermoscopic changes in malignant melanoma after successful treatment with nivolumab: A case report. <i>Journal of Dermatology</i> , 2017, 44, 547-548.	1.2	2
730	Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 394-400.	2.0	57
731	Radiotherapy combination opportunities leveraging immunity for the next oncology practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 65-85.	329.8	344
732	Pathology and Molecular Pathology of Melanoma. , 2017, , 613-653.		1
733	Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 629-634.	0.9	11
734	Symptom prevalence in patients with advanced skin cancer. <i>Journal of Dermatology</i> , 2017, 44, 123-126.	1.2	6
735	Global chemotherapy development for gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 92-101.	5.3	38
736	Ultrasonographic findings can identify "pseudoprogression"™ under nivolumab therapy. <i>British Journal of Dermatology</i> , 2017, 177, 1726-1731.	1.5	11
737	Metastasectomy in cutaneous melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 572-580.	1.0	18
738	Noninvasive monitoring of cancer therapy induced activated T cells using [¹⁸ F]FB-IL-2 PET imaging. <i>Oncolmunology</i> , 2017, 6, e1248014.	4.6	51
739	A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. <i>CNS Oncology</i> , 2017, 6, 29-43.	3.0	34
740	Are we entering the era of combination therapy for melanoma?. <i>Melanoma Management</i> , 2017, 4, 5-8.	0.5	0
741	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	1.6	9
742	Toxicité pulmonaire de l'immunothérapie par les inhibiteurs de point de contrôle. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 469-474.	0.0	1
743	Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab. <i>Annals of Oncology</i> , 2017, 28, 3106-3107.	1.2	16
744	Adaptive Resistance to Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 213-227.	1.6	15
746	Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 87-97.	0.8	26
747	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 37-45.	2.8	183

#	ARTICLE	IF	CITATIONS
748	Serial pseudoprogession of metastatic malignant melanoma in a patient treated with nivolumab: a case report. BMC Cancer, 2017, 17, 778.	2.6	22
749	PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget, 2017, 8, 53978-53988.	1.8	32
750	Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 325-339.	1.8	52
751	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Frontiers in Pharmacology, 2017, 8, 49.	3.5	459
752	Immune Checkpoint in Glioblastoma: Promising and Challenging. Frontiers in Pharmacology, 2017, 8, 242.	3.5	133
753	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Frontiers in Pharmacology, 2017, 8, 730.	3.5	350
754	Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. Journal of Cancer, 2017, 8, 410-416.	2.5	176
755	Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean Journal of Radiology, 2017, 18, 42.	3.4	33
756	Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?. Current Cancer Drug Targets, 2017, 18, 5-15.	1.6	4
757	Treatment of advanced melanoma - A changing landscape. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2017, 63, 814-823.	0.7	15
758	Cancer immunology and melanoma immunotherapy. Anais Brasileiros De Dermatologia, 2017, 92, 830-835.	1.1	8
759	Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients. Acta Dermato-Venereologica, 2017, 97, 1212-1218.	1.3	29
760	Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?. International Journal of Molecular Sciences, 2017, 18, 2382.	4.1	8
761	New Immunotherapy Strategies in Breast Cancer. International Journal of Environmental Research and Public Health, 2017, 14, 68.	2.6	76
763	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Frontiers in Pharmacology, 2017, 8, 561.	3.5	1,276
764	Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. International Journal of Molecular Sciences, 2017, 18, 1660.	4.1	33
765	Tumor abolition and antitumor immunostimulation by physico-chemical tumor nbsp ablation. Frontiers in Bioscience - Landmark, 2017, 22, 310-347.	3.0	38
766	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Donâ€™t Forget the Fuel. Frontiers in Immunology, 2017, 8, 267.	4.8	61

#	ARTICLE	IF	CITATIONS
767	Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release. <i>Frontiers in Immunology</i> , 2017, 8, 1342.	4.8	22
768	Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. <i>BioMed Research International</i> , 2017, 2017, 1-10.	1.9	6
769	Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells. <i>Mediators of Inflammation</i> , 2017, 2017, 1-9.	3.0	33
770	Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-4.	0.3	11
771	Melanoma: tumor microenvironment and new treatments. <i>Anais Brasileiros De Dermatologia</i> , 2017, 92, 156-166.	1.1	35
772	Effects of nivolumab in peritoneal carcinomatosis of malign melanoma in mouse model. <i>Acta Cirurgica Brasileira</i> , 2017, 32, 1006-1012.	0.7	4
773	Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. <i>Cancer Management and Research</i> , 2017, Volume 9, 207-213.	1.9	128
774	Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 8337-8351.	6.7	19
775	Targeted therapy for soft tissue sarcomas in adolescents and young adults. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 41-55.	0.9	11
776	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. <i>Oncolimmunology</i> , 2017, 6, e1344805.	4.6	142
777	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. <i>Tumori</i> , 2017, 103, 405-421.	1.1	52
778	Addressing the challenges of applying precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 28.	5.4	43
779	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2017, 17, 618.	2.6	42
780	Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model. <i>BMC Systems Biology</i> , 2017, 11, 70.	3.0	37
781	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 174.	17.0	92
782	Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. , 2017, 5, 56.		9
783	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
784	Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. <i>Surgical Case Reports</i> , 2017, 3, 94.	0.6	14

#	ARTICLE	IF	CITATIONS
785	Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, efficacy and Resistance. Journal of Biomedical Sciences, 2017, 06, .	0.3	0
786	The combination of checkpoint immunotherapy and targeted therapy in cancer. Annals of Translational Medicine, 2017, 5, 388-388.	1.7	54
787	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerging Topics in Life Sciences, 2017, 1, 471-486.	2.6	5
788	Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities. Case Reports in Oncology, 2017, 9, 644-649.	0.7	13
789	Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. Kidney Cancer, 2017, 1, 15-29.	0.4	4
790	Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer. International Journal of Molecular Sciences, 2017, 18, 1542.	4.1	25
791	Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. Japanese Journal of Clinical Oncology, 2017, 47, 175-178.	1.3	52
792	First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets and Therapy, 2017, Volume 6, 1-10.	5.8	26
793	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. Diagnostics, 2017, 7, 23.	2.6	13
794	Management of intracranial melanomas in the era of precision medicine. Oncotarget, 2017, 8, 89326-89347.	1.8	16
795	Avismine (ME-503)-Skin Reaction as significant Factor for its Efficacy Expanded Evaluation of the Results from the Phase II Trial NCT00658437. Immunotherapy (Los Angeles, Calif), 2017, 03, .	0.1	1
796	PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget, 2017, 8, 2171-2186.	1.8	234
797	Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis. Oncotarget, 2017, 8, 83637-83649.	1.8	7
798	Potential Risk Factors for Nivolumab-induced Thyroid Dysfunction. In Vivo, 2017, 31, 1225-1228.	1.3	14
799	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. Journal of Clinical Oncology, 2017, 35, 2193-2202.	1.6	209
800	Complete Serologic Response to Pembrolizumab in a Woman With Chemoresistant Metastatic Choriocarcinoma. Journal of Clinical Oncology, 2017, 35, 3172-3174.	1.6	43
801	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. Oncotarget, 2017, 8, 75675-75686.	1.8	42
802	Bistability of the cytokine-immune cell network in a cancer microenvironment. Convergent Science Physical Oncology, 2017, 3, 024002.	2.6	12

#	ARTICLE	IF	CITATIONS
803	Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. <i>Journal of Clinical Oncology</i> , 2017, 35, 139-140.	1.6	22
804	Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. <i>OncImmunology</i> , 2018, 7, e1438111.	4.6	119
805	Combined laparoscopic abdomino-endoscopic perineal total mesorectal excision for anorectal malignant melanoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2018, 44, 135-138.	0.6	4
806	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 222-234.	17.8	82
807	Higher than reported adolescent and young adult clinical trial enrollment during the "Golden Age" of melanoma clinical trials. <i>Cancer Medicine</i> , 2018, 7, 991-996.	2.8	12
808	Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance. <i>Journal of Dermatology</i> , 2018, 45, 408-415.	1.2	38
809	Cancer immunotherapy in patients with brain metastases. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 703-711.	4.2	15
810	Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 159-160.	1.2	17
811	Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand in $\Delta\gamma\Delta^{1/2}$ vitro. <i>Oncology Letters</i> , 2018, 15, 5345-5351.	1.8	10
812	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	7.0	73
813	Emerging facets in the treatment of patients with hepatopancreaticobiliary malignancies. <i>Current Problems in Cancer</i> , 2018, 42, 8-11.	2.0	0
814	Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. <i>Journal of Immunotherapy</i> , 2018, 41, 241-247.	2.4	40
815	A Dual Immunotherapy Nanoparticle Improves T Cell Activation and Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1706098.	21.0	130
816	Digital image analysis improves precision of $\langle\text{scp}\rangle\text{PD}\langle\text{scp}\rangle\text{L1}$ scoring in cutaneous melanoma. <i>Histopathology</i> , 2018, 73, 397-406.	2.9	54
817	Regulatory T cells: a potential target in cancer immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1417, 104-115.	3.8	184
818	Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. <i>Autoimmunity Reviews</i> , 2018, 17, 610-616.	5.8	91
819	Metastasis-specific patterns of response and progression with anti- $\langle\text{scp}\rangle\text{PD}\langle\text{scp}\rangle\text{L1}$ treatment in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 404-410.	3.3	34
820	MicroRNA-374b inhibits liver cancer progression via down regulating programmed cell death-1 expression on cytokine-induced killer cells. <i>Oncology Letters</i> , 2018, 15, 4797-4804.	1.8	29

#	ARTICLE	IF	CITATIONS
821	The role of neoadjuvant chemotherapy in ovarian cancer. Expert Review of Anticancer Therapy, 2018, 18, 555-566.	2.4	34
822	Role of PD-1 during effector CD8 T cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4749-4754.	7.1	327
823	Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1. Veterinary Immunology and Immunopathology, 2018, 198, 19-25.	1.2	31
825	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2467-2472.	7.1	131
826	Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Current Neurology and Neuroscience Reports, 2018, 18, 3.	4.2	83
827	Targeted cancer therapies. Journal of the American Dental Association, 2018, 149, 100-111.	1.5	12
828	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. Targeted Oncology, 2018, 13, 1-20.	3.6	31
829	Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer. Journal of Immunotherapy, 2018, 41, 201-207.	2.4	21
830	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2018, 17, 710-716.	4.1	25
831	Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies. Cell Death and Disease, 2018, 9, 112.	6.3	94
832	Clinical Development of PD-1 in Advanced Melanoma. Cancer Journal (Sudbury, Mass), 2018, 24, 7-14.	2.0	37
833	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401774974.	3.2	200
834	Role of immune-checkpoint inhibitors in lung cancer. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346581775007.	2.6	88
835	Impact of genomics on the surgical management of melanoma. British Journal of Surgery, 2018, 105, e31-e47.	0.3	3
836	The role of nivolumab in melanoma. Future Oncology, 2018, 14, 1241-1252.	2.4	12
837	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunology Research, 2018, 6, 402-408.	3.4	56
838	The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis. Journal of Immunotherapy, 2018, 41, 101-108.	2.4	57
840	M7824, a novel bifunctional anti-PD-L1/TCF β Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. OncoImmunology, 2018, 7, e1426519.	4.6	162

#	ARTICLE	IF	CITATIONS
841	The differences in the assessments of side effects at an oncology outpatient clinic. International Journal of Clinical Pharmacy, 2018, 40, 386-393.	2.1	7
842	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clinical Cancer Research, 2018, 24, 1805-1815.	7.0	45
843	Toxicities Associated With PD-1/PD-L1 Blockade. Cancer Journal (Sudbury, Mass), 2018, 24, 36-40.	2.0	72
844	Reprogramming immune proteins as therapeutics using molecular engineering. Current Opinion in Chemical Engineering, 2018, 19, 27-34.	7.8	9
845	Cancer immunotherapy: A need for peripheral immunodynamic monitoring. American Journal of Reproductive Immunology, 2018, 79, e12793.	1.2	5
846	PD1 Checkpoint Blockade in Melanoma: From Monotherapy to Combination Therapies. , 2018, , 321-331.		0
847	Immune Therapies in Phase 1 Trials. , 2018, , 547-563.		0
848	Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors. , 2018, , 565-578.		1
849	Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting. , 2018, , 579-591.		0
850	A new enzyme immunoassay for the determination of highly sialylated and fucosylated human α 1-acid glycoprotein as a biomarker of tumorigenesis. Clinica Chimica Acta, 2018, 478, 120-128.	1.1	10
851	Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. OncoImmunology, 2018, 7, e1405205.	4.6	124
852	Inhibitors of the PD-1 Pathway in Tumor Therapy. Journal of Immunology, 2018, 200, 375-383.	0.8	112
853	Multimodality imaging of endocrine immune related adverse events: a primer for radiologists. Clinical Imaging, 2018, 50, 96-103.	1.5	23
854	Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. New England Journal of Medicine, 2018, 378, 158-168.	27.0	3,047
855	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. Journal of the National Cancer Institute, 2018, 110, 777-786.	6.3	58
856	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. International Immunology, 2018, 30, 13-22.	4.0	74
857	Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. Journal of Translational Medicine, 2018, 16, 87.	4.4	35
858	Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends. Oncology Research and Treatment, 2018, 41, 286-290.	1.2	6

#	ARTICLE	IF	CITATIONS
859	Noninvasive detection of PD-L1 on circulating tumor cells in patient blood samples. <i>Future Oncology</i> , 2018, 14, 1237-1240.	2.4	5
860	Targeted polypyrrole nanoparticles for the identification and treatment of hepatocellular carcinoma. <i>Nanoscale</i> , 2018, 10, 9594-9601.	5.6	30
861	Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunities. <i>OncImmunology</i> , 2018, 7, e1466019.	4.6	4
862	CHECKPOINT INHIBITOR IMMUNE THERAPY. <i>Retina</i> , 2018, 38, 1063-1078.	1.7	252
863	Eighteen cases of mucosal malignant melanoma of the nasal/paranasal cavity at our hospital. <i>Journal of Japan Society for Head and Neck Surgery</i> , 2018, 27, 319-323.	0.0	0
864	¹⁸ F-FDG PET/CT Can Predict Development of Thyroiditis Due to Immunotherapy for Lung Cancer. <i>Journal of Nuclear Medicine Technology</i> , 2018, 46, 260-264.	0.8	40
865	Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients. <i>Oncology</i> , 2018, 94, 259-273.	1.9	15
866	Pseudoprogression and hyperprogression after checkpoint blockade. <i>International Immunopharmacology</i> , 2018, 58, 125-135.	3.8	121
867	Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma. <i>Modern Pathology</i> , 2018, 31, 1201-1210.	5.5	19
868	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. <i>Cancer Treatment Reviews</i> , 2018, 65, 78-86.	7.7	32
869	Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. <i>Journal of the Endocrine Society</i> , 2018, 2, 241-251.	0.2	146
870	The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 293-302.	2.5	16
871	Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 90-94.	1.3	8
872	PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. <i>Seminars in Cancer Biology</i> , 2018, 48, 91-103.	9.6	257
873	Tumor infiltrating lymphocytes in early breast cancer. <i>Breast</i> , 2018, 37, 207-214.	2.2	108
874	PD-1 and cancer: molecular mechanisms and polymorphisms. <i>Immunogenetics</i> , 2018, 70, 73-86.	2.4	100
875	PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. <i>Journal of Clinical Pathology</i> , 2018, 71, 46-51.	2.0	17
876	Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26837.	1.5	16

#	ARTICLE	IF	CITATIONS
877	Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 311-325.	4.2	40
878	Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 250-255.	1.2	304
879	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. <i>Investigational New Drugs</i> , 2018, 36, 601-607.	2.6	90
880	PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene. <i>Gene</i> , 2018, 638, 20-25.	2.2	87
881	Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients. <i>Journal of Dermatology</i> , 2018, 45, 3-9.	1.2	58
882	Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 74-77.	1.3	34
883	Clinical significance of programmed cell death ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. <i>International Journal of Cancer</i> , 2018, 142, 822-832.	5.1	55
884	Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study. <i>Melanoma Research</i> , 2018, 28, 56-60.	1.2	25
885	A review of immune therapy in cancer and a question: can thermal therapy increase tumor response?. <i>International Journal of Hyperthermia</i> , 2018, 34, 840-852.	2.5	24
886	The diverse functions of the PD1 inhibitory pathway. <i>Nature Reviews Immunology</i> , 2018, 18, 153-167.	22.7	1,210
887	Immune checkpoint blockade in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 91-104.	22.7	407
888	Endocrinopathies with use of cancer immunotherapies. <i>Clinical Endocrinology</i> , 2018, 88, 327-332.	2.4	20
889	Synergistic effects of interferon-beta and nivolumab in oral mucosal melanoma. <i>Journal of Dermatology</i> , 2018, 45, 87-90.	1.2	6
890	Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26719.	1.5	39
891	Cytotoxic antimelanoma drugs suppress the activation of M2 macrophages. <i>Experimental Dermatology</i> , 2018, 27, 64-70.	2.9	18
892	Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. <i>Clinical Cancer Research</i> , 2018, 24, 730-736.	7.0	16
893	Molecular Diagnosis and Targeted Therapy for Gastric Cancer. <i>Current Human Cell Research and Applications</i> , 2018, , 63-80.	0.1	0
895	Towards personalized, tumour-specific, therapeutic vaccines for cancer. <i>Nature Reviews Immunology</i> , 2018, 18, 168-182.	22.7	736

#	ARTICLE	IF	CITATIONS
896	Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors <scp>PD</scp>â€¹, <scp>TIGIT</scp>, and <scp>TIM</scp>â€³ in Lymphocytes From Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 566-577.	5.6	26
897	Current and future immunotherapies for thyroid cancer. Expert Review of Anticancer Therapy, 2018, 18, 149-159.	2.4	47
898	Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 2018, 31, 214-234.	5.5	278
899	Pneumonitis in Irradiated Lungs After Nivolumab: A Brief Communication and Review of the Literature. Journal of Immunotherapy, 2018, 41, 96-99.	2.4	23
900	Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. Cancer Immunology Research, 2018, 6, 178-188.	3.4	121
901	Liposome-based immunity-inducing systems for cancer immunotherapy. Molecular Immunology, 2018, 98, 8-12.	2.2	53
902	Immune checkpoint inhibitors: new strategies to checkmate cancer. Clinical and Experimental Immunology, 2018, 191, 133-148.	2.6	57
903	Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. Journal of Neuro-Oncology, 2018, 136, 453-461.	2.9	34
904	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. American Journal of Clinical Dermatology, 2018, 19, 303-317.	6.7	78
905	Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. International Journal of Clinical Oncology, 2018, 23, 201-234.	2.2	47
906	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646.	2.6	149
907	A novel immunization strategy using cytokine/chemokines induces new effective systemic immune responses, and frequent complete regressions of human metastatic melanoma. Oncoimmunology, 2018, 7, e1386827.	4.6	3
908	New Molecular, Biological, and Immunological Agents Inducing Hypophysitis. Neuroendocrinology, 2018, 106, 89-100.	2.5	14
909	Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer, 2018, 21, 31-40.	5.3	75
910	Downregulation of lncRNA H19 inhibits the migration and invasion of melanoma cells by inactivating the NFâ€¹B and PI3K/Akt signaling pathways. Molecular Medicine Reports, 2018, 17, 7313-7318.	2.4	34
911	Diagnosis and Management of Treatment-Related Pulmonary Complications. , 2018, , 221-241.		0
912	Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study. Oncotarget, 2018, 9, 15542-15551.	1.8	80
913	Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight, 2018, 3, .	5.0	73

#	ARTICLE	IF	CITATIONS
914	Time Is Money: Optimizing the Scheduling of Nivolumab. Journal of Clinical Oncology, 2018, 36, 3074-3076.	1.6	42
915	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. Journal of Clinical Oncology, 2018, 36, 1675-1684.	1.6	584
916	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1714-1768.	1.6	2,691
917	Combination Immunotherapy Development in Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 197-207.	3.8	39
918	Do immune checkpoint inhibitors need new studies methodology?. Journal of Thoracic Disease, 2018, 10, S1564-S1580.	1.4	58
919	Heart failure in cancer: role of checkpoint inhibitors. Journal of Thoracic Disease, 2018, 10, S4323-S4334.	1.4	15
920	SERUM CYTOKINE OF IL-2, IL-10 AND IL-12 LEVELS IN PATIENTS WITH STOMACH ADENOCARCINOMA. Arquivos De Gastroenterologia, 2018, 55, 385-389.	0.8	16
922	Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. Medicine (United States), 2018, 97, e12344.	1.0	4
923	Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma. Scientifica, 2018, 2018, 1-7.	1.7	14
924	The Modern Approach to Targeting Melanoma. , 2018, , .		2
926	Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors. Oncologist, 2018, 23, 1388-1390.	3.7	17
927	Immune Checkpoints of CD8+ T Cells in Acute Myeloid Leukemia. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2018, 12, .	0.1	0
928	Tumor Immunology: Uncovering Relationship Between Cancer and Immune System. Journal of Cancer Science & Therapy, 2018, 10, .	1.7	0
929	Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. Frontiers in Immunology, 2018, 9, 3081.	4.8	116
930	Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model. Medical Science Monitor, 2018, 24, 5501-5508.	1.1	59
931	Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha. Anticancer Research, 2018, 38, 6393-6397.	1.1	3
932	Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers. Frontiers in Oncology, 2018, 8, 513.	2.8	29
933	Combatting mucosal melanoma: recent advances and future perspectives. Melanoma Management, 2018, 5, MMT11.	0.5	75

#	ARTICLE	IF	CITATIONS
934	Minimally invasive isolated limb perfusion “ technical details and initial outcome of a new treatment method for limb malignancies. International Journal of Hyperthermia, 2018, 35, 667-673.	2.5	5
935	A meta-analysis of nivolumab for the treatment of advanced non-small-cell lung cancer. OncoTargets and Therapy, 2018, Volume 11, 7691-7697.	2.0	6
936	Multifunctional Nanoparticle Approach for Targeting Melanoma. Journal of Investigative Dermatology Symposium Proceedings, 2018, 19, S89-S90.	0.8	0
937	The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments. Journal of Immunology Research, 2018, 2018, 1-10.	2.2	26
938	Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma. Gastroenterology, 2018, 155, 1936-1950.e17.	1.3	211
939	⁶⁸ Ga-DOTA-GCNle-CycMSH _{hex} targets the melanocortin-1 receptor for melanoma imaging. Science Translational Medicine, 2018, 10, .	12.4	30
940	Effects of mir-128a on the invasion and proliferation of glioma U251 cells. Oncology Letters, 2018, 17, 891-896.	1.8	3
941	A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. , 2018, 6, 156.		58
942	Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma. Journal of Oncology, 2018, 2018, 1-9.	1.3	53
943	Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics, 2018, 8, 5690-5702.	10.0	45
944	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. Npj Breast Cancer, 2018, 4, 40.	5.2	36
945	Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. Scientific Reports, 2018, 8, 17812.	3.3	39
946	The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection”A Mini Comment on the 2018 Medicine Nobel Prize. Virologica Sinica, 2018, 33, 467-471.	3.0	9
947	Immune Checkpoint Inhibitors-Induced Hepatitis. Advances in Experimental Medicine and Biology, 2018, 995, 159-164.	1.6	26
948	Immune checkpoint inhibitors in cancer therapy. Journal of Biomedical Research, 2018, 32, 317.	1.6	101
949	Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. Frontiers in Oncology, 2018, 8, 563.	2.8	35
951	Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3. Cancers, 2018, 10, 478.	3.7	30
952	Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma. , 2018, 6, 130.		10

#	ARTICLE	IF	CITATIONS
953	Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma. <i>Thoracic Cancer</i> , 2018, 9, 1522-1524.	1.9	9
954	Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880116.	2.6	5
955	Thyroid disorders induced by checkpoint inhibitors. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 325-333.	5.7	87
957	Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 466-479.	6.1	15
958	A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. <i>Cell</i> , 2018, 175, 313-326.	28.9	985
959	Vitiligo after immune checkpoint inhibitor therapy in a woman with metastatic melanoma. <i>Journal of Cancer Research and Practice</i> , 2018, 5, 161-164.	0.2	5
960	Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Caseâ€“Control Study. <i>Cancer Immunology Research</i> , 2018, 6, 1453-1458.	3.4	35
961	Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). <i>BMC Cancer</i> , 2018, 18, 946.	2.6	32
962	Nivolumab for the treatment of hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1169-1175.	2.4	99
963	Tumor Type-Agnostic Treatment and the Future of Cancer Therapy. <i>Targeted Oncology</i> , 2018, 13, 541-544.	3.6	7
964	Checkpoint-inhibition in ovarian cancer: rising star or just a dream?. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e93.	2.2	37
965	Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression. <i>Nature Communications</i> , 2018, 9, 4297.	12.8	101
966	Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature. <i>Frontiers in Medicine</i> , 2018, 5, 268.	2.6	49
967	Immunodiagnostics and Immunotherapy Possibilities for Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1096, 185-194.	1.6	6
968	Design, Synthesis, and Characterization of Globular Orphan Nuclear Receptor Regulator with Biological Activity in Soft Tissue Sarcoma. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10739-10752.	6.4	2
969	Stereotactic Body Radiation Therapy for Spinal Malignancies. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880230.	1.9	24
970	Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes. <i>Trends in Molecular Medicine</i> , 2018, 24, 931-941.	6.7	34
971	Stromal Fibroblasts Mediate Antiâ€“PD-1 Resistance via MMP-9 and Dictate TGFÎ² Inhibitor Sequencing in Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 1459-1471.	3.4	81

#	ARTICLE	IF	CITATIONS
972	Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. <i>Onc Immunology</i> , 2018, 7, e1500107.	4.6	66
973	Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Current Rheumatology Reports</i> , 2018, 20, 65.	4.7	39
974	Immune Checkpoint Inhibition in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 310.	2.8	103
975	Impact of PD-L1, transforming growth factor- β expression and tumor-infiltrating CD8 ⁺ T cells on clinical outcome of patients with advanced thymic epithelial tumors. <i>Thoracic Cancer</i> , 2018, 9, 1341-1353.	1.9	20
976	Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy. <i>Bioscience Reports</i> , 2018, 38, .	2.4	28
977	Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy. <i>Cureus</i> , 2018, 10, e3700.	0.5	25
978	T-cell tracking using Cerenkov and radioluminescence imaging. <i>Journal of Biophotonics</i> , 2018, 11, e201800093.	2.3	13
979	Prevention and treatment of relapse after stem cell transplantation with immunotherapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 664-672.	2.4	11
980	Advances in the systemic treatment of melanoma brain metastases. <i>Annals of Oncology</i> , 2018, 29, 1509-1520.	1.2	31
981	In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma. <i>Molecular Pharmaceutics</i> , 2018, 15, 3700-3716.	4.6	79
982	Retrospective study of nivolumab for patients with recurrent high grade gliomas. <i>Journal of Neuro-Oncology</i> , 2018, 139, 625-631.	2.9	25
983	A Theoretical Basis for the Efficacy of Cancer Immunotherapy and Immunogenic Tumor Dormancy: The Adaptation Model of Immunity. <i>Advances in Cancer Research</i> , 2018, 137, 17-36.	5.0	12
984	Cutaneous toxicities of new treatments for melanoma. <i>Clinical and Translational Oncology</i> , 2018, 20, 1373-1384.	2.4	24
985	Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. <i>Vaccine</i> , 2018, 36, 3247-3253.	3.8	18
986	Are intra-pleural bacterial products associated with longer survival in adults with malignant pleural effusions? A systematic review. <i>Lung Cancer</i> , 2018, 122, 249-256.	2.0	6
987	Anti-PD-1 Therapy-Associated Perforating Colitis. <i>Case Reports in Gastrointestinal Medicine</i> , 2018, 2018, 1-3.	0.3	24
988	Antiphospholipid Antibody Induced by Nivolumab. <i>Case Reports in Hematology</i> , 2018, 2018, 1-3.	0.4	6
989	Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs. <i>Vaccines</i> , 2018, 6, 42.	4.4	8

#	ARTICLE	IF	CITATIONS
990	Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1645-1657.	4.3	19
991	Thyroid cancer phenotypes in relation to inflammation and autoimmunity. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 2267-2282.	3.0	19
992	Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. , 2018, 6, 35.		172
993	The use of SAME in chemotherapy-induced liver injury. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 70-77.	4.4	21
994	Clinical Remission of Cutaneous Squamous Cell Carcinoma of the Auricle with Cetuximab and Nivolumab. <i>Journal of Clinical Medicine</i> , 2018, 7, 10.	2.4	41
995	Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. <i>Molecular Cancer</i> , 2018, 17, 106.	19.2	46
996	Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. <i>Clinical Cancer Research</i> , 2018, 24, 5368-5380.	7.0	189
997	Combination Immunotherapy: Taking Cancer Vaccines to the Next Level. <i>Frontiers in Immunology</i> , 2018, 9, 610.	4.8	46
998	Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 1370.	4.8	49
999	Interferon Signaling Is Frequently Downregulated in Melanoma. <i>Frontiers in Immunology</i> , 2018, 9, 1414.	4.8	28
1000	Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 185.	2.8	60
1001	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. <i>Biomedicines</i> , 2018, 6, 26.	3.2	16
1002	Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2018, 10, 32.	3.7	54
1003	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 39.	3.7	44
1004	Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences. <i>Journal of Controlled Release</i> , 2018, 285, 56-66.	9.9	28
1005	Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). <i>Annals of Oncology</i> , 2018, 29, 1853-1860.	1.2	304
1006	Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1389.	4.1	77
1007	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). , 2018, 6, 63.		344

#	ARTICLE	IF	CITATIONS
1008	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1693-1698.	6.1	39
1009	Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. , 2018, 6, 22.		45
1010	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. <i>Journal of Translational Medicine</i> , 2018, 16, .	4.4	2
1011	Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. <i>JAMA Oncology</i> , 2018, 4, e180798.	7.1	86
1012	Egr2-independent, Klf1-mediated induction of PD-L1 in CD4+ T cells. <i>Scientific Reports</i> , 2018, 8, 7021.	3.3	10
1013	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. <i>Endocrine Connections</i> , 2018, 7, R196-R211.	1.9	10
1014	New Directions in the Study and Treatment of Metastatic Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 258.	2.8	14
1015	Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions. <i>Biology</i> , 2018, 7, 5.	2.8	3
1016	Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities. <i>Annals of Surgical Oncology</i> , 2018, 25, 3476-3482.	1.5	6
1017	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 1739.	4.8	174
1018	Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab. <i>Cancer Medicine</i> , 2018, 7, 4870-4879.	2.8	27
1019	Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-13.	7.7	152
1021	Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review). <i>Oncology Letters</i> , 2018, 16, 4105-4113.	1.8	58
1022	Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300-mediated NF- κ B signaling. <i>International Journal of Oncology</i> , 2018, 53, 1469-1480.	3.3	63
1023	Craniopharyngioma: a roadmap for scientific translation. <i>Neurosurgical Focus</i> , 2018, 44, E12.	2.3	26
1024	Safety of combining radiotherapy with immune-checkpoint inhibition. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 477-494.	27.6	208
1025	Surgery for Stage IV Metastatic Melanoma. , 2018, , 467-481.		1
1026	Current Immunotherapy of Melanoma. , 2018, , 567-576.		0

#	ARTICLE	IF	CITATIONS
1027	Immune-Related Adverse Toxicities and Clinical Management. , 2018, , 577-589.		0
1028	Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. Journal of Neuro-Oncology, 2018, 140, 55-62.	2.9	25
1029	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. Clinical Pharmacology and Therapeutics, 2019, 105, 582-597.	4.7	8
1030	Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrology Dialysis Transplantation, 2019, 34, 108-117.	0.7	137
1031	Nivolumab-induced thyroid dysfunction in patients with lung cancer. Endocrinologia, Diabetes Y Nutrici3n, 2019, 66, 26-34.	0.3	17
1032	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treatment Reviews, 2019, 74, 49-60.	7.7	38
1033	Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors. Oncologist, 2019, 24, 86-95.	3.7	11
1034	Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab. Journal of Oncology Pharmacy Practice, 2019, 25, 1261-1264.	0.9	1
1035	Medication use evaluation of programmed death-1 inhibitors in a veteran population. Journal of Oncology Pharmacy Practice, 2019, 25, 1066-1075.	0.9	1
1036	Oral Mucosal Injury Caused by Targeted Cancer Therapies. Journal of the National Cancer Institute Monographs, 2019, 2019, .	2.1	14
1037	Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. Journal of Autoimmunity, 2019, 104, 102310.	6.5	57
1038	A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. Case Reports in Oncological Medicine, 2019, 2019, 1-6.	0.3	8
1039	On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment. Chemotherapy, 2019, 64, 62-80.	1.6	34
1040	TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2. Frontiers in Immunology, 2019, 10, 1644.	4.8	24
1041	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiation Oncology, 2019, 14, 141.	2.7	285
1042	Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. Head and Neck, 2019, 41, 4036-4050.	2.0	3
1043	Immune microenvironment modulation unmask therapeutic benefit of radiotherapy and checkpoint inhibition. , 2019, 7, 216.		56
1044	PD-L1 Distribution and Perspective for Cancer Immunotherapy's Blockade, Knockdown, or Inhibition. Frontiers in Immunology, 2019, 10, 2022.	4.8	270

#	ARTICLE	IF	CITATIONS
1045	Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1767.	4.8	44
1046	Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?. <i>Journal of Global Oncology</i> , 2019, 5, 1-5.	0.5	36
1047	Pseudoprogression: an indicator for cure in combined immunotherapy?. <i>Immunotherapy</i> , 2019, 11, 1087-1093.	2.0	6
1048	Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. <i>ESMO Open</i> , 2019, 4, e000464.	4.5	21
1049	Usefulness of the nCounter Analysis System to Monitor Immune-related Biomarkers in PBMCs During Anti-PD-1 Therapy. <i>Anticancer Research</i> , 2019, 39, 4517-4523.	1.1	1
1050	Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice. <i>Immunology</i> , 2019, 158, 35-46.	4.4	32
1051	Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus. <i>Oncology Letters</i> , 2019, 18, 1872-1880.	1.8	12
1052	Novel Delivery Systems for Checkpoint Inhibitors. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 74.	1.4	24
1053	Invasive fungal infections in the immunocompromised host: Mechanistic insights in an era of changing immunotherapeutics. <i>Medical Mycology</i> , 2019, 57, S307-S317.	0.7	23
1054	Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019, 9, 530.	2.8	31
1055	Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. , 2019, 7, 165.		135
1056	Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. <i>Cancer Medicine</i> , 2019, 8, 4986-4999.	2.8	27
1057	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019, 5, 1411.	7.1	388
1058	Low Expression of miR-424-3p is Highly Correlated with Clinical Failure in Prostate Cancer. <i>Scientific Reports</i> , 2019, 9, 10662.	3.3	32
1059	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. <i>Current Oncology Reports</i> , 2019, 21, 76.	4.0	18
1060	Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma. <i>British Journal of Cancer</i> , 2019, 121, 417-420.	6.4	24
1061	Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials?. <i>Journal of Clinical Oncology</i> , 2019, 37, 2587-2591.	1.6	8
1062	Immunotherapy Toxicities. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 387-401.	1.5	10

#	ARTICLE	IF	CITATIONS
1063	Application of immune repertoire sequencing in cancer immunotherapy. International Immunopharmacology, 2019, 74, 105688.	3.8	7
1064	First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors. OncoImmunology, 2019, 8, e1665977.	4.6	21
1065	Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment. Biomedicines, 2019, 7, 80.	3.2	0
1066	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 1747-1757.	4.2	16
1067	Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. Melanoma Management, 2019, 6, MMT20.	0.5	9
1068	Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. Cancer Medicine, 2019, 8, 6585-6594.	2.8	31
1069	Surgery for Metastatic Melanoma: an Evolving Concept. Current Oncology Reports, 2019, 21, 98.	4.0	11
1070	Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 1033.	2.8	15
1071	Secondary resistance to immunotherapy associated with β -catenin pathway activation or PTEN loss in metastatic melanoma. , 2019, 7, 295.		98
1072	Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics, 2019, 9, 7906-7923.	10.0	100
1073	Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized β -Melanocyte-Stimulating Hormone Peptide. Cancer Biotherapy and Radiopharmaceuticals, 2019, 34, 597-603.	1.0	11
1074	PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms. Journal of Clinical Medicine, 2019, 8, 1833.	2.4	19
1075	Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer, 2019, 19, 974.	2.6	104
1076	Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. Vaccines, 2019, 7, 100.	4.4	30
1077	Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1. Kidney International Reports, 2019, 4, 1152-1160.	0.8	44
1078	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16
1079	Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. , 2019, 7, 227.		58
1080	Programmed Death-Ligand-1 Expression in Non-Small Cell Lung Cancer and Prognosis. Balkan Medical Journal, 2019, 36, 184-189.	0.8	7

#	ARTICLE	IF	CITATIONS
1081	Cancer immunotherapy and its renal effects. <i>Journal of Onco-Nephrology</i> , 2019, 3, 151-159.	0.6	3
1082	Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 1574-1579.	3.4	33
1083	Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC. <i>Russian Journal of Bioorganic Chemistry</i> , 2019, 45, 225-240.	1.0	6
1084	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. <i>Journal of Clinical Investigation</i> , 2019, 129, 2056-2070.	8.2	159
1085	Glycan-Modified Melanoma-Derived Apoptotic Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination. <i>Cancers</i> , 2019, 11, 1266.	3.7	47
1086	Postoperative Development of Polymyalgia Rheumatica Due to Nivolumab Administration in a Patient with Recurrent Anorectal Malignant Melanoma. <i>Japanese Journal of Gastroenterological Surgery</i> , 2019, 52, 327-335.	0.1	1
1087	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. <i>Frontiers in Immunology</i> , 2019, 10, 2109.	4.8	32
1088	Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation. , 0, , .		7
1089	Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. , 2019, 7, 254.		14
1090	Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 857.	2.8	12
1091	Transperineal abdominoperineal resection for anorectal melanoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2019, 61, 214-217.	0.6	1
1092	Germline genetic host factors as predictive biomarkers in immuno-oncology. <i>Immuno-Oncology Technology</i> , 2019, 2, 14-21.	0.3	2
1093	Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. <i>Nature Protocols</i> , 2019, 14, 2900-2930.	12.0	92
1094	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	2.4	41
1095	Programmed death-ligand 1 and survival in colorectal cancers: A meta-analysis. <i>International Journal of Biological Markers</i> , 2019, 34, 356-363.	1.8	8
1096	Current Perspectives in Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1472.	3.7	149
1097	Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 835.	2.8	32
1098	Immune-Related Adverse Events of Immune Checkpoint Inhibitorsâ€”From a Clinical to Pathophysiological Viewâ€”In Reply. <i>JAMA Oncology</i> , 2019, 5, 1805.	7.1	5

#	ARTICLE	IF	CITATIONS
1099	Radiosurgery and Immunotherapy in the Treatment of Brain Metastases. <i>World Neurosurgery</i> , 2019, 130, 615-622.	1.3	13
1100	Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human <i>PD-1xLAG-3</i>“Knockin Mice. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2051-2062.	4.1	48
1101	Role of evaluating tumorâ€infiltrating lymphocytes, programmed deathâ€1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. <i>International Journal of Oncology</i> , 2019, 55, 1157-1164.	3.3	13
1102	Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART. <i>PLoS ONE</i> , 2019, 14, e0211112.	2.5	16
1103	Immune therapy of melanoma: Overview of therapeutic vaccines. <i>Journal of Cellular Physiology</i> , 2019, 234, 14612-14621.	4.1	25
1104	Immunotherapy Toxicity. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 275-290.	2.2	23
1105	Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e454-e460.	1.9	14
1106	CITR ligation enhances functionality of tumorâ€infiltrating T cells in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 1111-1124.	5.1	42
1107	Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. <i>Annals of Oncology</i> , 2019, 30, 582-588.	1.2	641
1108	Regulatory T Cells and Their Clinical Applications in Antitumor Immunotherapy. <i>Engineering</i> , 2019, 5, 132-139.	6.7	4
1109	Early-phase clinical drug development of novel agents: a changing paradigm. <i>Annals of Oncology</i> , 2019, 30, 1033-1037.	1.2	5
1110	<p>Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3671-3682.	2.0	40
1111	Recent advances in the clinical development of immune checkpoint blockade therapy. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 609-626.	4.4	76
1112	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. <i>Frontiers in Immunology</i> , 2019, 10, 1181.	4.8	20
1113	Management of metastatic cutaneous melanoma: updates in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985166.	3.2	29
1114	Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 1208-1227.	9.4	81
1115	Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1171-1178.	4.2	48
1116	The 100 top-cited studies in cancer immunotherapy. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 2282-2292.	2.8	26

#	ARTICLE	IF	CITATIONS
1117	Pharmacoeugenetics of Acute Myeloid Leukemia. , 2019, , 541-549.		0
1118	Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study. JAMA Oncology, 2019, 5, 1332.	7.1	153
1119	Cardiotoxicity of Immune Checkpoint Inhibitors. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 32.	0.9	42
1120	Long-Term Outcomes of Carbon-Ion Radiotherapy for Malignant Gynecological Melanoma. Cancers, 2019, 11, 482.	3.7	13
1121	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. International Journal of Molecular Sciences, 2019, 20, 2560.	4.1	72
1122	Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. Journal of Hematology and Oncology, 2019, 12, 54.	17.0	416
1123	Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chemical Society Reviews, 2019, 48, 3771-3810.	38.1	292
1124	Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer, 2019, 19, 558.	2.6	106
1125	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. Frontiers in Medicine, 2019, 6, 119.	2.6	145
1126	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacological Research, 2019, 145, 104258.	7.1	115
1127	Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors. Oncologist, 2019, 24, 640-647.	3.7	32
1128	Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. , 2019, 7, 119.		35
1129	Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCR β diversity. Cancer Immunology, Immunotherapy, 2019, 68, 1095-1106.	4.2	5
1130	Immunophenotype of T Cells Expressing Programmed Death-1 and Cytotoxic T Cell Antigen-4 in Early Lung Cancer: Local vs. Systemic Immune Response. Cancers, 2019, 11, 567.	3.7	17
1131	Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2019, 138, 178-189.	4.4	31
1132	Can CpG methylation serve as surrogate markers for immune infiltration in cancer?. Advances in Cancer Research, 2019, 143, 351-384.	5.0	19
1133	Nivolumab-induced thyroid dysfunction in patients with lung cancer. Endocrinology & Diabetes Y Nutrition (English Ed), 2019, 66, 26-34.	0.2	1
1134	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. JAMA Oncology, 2019, 5, 1008.	7.1	526

#	ARTICLE	IF	CITATIONS
1135	The nephrotoxicity of new immunotherapies. Expert Review of Clinical Pharmacology, 2019, 12, 513-521.	3.1	12
1136	Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. Journal of Experimental and Clinical Cancer Research, 2019, 38, 162.	8.6	116
1137	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Frontiers in Immunology, 2019, 10, 453.	4.8	177
1138	Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy. , 2019, 7, 82.		76
1139	PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma. Clinical Cancer Research, 2019, 25, 3443-3454.	7.0	24
1140	Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma. Journal of Cellular Physiology, 2019, 234, 17975-17989.	4.1	20
1141	Modulation of immune checkpoint molecule expression in mantle cell lymphoma. Leukemia and Lymphoma, 2019, 60, 2498-2507.	1.3	21
1142	Divergent <scp>SATB</scp>1 expression across human life span and tissue compartments. Immunology and Cell Biology, 2019, 97, 498-511.	2.3	20
1143	Targeting immune cells for cancer therapy. Redox Biology, 2019, 25, 101174.	9.0	151
1144	A Dualâ€Bioresponsive Drugâ€Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade. Advanced Materials, 2019, 31, e1806957.	21.0	145
1145	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Hormone and Metabolic Research, 2019, 51, 145-156.	1.5	234
1146	<p>Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis</p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 293-302.	2.0	27
1147	Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses. Stem Cells, 2019, 37, 716-723.	3.2	25
1148	Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. Anticancer Research, 2019, 39, 1749-1760.	1.1	30
1149	FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway. Journal of Immunology, 2019, 202, 3065-3075.	0.8	111
1150	Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1651-1660.	2.5	31
1151	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Annals of Oncology, 2019, 30, 1154-1161.	1.2	170
1152	Ocular Complications of Targeted Therapy. , 2019, , 143-159.		0

#	ARTICLE	IF	CITATIONS
1153	Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma. Clinical Cancer Research, 2019, 25, 4530-4541.	7.0	69
1154	Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy. Nano Letters, 2019, 19, 2774-2783.	9.1	155
1155	Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell, 2019, 177, 556-571.e16.	28.9	405
1156	Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. Journal of Dermatology, 2019, 46, 498-506.	1.2	13
1157	Prospective validation of the prognostic 31â€ gene expression profiling test in primary cutaneous melanoma. Cancer Medicine, 2019, 8, 2205-2212.	2.8	58
1158	Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. Journal of Clinical Oncology, 2019, 37, 52-60.	1.6	218
1159	Bevacizumab as a steroidâ€sparing agent during immunotherapy for melanoma brain metastases: A case series. Health Science Reports, 2019, 2, e115.	1.5	29
1160	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. Advanced Healthcare Materials, 2019, 8, e1801320.	7.6	43
1161	Late-onset isolated adrenocorticotrophic hormone deficiency caused by nivolumab: a case report. BMC Endocrine Disorders, 2019, 19, 25.	2.2	27
1162	<p>Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis</p>. Drug Design, Development and Therapy, 2019, Volume 13, 523-538.	4.3	23
1163	Emerging Nanoâ€Microapproaches for Cancer Immunotherapy. Advanced Science, 2019, 6, 1801847.	11.2	136
1164	Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. , 2019, 7, 37.		123
1165	Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. Oncologist, 2019, 24, 549-554.	3.7	105
1166	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. Current Problems in Cancer, 2019, 43, 487-494.	2.0	9
1167	Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature. Internal Medicine, 2019, 58, 1747-1752.	0.7	23
1168	Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clinical Pharmacokinetics, 2019, 58, 835-857.	3.5	222
1169	PDâ€1/PDâ€L1 pathway: Basic biology and role in cancer immunotherapy. Journal of Cellular Physiology, 2019, 234, 16824-16837.	4.1	279
1170	Computational Analysis of Epigenetic Modifications in Melanoma. , 2019, , 327-342.		1

#	ARTICLE	IF	CITATIONS
1171	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102
1172	Late-onset Stevensâ€“Johnson syndrome due to nivolumab use for hepatocellular carcinoma. Journal of Oncology Pharmacy Practice, 2019, 25, 2052-2055.	0.9	31
1173	Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting. Molecular Pharmaceutics, 2019, 16, 1694-1702.	4.6	26
1174	Treatment in metastatic melanomaâ€”time to re-think. Annals of Oncology, 2019, 30, 501-503.	1.2	8
1175	Immunotherapy for Treatment of Cancer. , 2019, , .		4
1177	Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment. Frontiers in Pharmacology, 2019, 10, 1456.	3.5	16
1178	Toxicity of tumor immune checkpoint inhibitorsâ€”more attention should be paid. Translational Lung Cancer Research, 2019, 8, 1125-1133.	2.8	7
1179	Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. Seminars in Oncology, 2019, 46, 397-402.	2.2	16
1180	20 Carcinoma of the Nasal Cavity and Anterior Skull Base. , 2019, , .		0
1181	Atypisches Ansprechen mit Pseudoprogression im Knochen unter Nivolumab bei einem Patienten mit fortgeschrittenem kutanem Plattenepithelkarzinom. Karger Kompass Dermatologie, 2019, 7, 149-153.	0.0	0
1182	Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer. Medicine (United States), 2019, 98, e18310.	1.0	2
1183	Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor. Scientific Reports, 2019, 9, 17830.	3.3	13
1184	Durvalumab for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2019, 19, 1009-1016.	2.4	20
1185	Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage (â€œSEEâ€) Signal to Facilitate the Elimination of â€œCold, Non-Responsiveâ€ Low PD-L1-Expressing Tumors by PD-L1 Blockade. International Journal of Molecular Sciences, 2019, 20, 5969.	4.1	9
1186	Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient. , 2019, 7, 336.		21
1187	Reprioritizing Risk and Benefit: The Future of Study Design in Earlyâ€Phase Cancer Research. Ethics & Human Research, 2019, 41, 2-11.	0.9	8
1188	Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma. Journal of Cancer, 2019, 10, 6114-6123.	2.5	3
1189	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. Journal of Biomedical Science, 2019, 26, 96.	7.0	26

#	ARTICLE	IF	CITATIONS
1190	Adjuvant systemic therapy in high-risk melanoma. <i>Melanoma Research</i> , 2019, 29, 358-364.	1.2	16
1191	Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. <i>Current Opinion in Neurology</i> , 2019, 32, 500-510.	3.6	57
1192	Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma. <i>Journal of Immunotherapy</i> , 2019, 42, 321-330.	2.4	31
1193	Tumour flare reaction in cancer treatments. <i>Anti-Cancer Drugs</i> , 2019, 30, 953-958.	1.4	17
1194	Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review. <i>Melanoma Research</i> , 2019, 29, 212-215.	1.2	37
1195	Photosensitive Eruption in a Patient With Metastatic Non-Small Cell Lung Cancer: Answer. <i>American Journal of Dermatopathology</i> , 2019, 41, 528-529.	0.6	2
1196	Effect and changes in PD-1 expression of CD19 CAR-T cells from T cells highly expressing PD-1 combined with reduced-dose PD-1 inhibitor. <i>Oncology Reports</i> , 2019, 41, 3455-3463.	2.6	15
1198	Predictive potential and need for standardization of PD-L1 immunohistochemistry. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 475-484.	2.8	32
1199	Toxicities in Immune Checkpoint Inhibitors. , 2019, , 205-226.		2
1200	The applications of anti-CD20 antibodies to treat various B cells disorders. <i>Biomedicine and Pharmacotherapy</i> , 2019, 109, 2415-2426.	5.6	43
1201	Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. <i>European Journal of Cancer</i> , 2019, 107, 1-7.	2.8	48
1202	Promising immunotherapy: Highlighting cytokine-induced killer cells. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 8863-8883.	2.6	11
1203	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 142-151.	0.8	118
1204	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 199-224.	7.4	53
1205	Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy. <i>Laboratory Investigation</i> , 2019, 99, 1400-1413.	3.7	18
1206	T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. <i>Modern Pathology</i> , 2019, 32, 576-584.	5.5	29
1207	Advanced stage melanoma therapies: Detailing the present and exploring the future. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 99-111.	4.4	48
1208	Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1557-1563.	7.0	249

#	ARTICLE	IF	CITATIONS
1209	Recent Advances in Anti-cancer Protein/Peptide Delivery. <i>Bioconjugate Chemistry</i> , 2019, 30, 305-324.	3.6	113
1210	Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2019, 293, 104-112.	9.9	51
1211	Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 12-23.	2.8	171
1212	Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 7.	17.0	113
1213	Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma. <i>Cancer Letters</i> , 2019, 446, 25-37.	7.2	28
1214	Delivery technologies for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 175-196.	46.4	1,562
1215	T-cell receptor gene-modified cells: past promises, present methodologies and future challenges. <i>Cytotherapy</i> , 2019, 21, 341-357.	0.7	10
1216	PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers. <i>Human Pathology</i> , 2019, 86, 108-114.	2.0	20
1217	Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. <i>Oncolmunology</i> , 2019, 8, e1539614.	4.6	17
1218	Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. <i>Cancer</i> , 2019, 125, 278-289.	4.1	24
1219	Melanoma: Where we are and where we go. <i>Journal of Cellular Physiology</i> , 2019, 234, 3307-3320.	4.1	53
1220	Early PD-1 Therapy Discontinuation in Responding Metastatic Cancer Patients. <i>Oncology</i> , 2019, 96, 125-131.	1.9	22
1221	The Human Papillomavirus as a Common Pathogen in Oropharyngeal, Anal and Cervical Cancers. <i>Clinical Oncology</i> , 2019, 31, 81-90.	1.4	30
1222	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. <i>Oncolmunology</i> , 2019, 8, e1537581.	4.6	61
1223	Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. <i>Seminars in Immunopathology</i> , 2019, 41, 21-30.	6.1	49
1224	Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 253-259.	2.5	44
1225	Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma. <i>Oncolmunology</i> , 2019, 8, e1507669.	4.6	41
1226	Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma. <i>Journal of Dermatological Science</i> , 2019, 93, 33-40.	1.9	15

#	ARTICLE	IF	CITATIONS
1227	The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 53-68.	3.4	6
1228	Regression of multiple melanocytic nevi associated with nivolumab treatment for metastatic melanoma. <i>International Journal of Dermatology</i> , 2019, 58, 1331-1333.	1.0	2
1229	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. <i>BJU International</i> , 2019, 123, 947-958.	2.5	9
1230	Cancer Immunotherapy: The Dawn of Antibody Cocktails. <i>Methods in Molecular Biology</i> , 2019, 1904, 11-51.	0.9	25
1231	Rational combination immunotherapeutic approaches for effective cancer treatment. <i>Journal of Controlled Release</i> , 2019, 294, 114-130.	9.9	28
1232	Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles. <i>Oncogene</i> , 2019, 38, 2380-2393.	5.9	178
1233	The use of cytological material in melanoma for programmed death ligand 1 immunostaining. <i>Cytopathology</i> , 2019, 30, 61-67.	0.7	5
1234	Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 53-62.	3.0	7
1235	Immunotherapy-induced autoimmune hypophysitis. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 217-220.	0.9	10
1236	Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. <i>Journal of Drug Targeting</i> , 2019, 27, 244-256.	4.4	86
1237	Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1508-1514.	2.2	13
1238	Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 762-764.	0.9	27
1239	Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis. <i>Seminars in Cancer Biology</i> , 2020, 64, 29-35.	9.6	76
1240	Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. <i>Immunology Letters</i> , 2020, 220, 88-96.	2.5	23
1241	The Immune Microenvironment and Cancer Metastasis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a037424.	6.2	57
1242	¹⁸ F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 178-184.	6.4	11
1243	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. <i>Annals of Emergency Medicine</i> , 2020, 75, 264-286.	0.6	3
1244	Histologic patterns of liver injury induced by anti-PD-1 therapy. <i>Gastroenterology Report</i> , 2020, 8, 50-55.	1.3	24

#	ARTICLE	IF	CITATIONS
1245	Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients. Digestive Endoscopy, 2020, 32, 616-620.	2.3	19
1246	Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patients. Journal of Oncology Pharmacy Practice, 2020, 26, 761-767.	0.9	12
1247	Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases. Modern Pathology, 2020, 33, 138-152.	5.5	12
1248	Nivolumab-induced lichen planus. Journal of Oncology Pharmacy Practice, 2020, 26, 758-760.	0.9	13
1249	Evidence and impact of neutrophil extracellular traps in malignant melanoma. Pigment Cell and Melanoma Research, 2020, 33, 63-73.	3.3	62
1250	Immunotherapy-induced severe neutropenia with neurotoxicity: A case of a 75-year-old woman with ulcerative colitis diagnosed with melanoma. Journal of Oncology Pharmacy Practice, 2020, 26, 730-734.	0.9	6
1251	Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic. Journal of Oncology Pharmacy Practice, 2020, 26, 595-602.	0.9	5
1252	Quantitative evaluation of tumor-specific T cells in tumors and lymphoid tissues. Methods in Enzymology, 2020, 635, 149-166.	1.0	4
1253	Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?. Kidney International, 2020, 97, 62-74.	5.2	121
1254	Current Development of Monoclonal Antibodies in Cancer Therapy. Recent Results in Cancer Research, 2020, 214, 1-70.	1.8	16
1255	Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy. Advances in Biological Regulation, 2020, 75, 100663.	2.3	12
1256	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. Journal of Cancer, 2020, 11, 41-50.	2.5	3
1257	Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology, 2020, 159, 167-177.	4.4	75
1258	Supersonic aerodynamic piezoelectric energy harvesting performance of functionally graded beams. Composite Structures, 2020, 233, 111537.	5.8	21
1259	Stromal PD-1+ tumor-associated macrophages predict poor prognosis in lung adenocarcinoma. Human Pathology, 2020, 97, 68-79.	2.0	22
1260	The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals. Journal of Biological Chemistry, 2020, 295, 4372-4380.	3.4	56
1261	Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies. Journal of Theoretical Biology, 2020, 488, 110136.	1.7	4
1262	Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment. Acta Radiologica, 2020, 61, 983-991.	1.1	9

#	ARTICLE	IF	CITATIONS
1263	The non-responding adrenal metastasis in melanoma: The case for minimally invasive adrenalectomy in the age of modern therapies. American Journal of Surgery, 2020, 220, 349-353.	1.8	8
1264	The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer. Expert Review of Respiratory Medicine, 2020, 14, 137-147.	2.5	6
1265	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. Cellular and Molecular Immunology, 2020, 17, 13-26.	10.5	76
1266	Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer. Critical Care Medicine, 2020, 48, 10-21.	0.9	42
1267	Nivolumab-induced small bowel obstruction and perforation: a rare but life-threatening side effect of immunotherapy. Emergency Radiology, 2020, 27, 107-110.	1.8	8
1268	Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs. Pathology and Oncology Research, 2020, 26, 651-663.	1.9	18
1269	Evaluation of the Metastatic Spine Disease Multidisciplinary Working Group Algorithms as Part of a Multidisciplinary Spine Tumor Conference. Global Spine Journal, 2020, 10, 888-895.	2.3	1
1270	Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer. , 2020, 8, e000889.		29
1271	<p>>Application and Prospects of Molecular Imaging in Immunotherapy</p>>. Cancer Management and Research, 2020, Volume 12, 9389-9403.	1.9	8
1272	Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8+ T cells in liver cancer. Cancer Letters, 2020, 495, 1-11.	7.2	13
1273	Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model. Frontiers in Oncology, 2020, 10, 1771.	2.8	7
1274	From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. Cancers, 2020, 12, 3057.	3.7	50
1275	Primary esophageal malignant melanoma successfully treated with anti-PD-1 antibody for retroperitoneal recurrence after esophagectomy: A case report. International Journal of Surgery Case Reports, 2020, 75, 152-156.	0.6	5
1276	Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer, 2020, 9, 596-612.	7.7	10
1277	Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma. Current Medical Research and Opinion, 2020, 36, 1813-1823.	1.9	0
1278	The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients. Medicine (United States), 2020, 99, e22567.	1.0	5
1280	Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. Communications Biology, 2020, 3, 571.	4.4	31
1281	A low-intensity focused ultrasound-assisted nanocomposite for advanced triple cancer therapy: local chemotherapy, therapeutic extracellular vesicles and combined immunotherapy. Biomaterials Science, 2020, 8, 6703-6717.	5.4	16

#	ARTICLE	IF	CITATIONS
1282	Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. <i>Melanoma Research</i> , 2020, 30, 364-375.	1.2	42
1283	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. , 2020, 8, e000648.		15
1284	Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. <i>Science Immunology</i> , 2020, 5, .	11.9	36
1285	Therapy preferences in melanoma treatmentâ€”Willingness to pay and preference of quality versus length of life of patients, physicians, healthy individuals and physicians with oncological disease. <i>Cancer Medicine</i> , 2020, 9, 6132-6140.	2.8	12
1286	Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 270.	17.1	18
1287	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (donâ€™t) know. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 236.	8.6	44
1288	PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. , 2020, 8, e001631.		44
1289	Effects of Tussilago farfara L. Polysaccharides on the Expression of PD-1 (CD279) and PD-L1 (CD274) in Peripheral Blood and Tumor Tissue Lymphocytes in Mice with Lewis Lung Carcinoma. <i>Bulletin of Experimental Biology and Medicine</i> , 2020, 169, 378-382.	0.8	5
1290	<p>Tumor-Associated CD163<sup>+</sup> M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer<p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5831-5843.	1.9	8
1291	Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 798.e17-798.e24.	1.6	6
1292	Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. <i>Radiology</i> , 2020, 297, 87-96.	7.3	70
1293	Immune-Checkpoint Blockade Therapy in Lymphoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5456.	4.1	24
1294	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	6.5	37
1295	Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling. <i>Cell Death and Disease</i> , 2020, 11, 575.	6.3	41
1296	Nivolumab-Induced Autoimmune-Like Cholestatic Hepatitis in a Liver Transplant Recipient. <i>ACG Case Reports Journal</i> , 2020, 7, e00416.	0.4	17
1297	Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A realâ€world pharmacoepidemiology study of postâ€marketing surveillance data. <i>Cancer Medicine</i> , 2020, 9, 6576-6585.	2.8	21
1298	A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy. <i>Frontiers in Endocrinology</i> , 2020, 11, 471.	3.5	5
1299	Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093761.	3.2	78

#	ARTICLE	IF	CITATIONS
1300	Progress in Neoantigen Targeted Cancer Immunotherapies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 728.	3.7	28
1301	The Potential of Five Immune-Related Prognostic Genes to Predict Survival and Response to Immune Checkpoint Inhibitors for Soft Tissue Sarcomas Based on Multi-Omic Study. <i>Frontiers in Oncology</i> , 2020, 10, 1317.	2.8	18
1302	Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis. <i>Cancers</i> , 2020, 12, 2085.	3.7	17
1303	A brief review concerning Chimeric Antigen Receptors T cell therapy. <i>Journal of Cancer</i> , 2020, 11, 5424-5431.	2.5	4
1304	Novel [99mTc]-Tricarboxyl-NOTA-Conjugated Lactam-Cyclized Alpha-MSH Peptide with Enhanced Melanoma Uptake and Reduced Renal Uptake. <i>Molecular Pharmaceutics</i> , 2020, 17, 3581-3588.	4.6	14
1305	The role of gut microbiota in cancer treatment: friend or foe?. <i>Gut</i> , 2020, 69, 1867-1876.	12.1	189
1306	Atypical patterns of response and progression in the era of immunotherapy combinations. <i>Future Oncology</i> , 2020, 16, 1707-1713.	2.4	11
1307	Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2020, 10, 1061.	4.0	59
1308	A case of multiple metastatic gastric cancer with primary lesion vanished after administrating nivolumab, and the effect remains even after discontinuance of therapy. <i>International Cancer Conference Journal</i> , 2020, 9, 187-192.	0.5	6
1309	Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e160-e178.	1.1	6
1310	Management of Immune-Related Cutaneous Adverse Reactions to PD-1 and PD-L1 Inhibitors for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 2020, 9, 231-243.	2.1	4
1311	The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies. <i>Frontiers in Oncology</i> , 2020, 10, 546604.	2.8	15
1312	Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. <i>Journal of Cancer</i> , 2020, 11, 7001-7008.	2.5	17
1313	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	2.4	7
1314	The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6866.	4.1	20
1315	Design for immuno-oncology clinical trials enrolling both responders and nonresponders. <i>Statistics in Medicine</i> , 2020, 39, 3914-3936.	1.6	2
1316	Retrospective Multicenter Analysis of the Outcome of a Re-Induction with Immune Checkpoint Inhibitors in Advanced Merkel Cell Carcinoma. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2202-2207.	0.6	6
1317	Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review. <i>Thoracic Cancer</i> , 2020, 11, 3001-3006.	1.9	5

#	ARTICLE	IF	CITATIONS
1318	Interventional Pharmacoeconomics. Cancer Journal (Sudbury, Mass), 2020, 26, 330-334.	2.0	8
1319	Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy. Light: Science and Applications, 2020, 9, 161.	16.6	145
1320	Radiological imaging features of the salivary glands in xerostomia induced by an immune checkpoint inhibitor. Oral Radiology, 2021, 37, 531-536.	1.9	1
1321	A rare case of immunotherapy-induced cholangitis and gastritis. Clinical Journal of Gastroenterology, 2020, 13, 1083-1090.	0.8	11
1322	CAR T Cell Therapy for Pediatric Brain Tumors. Frontiers in Oncology, 2020, 10, 1582.	2.8	37
1323	<p></p>A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies</p>. Cancer Management and Research, 2020, Volume 12, 6493-6509.	1.9	19
1324	Development of Mannose-Modified Carboxylated Curdlan-Coated Liposomes for Antigen Presenting Cell Targeted Antigen Delivery. Pharmaceutics, 2020, 12, 754.	4.5	12
1326	Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patientsâ€”Literature Review. Cancers, 2020, 12, 2314.	3.7	13
1327	Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000â€”2016. Cancers, 2020, 12, 2354.	3.7	8
1328	Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkinâ€™s lymphoma. Journal of Oncology Pharmacy Practice, 2020, 27, 107815522097679.	0.9	6
1329	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapiesâ€”Beyond BRAF Mutant Detection. Cancers, 2020, 12, 3793.	3.7	12
1330	Breast Cancer During Pregnancy: A Marked Propensity to Triple-Negative Phenotype. Frontiers in Oncology, 2020, 10, 580345.	2.8	13
1331	Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors. Journal of Immunology Research, 2020, 2020, 1-12.	2.2	13
1332	Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma. International Immunopharmacology, 2020, 89, 107162.	3.8	12
1333	Panuveitis in patient on ipilimumab/nivolumab combination for small-cell lung cancer treated with an intravitreal dexamethasone implant. Journal of Oncology Pharmacy Practice, 2020, 27, 107815522096979.	0.9	5
1334	Future of immune checkpoint inhibitors: focus on tumor immune microenvironment. Annals of Translational Medicine, 2020, 8, 1095-1095.	1.7	27
1335	Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation. Oncoimmunology, 2020, 9, 1737385.	4.6	23
1336	A Case of Nivolumab-Induced Cutaneous Toxicity with Multiple Morphologies. Dermatopathology (Basel, Switzerland), 2019, 6, 255-259.	1.5	9

#	ARTICLE	IF	CITATIONS
1337	Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 653-659.	2.4	7
1338	A Combination of Cowpea Mosaic Virus and Immune Checkpoint Therapy Synergistically Improves Therapeutic Efficacy in Three Tumor Models. Advanced Functional Materials, 2020, 30, 2002299.	14.9	37
1339	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clinical Cancer Research, 2020, 26, 1141-1151.	7.0	43
1340	Current Molecular Markers of Melanoma and Treatment Targets. International Journal of Molecular Sciences, 2020, 21, 3535.	4.1	45
1341	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. Cancers, 2020, 12, 1176.	3.7	11
1342	Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. BioDrugs, 2020, 34, 463-476.	4.6	49
1343	Review of gynaecological malignant melanomas. The Obstetrician and Gynaecologist, 2020, 22, 199-207.	0.4	0
1344	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. Cancers, 2020, 12, 1153.	3.7	4
1345	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients â€” A Potential Paradigm Shift in Management. Annals of Surgical Oncology, 2020, 27, 2188-2200.	1.5	4
1346	Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma. Future Oncology, 2020, 16, 1441-1453.	2.4	7
1347	The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. Frontiers in Immunology, 2020, 11, 940.	4.8	423
1348	Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy. Biochemical and Biophysical Research Communications, 2020, 527, 226-231.	2.1	21
1349	Immune checkpoint inhibitorâ€”related dermatologic adverse events. Journal of the American Academy of Dermatology, 2020, 83, 1255-1268.	1.2	221
1350	Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy. , 2020, 8, e000898.		3
1351	A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 4511-4520.	7.0	56
1352	The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea. BMC Public Health, 2020, 20, 797.	2.9	4
1353	Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. Journal of Hematology and Oncology, 2020, 13, 74.	17.0	17
1354	Primary tumor characteristics and nextâ€”generation sequencing mutations as biomarkers for melanoma immunotherapy response. Pigment Cell and Melanoma Research, 2020, 33, 878-888.	3.3	5

#	ARTICLE	IF	CITATIONS
1355	Ocular side effects of target therapy and immunotherapy in patients with cutaneous malignant melanoma. <i>European Journal of Ophthalmology</i> , 2021, 31, 1391-1398.	1.3	9
1356	Nivolumab in Metastatic Melanoma: Good Efficacy and Tolerability in Elderly Patients. <i>Current Oncology</i> , 2020, 27, 75-80.	2.2	8
1357	Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 369.	4.8	291
1358	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	2.8	84
1359	“The same old story”: thoughts on authorized doses of anticancer drugs. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090541.	3.2	5
1360	Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor. <i>Medicine (United States)</i> , 2020, 99, e19440.	1.0	3
1361	Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 421-430.	4.4	23
1362	Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors. <i>Current Treatment Options in Oncology</i> , 2020, 21, 29.	3.0	11
1363	Case of small bowel perforation secondary to nivolumab and ipilimumab related tumour regression. <i>BMJ Case Reports</i> , 2020, 13, e232304.	0.5	4
1364	Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study. <i>BMC Research Notes</i> , 2020, 13, 176.	1.4	7
1365	Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 951.	2.8	35
1366	Primary anorectal malignant melanoma with laparoscopic abdominoperineal resection: a case study and review of the relevant literature. <i>International Cancer Conference Journal</i> , 2020, 9, 116-122.	0.5	1
1367	Article Commentary: Cancer Immunotherapy for the General Surgeon. <i>American Surgeon</i> , 2020, 86, 284-292.	0.8	0
1368	Severe chronic nonlichenoid oral mucositis in pembrolizumab-treated patients: new cases and a review of the literature. <i>Immunotherapy</i> , 2020, 12, 777-784.	2.0	6
1369	Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location. <i>Oncology and Therapy</i> , 2020, 8, 59-66.	2.6	4
1370	Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	49
1371	FIP200 Suppresses Immune Checkpoint Therapy Responses in Breast Cancers by Limiting AZI2/TBK1/IRF Signaling Independent of Its Canonical Autophagy Function. <i>Cancer Research</i> , 2020, 80, 3580-3592.	0.9	19
1372	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	1.9	40

#	ARTICLE	IF	CITATIONS
1373	Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. JCO Precision Oncology, 2020, 4, 20-31.	3.0	19
1374	Early stage triple negative breast cancer: Management and future directions. Seminars in Oncology, 2020, 47, 201-208.	2.2	23
1375	Immunotherapy in sinonasal melanoma: treatment patterns and outcomes compared to cutaneous melanoma. International Forum of Allergy and Rhinology, 2020, 10, 1087-1095.	2.8	9
1376	Transgenic T-cell receptor immunotherapy for cancer: building on clinical success. , 2020, 8, 251513552093350.	2.3	10
1377	Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab. Expert Opinion on Biological Therapy, 2020, 20, 319-326.	3.1	12
1378	When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?. American Journal of Clinical Dermatology, 2020, 21, 313-321.	6.7	3
1379	Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. Oncologist, 2020, 25, 669-679.	3.7	30
1380	Nanotechnology approaches in the current therapy of skin cancer. Advanced Drug Delivery Reviews, 2020, 153, 109-136.	13.7	65
1381	Assessing Treatment Benefit in Immuno-oncology. Statistics in Biosciences, 2020, 12, 83-103.	1.2	10
1382	Normalization Cancer Immunotherapy for Melanoma. Journal of Investigative Dermatology, 2020, 140, 1134-1142.	0.7	13
1383	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. Gastroenterology Report, 2020, 8, 11-24.	1.3	68
1384	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 91.	2.8	112
1385	Targeting the IL-9 pathway in cancer immunotherapy. Human Vaccines and Immunotherapeutics, 2020, 16, 2333-2340.	3.3	26
1386	Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma. Nature Communications, 2020, 11, 853.	12.8	23
1387	Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. Acta Oncologica, 2020, 59, 652-659.	1.8	28
1388	Metastatic melanoma: Surgical treatment of brain metastases â€” Analysis of 110 patients. Journal of Clinical Neuroscience, 2020, 73, 144-149.	1.5	11
1389	Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment. Journal of Cellular Physiology, 2020, 235, 5449-5460.	4.1	42
1390	Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer. International Journal of Clinical Oncology, 2020, 25, 851-860.	2.2	4

#	ARTICLE	IF	CITATIONS
1391	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. <i>International Journal of Molecular Sciences</i> , 2020, 21, 556.	4.1	21
1392	Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 147.	2.4	14
1393	Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 137-145.	2.4	16
1394	Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 683.	4.8	102
1395	HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2020, 12, 1060.	3.7	40
1396	Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2531.	4.1	56
1397	The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. <i>Journal of Advanced Research</i> , 2020, 24, 139-148.	9.5	50
1398	Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. , 2020, 8, e000371.		14
1399	Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis. <i>Genes</i> , 2020, 11, 435.	2.4	14
1400	T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma. <i>Oncoimmunology</i> , 2020, 9, 1749476.	4.6	22
1401	Construction and evaluation of hyaluronic acid-based copolymers as a targeted chemotherapy drug carrier for cancer therapy. <i>Nanotechnology</i> , 2020, 31, 305702.	2.6	8
1402	Drug Selection for Formulary Inclusion: An Exploratory Case Study of Oncology Medicines in Jordan. <i>Value in Health Regional Issues</i> , 2020, 21, 211-221.	1.2	2
1403	Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples. <i>BMC Cancer</i> , 2020, 20, 344.	2.6	13
1404	Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care. <i>International Immunopharmacology</i> , 2020, 83, 106417.	3.8	31
1405	An update on the safety of nivolumab for the treatment of advanced melanoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 409-421.	2.4	5
1406	Microenvironmental Determinants of Pancreatic Cancer. <i>Physiological Reviews</i> , 2020, 100, 1707-1751.	28.8	156
1407	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. <i>Cells</i> , 2020, 9, 940.	4.1	8
1409	Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2153-2160.	2.5	8

#	ARTICLE	IF	CITATIONS
1410	Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy. <i>Radiologia</i> , 2020, 62, 131-138.	0.5	6
1411	Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer. , 2020, 8, e000376.		111
1412	Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4250-4259.	7.0	104
1413	The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019. <i>Journal of Translational Medicine</i> , 2020, 18, 171.	4.4	2
1414	Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model. <i>Cancers</i> , 2020, 12, 804.	3.7	19
1415	CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 142-148.	6.1	5
1416	Advances on immune-related adverse events associated with immune checkpoint inhibitors. <i>Frontiers of Medicine</i> , 2021, 15, 33-42.	3.4	24
1417	Artificial intelligence and the interplay between tumor and immunity. , 2021, , 211-235.		1
1418	Efficacy of immune checkpoint inhibitors in different types of melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4-13.	3.3	19
1419	A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation. <i>International Journal of Cancer</i> , 2021, 148, 437-447.	5.1	11
1420	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. <i>European Radiology</i> , 2021, 31, 1853-1862.	4.5	10
1421	Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. <i>Modern Pathology</i> , 2021, 34, 823-833.	5.5	6
1422	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. <i>Journal of Advanced Research</i> , 2021, 29, 45-54.	9.5	31
1423	Dicarbonyl Electrophiles Mediate Inflammation-Induced Gastrointestinal Carcinogenesis. <i>Gastroenterology</i> , 2021, 160, 1256-1268.e9.	1.3	17
1424	Corticotropin insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology. <i>Annales D'Endocrinologie</i> , 2021, 82, 8-14.	1.4	1
1425	The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. <i>Cancer Discovery</i> , 2021, 11, 678-695.	9.4	114
1427	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1134-1143.	2.4	17
1428	Cost-effectiveness of nivolumab in advanced melanoma: a drug review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 13-28.	1.4	1

#	ARTICLE	IF	CITATIONS
1429	Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. <i>British Journal of Radiology</i> , 2021, 94, 20200663.	2.2	13
1430	Proteogenomic Analysis Unveils the HLA Class I-Presented Immunoepitome in Melanoma and EGFR-Mutant Lung Adenocarcinoma. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100136.	3.8	19
1431	GI Toxicities from Cancer Therapy. , 2021, , 341-379.		0
1432	Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer. <i>Onc Immunology</i> , 2021, 10, 1873607.	4.6	20
1433	IFN- γ and CD38 in Hyperprogressive Cancer Development. <i>Cancers</i> , 2021, 13, 309.	3.7	17
1434	New Targeted Therapies for Multiple Myeloma Under Clinical Investigation. Resistance To Targeted Anti-cancer Therapeutics, 2021, , 129-145.	0.1	0
1435	A Case of Anorectal Malignant Melanoma with Lymph Node Recurrence Showing a Complete Response to Nivolumab Treatment. <i>Japanese Journal of Gastroenterological Surgery</i> , 2021, 54, 73-82.	0.1	0
1436	Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse. <i>Cancers</i> , 2021, 13, 442.	3.7	7
1437	Skin Cancer: Molecular Biomarker for Diagnosis, Prognosis, Prevention, and Targeted Therapy. , 2021, , 101-130.		0
1438	Ratio of the interferon- γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. <i>Npj Genomic Medicine</i> , 2021, 6, 7.	3.8	41
1439	Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 618215.	2.8	15
1440	NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. <i>Scientific Reports</i> , 2021, 11, 3258.	3.3	19
1441	Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma (Review). <i>Oncology Letters</i> , 2021, 21, 279.	1.8	36
1442	Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy. <i>Viruses</i> , 2021, 13, 355.	3.3	17
1443	Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study. <i>International Journal of Cancer</i> , 2021, 148, 2789-2798.	5.1	5
1444	Recent developments in cancer research: Expectations for a new remedy. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 419-426.	2.4	12
1445	Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune-Checkpoint Inhibitor Pneumonitis, From the AJR Special Series on Inflammation. <i>American Journal of Roentgenology</i> , 2021, , 1-9.	2.2	7
1446	Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod. <i>European Journal of Dermatology</i> , 2021, 31, 91-92.	0.6	1

#	ARTICLE	IF	CITATIONS
1447	Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 364-370.	1.2	3
1448	The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies. <i>Frontiers in Immunology</i> , 2021, 12, 625783.	4.8	34
1449	Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1691-1695.	2.2	11
1450	Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. <i>BMC Cancer</i> , 2021, 21, 323.	2.6	22
1451	Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions. <i>Cancer Immunology Research</i> , 2021, 9, 637-650.	3.4	6
1452	An in vivo method for diversifying the functions of therapeutic antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	3
1453	CCL5 production by fibroblasts through a local renin-angiotensin system in malignant melanoma affects tumor immune responses. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1993-2001.	2.5	9
1454	Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 537-547.	2.4	9
1455	Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors. <i>MedComm</i> , 2021, 2, 60-68.	7.2	16
1456	Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. <i>BMC Cancer</i> , 2021, 21, 331.	2.6	1
1457	Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model. <i>Cancers</i> , 2021, 13, 1256.	3.7	6
1458	An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells. <i>PLoS ONE</i> , 2021, 16, e0248870.	2.5	3
1459	Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings. <i>Frontiers in Oral Health</i> , 2021, 2, 653104.	3.0	2
1460	Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. <i>BMC Cancer</i> , 2021, 21, 425.	2.6	16
1461	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 562315.	2.8	38
1462	The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 329-342.	1.1	1
1463	Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4618.	4.1	30
1464	Anti-angiogenic agents "overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 527-540.	27.6	162

#	ARTICLE	IF	CITATIONS
1465	Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4557.	4.1	34
1466	Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects. <i>Frontiers in Medicine</i> , 2021, 8, 642380.	2.6	28
1467	Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. <i>International Immunopharmacology</i> , 2021, 93, 107403.	3.8	30
1468	Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. <i>JCO Precision Oncology</i> , 2021, 5, 432-441.	3.0	16
1469	Biomaterials-Based Delivery of Therapeutic Antibodies for Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002139.	7.6	21
1470	Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3313-3322.	4.2	17
1471	Z-guggulsterone induces PD-L1 upregulation partly mediated by FXR, Akt and Erk1/2 signaling pathways in non-small cell lung cancer. <i>International Immunopharmacology</i> , 2021, 93, 107395.	3.8	12
1472	Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1639.	3.7	13
1473	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021, 26, 619-623.	3.7	5
1474	Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade. <i>Scientific Reports</i> , 2021, 11, 7624.	3.3	5
1475	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. , 2021, 9, e002478.		59
1476	Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 923-941.	1.4	1
1477	Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-Inhibitors. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1588-1594.	1.8	8
1478	Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation. <i>Journal of Controlled Release</i> , 2021, 333, 328-338.	9.9	12
1479	Vaginal mucositis related to immunotherapy in endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2021, 36, 100742.	0.6	1
1481	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. <i>European Journal of Cancer</i> , 2021, 149, 37-48.	2.8	12
1482	Inmunoterapia personalizada contra el c�ncer basada en neoant�genos. Revisi�n de la literatura. <i>Revista Facultad De Medicina</i> , 2021, 69, e81633.	0.2	0
1483	Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non�Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2111113.	5.9	17

#	ARTICLE	IF	CITATIONS
1484	Sequential immunotherapy in melanoma. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 366-370.	1.2	3
1485	Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis. <i>Journal of Oncology</i> , 2021, 2021, 1-13.	1.3	6
1486	The role of CD47-SIRP α immune checkpoint in tumor immune evasion and innate immunotherapy. <i>Life Sciences</i> , 2021, 273, 119150.	4.3	45
1487	Chemotherapy in focus: A meta-analysis confronts immunotherapy in the treatment of advanced melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103304.	4.4	3
1488	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.	2.8	33
1489	Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. <i>Cancer Cell International</i> , 2021, 21, 262.	4.1	31
1490	Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. <i>Gynecologic Oncology</i> , 2021, 161, 645-652.	1.4	15
1491	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. , 2021, 9, e002344.		12
1492	Correlation Between 18F-FDG Uptake and Immune Cell Infiltration in Metastatic Brain Lesions. <i>Frontiers in Oncology</i> , 2021, 11, 618705.	2.8	5
1493	Current clinical trials and patent update on lung cancer: a retrospective review. <i>Lung Cancer Management</i> , 2021, 10, LMT45.	1.5	0
1494	Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience. <i>Cancers</i> , 2021, 13, 3074.	3.7	20
1495	Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 639-651.	6.7	15
1496	Neoantigens elicit T cell responses in breast cancer. <i>Scientific Reports</i> , 2021, 11, 13590.	3.3	17
1497	Association of Celiac Disease With Pembrolizumab. <i>Cureus</i> , 2021, 13, e15565.	0.5	5
1498	Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. , 2021, 9, e002296.		45
1499	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4859-4869.	7.0	33
1500	Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions. <i>Frontiers in Immunology</i> , 2021, 12, 680407.	4.8	68
1501	Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 345-352.	1.2	5

#	ARTICLE	IF	CITATIONS
1502	Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy. <i>Academic Radiology</i> , 2021, , .	2.5	2
1503	Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 659380.	2.8	10
1504	Optimization of the Administration Strategy for the Armed Oncolytic Adenovirus ZD55-IL-24 in Both Immunocompromised and Immunocompetent Mouse Models. <i>Human Gene Therapy</i> , 2021, , .	2.7	3
1505	Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. <i>Annals of Oncology</i> , 2021, 32, 917-925.	1.2	76
1506	Injectable Supramolecular Hydrogel for Locoregional Immune Checkpoint Blockade and Enhanced Cancer Chemo-Immunotherapy. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 33874-33884.	8.0	38
1507	Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. <i>Endocrine-Related Cancer</i> , 2021, 28, 419-431.	3.1	29
1508	Immunotherapy: New insights in breast cancer treatment. <i>Human Antibodies</i> , 2021, 29, 193-202.	1.5	3
1509	Trailblazing perspectives on targeting breast cancer stem cells. , 2021, 223, 107800.		20
1510	A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced Wild-Type BRAF Melanoma Patients. <i>Journal of Surgical Research</i> , 2021, 268, 737-747.	1.6	1
1511	The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 4301-4310.	1.4	6
1512	A Review of Therapeutic Antibodies in Breast Cancer. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2021, 24, 363-380.	2.1	1
1513	Sicca syndrome associated with immune checkpoint inhibitor therapy. <i>Oral Diseases</i> , 2022, 28, 2083-2092.	3.0	10
1514	Long-Term Follow-Up of Gemogenovatucl-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. <i>Vaccines</i> , 2021, 9, 894.	4.4	9
1515	Intestinal Regulatory T Cells as Specialized Tissue-Restricted Immune Cells in Intestinal Immune Homeostasis and Disease. <i>Frontiers in Immunology</i> , 2021, 12, 716499.	4.8	34
1516	Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment. <i>European Journal of Surgical Oncology</i> , 2022, 48, 383-390.	1.0	3
1517	Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 896-904.	4.9	13
1518	Nivolumab induced hypophysitis in a patient with recurrent non-small cell lung cancer. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 218-221.	1.5	2
1519	Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients. <i>PLoS ONE</i> , 2021, 16, e0255972.	2.5	1

#	ARTICLE	IF	CITATIONS
1520	Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti- PD-1 therapy. <i>European Journal of Cancer</i> , 2021, 153, 213-222.	2.8	7
1521	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. <i>Cancers</i> , 2021, 13, 3913.	3.7	5
1522	The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2018-2027.e4.	0.7	8
1523	Immune Checkpoint Inhibitors and Neurotoxicity. <i>Current Neuropharmacology</i> , 2021, 19, 1246-1263.	2.9	10
1524	Novel oncolytic adenovirus expressing enhanced cross-hybrid IgG A Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. , 2021, 9, e003000.		27
1525	Long-term Overall Survival and Predictors in Anti- PD-1 -naïve Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. <i>Journal of Immunotherapy</i> , 2021, 44, 307-318.	2.4	4
1526	Immune checkpoint inhibitor-related hepatotoxicity: A review. <i>World Journal of Gastroenterology</i> , 2021, 27, 5376-5391.	3.3	52
1527	Synchronizing the use of allogeneic hematopoietic cell transplantation in checkpoint blockade therapy for Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2021, 14, 809-818.	2.2	1
1528	Immune Checkpoints in Cancers: From Signaling to the Clinic. <i>Cancers</i> , 2021, 13, 4573.	3.7	35
1529	Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1211-1228.	2.4	1
1530	Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy. <i>Immunological Medicine</i> , 2022, 45, 108-118.	2.6	10
1531	Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy. <i>Scientific Reports</i> , 2021, 11, 19432.	3.3	6
1532	Tumor eradicated by combination of imiquimod and OX40 agonist for <i>in situ</i> vaccination. <i>Cancer Science</i> , 2021, 112, 4490-4500.	3.9	8
1533	Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases. <i>Cancers</i> , 2021, 13, 4928.	3.7	10
1534	¹⁸ F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 899-905.	5.0	36
1535	Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?. <i>PLoS ONE</i> , 2021, 16, e0257484.	2.5	8
1536	Tumors, tumor therapies, autoimmunity and the eye. <i>Autoimmunity Reviews</i> , 2021, 20, 102892.	5.8	7
1537	Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 953-966.	4.2	8

#	ARTICLE	IF	CITATIONS
1538	Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy. <i>Drugs in R and D</i> , 2021, 21, 399-406.	2.2	7
1539	Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. <i>Cancer</i> , 2021, 127, 4565-4573.	4.1	24
1540	Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice. <i>International Journal of Cancer</i> , 2022, 150, 317-326.	5.1	12
1541	Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer. , 2021, 227, 107870.		13
1542	Combinatorial therapy in tumor microenvironment: Where do we stand?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188585.	7.4	48
1543	Endocrinopathies Associated With Immune Checkpoint Inhibitors. , 2022, , 301-314.		0
1544	Oral Immune-Related Adverse Events – Current Concepts and their Management. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 604-609.	1.6	2
1545	Immune Checkpoint Inhibitors as an Armor for Targeted Immunotherapy of Colorectal Cancer. , 2021, , 309-326.		0
1546	Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 555-562.	1.3	8
1547	Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 58-66.	2.5	195
1548	Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. , 2020, , 1187-1214.		2
1549	The Immune System and Pathogenesis of Melanoma and Non-melanoma Skin Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1268, 211-226.	1.6	11
1550	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2019, , 1-27.		1
1552	Antibody Therapies in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 1-67.	1.6	8
1553	Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 33-59.	1.6	232
1554	Reacciones adversas inmunomediadas como predictoras de respuesta en pacientes oncológicos en tratamiento con inmunoterapia. <i>Radiología</i> , 2020, 62, 131-138.	0.5	5
1555	Potential role of diacylglycerol kinases in immune-mediated diseases. <i>Clinical Science</i> , 2020, 134, 1637-1658.	4.3	14
1556	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1047-1059.	3.1	9

#	ARTICLE	IF	CITATIONS
1557	PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. Journal of Experimental Medicine, 2021, 218, .	8.5	151
1558	Development of a bclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma. Melanoma Research, 2017, 27, 383-386.	1.2	5
1559	Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina. Journal of Lower Genital Tract Disease, 2021, 25, 146-151.	1.9	12
1560	Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade. Journal of Neuro-Ophthalmology, 2021, 41, 519-530.	0.8	22
1563	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. International Journal of Dermatology, 2019, 58, 1045-1052.	1.0	11
1564	Macrophage targeting in cancer. Annals of the New York Academy of Sciences, 2021, 1499, 18-41.	3.8	134
1565	The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis. Case Reports in Oncology, 2016, 9, 68-75.	0.7	6
1566	Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. JCI Insight, 2017, 2, .	5.0	48
1567	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. Journal of Clinical Investigation, 2015, 125, 3377-3383.	8.2	146
1568	Metabolic regulation of immune responses: therapeutic opportunities. Journal of Clinical Investigation, 2016, 126, 2031-2039.	8.2	78
1569	Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. Journal of Clinical Investigation, 2016, 126, 2334-2340.	8.2	312
1570	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. Journal of Clinical Investigation, 2019, 129, 1278-1294.	8.2	102
1571	Influence on [18F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor. EJNMMI Research, 2020, 10, 24.	2.5	10
1572	The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. Journal of Patient-Reported Outcomes, 2020, 4, 88.	1.9	19
1573	Biomarkers for immune therapy in melanoma. Seminars in Cutaneous Medicine and Surgery, 2018, 37, 120-126.	1.6	2
1574	Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report. World Journal of Clinical Cases, 2020, 8, 624-629.	0.8	8
1575	Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection. PLoS ONE, 2015, 10, e0124590.	2.5	9
1576	Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e132-e139.	3.8	11

#	ARTICLE	IF	CITATIONS
1577	Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. Journal of Clinical Medicine Research, 2016, 8, 63-75.	1.2	49
1578	PD-1 pathway-mediated regulation of islet-specific CD4+ T cell subsets in autoimmune diabetes. Immunoendocrinology (Houston, Tex), 2016, 3, .	1.0	14
1579	New-onset insulin-dependent diabetes due to nivolumab. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.5	14
1580	Radiation Therapy for Melanoma. , 0, , 101-120.		5
1581	Liquid Biopsies for Assessing Metastatic Melanoma Progression. Critical Reviews in Oncogenesis, 2016, 21, 141-154.	0.4	15
1582	Cabozantinib: from studies to clinical practice. Onkourologiya, 2019, 15, 28-41.	0.3	6
1583	Pharmacometrics and systems pharmacology of immune checkpoint inhibitor nivolumab in cancer translational medicine. Advances in Modern Oncology Research, 2016, 2, 18.	0.1	5
1584	CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Oncotarget, 2016, 7, 71455-71465.	1.8	42
1585	Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. Oncotarget, 2016, 7, 76891-76901.	1.8	9
1586	SCIB1, a hulgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. Oncotarget, 2016, 7, 83088-83100.	1.8	16
1587	The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. Oncotarget, 2016, 7, 81493-81511.	1.8	14
1588	Phase I study of nivolumab combined with IFN- γ for patients with advanced melanoma. Oncotarget, 2017, 8, 71181-71187.	1.8	21
1589	Tumor reductive therapies and antitumor immunity. Oncotarget, 2017, 8, 55736-55749.	1.8	11
1590	Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review. Oncotarget, 2017, 8, 96453-96459.	1.8	8
1591	Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. Oncotarget, 2017, 8, 103117-103128.	1.8	84
1592	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget, 2018, 9, 10284-10293.	1.8	44
1593	T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. Oncotarget, 2018, 9, 6536-6549.	1.8	37
1594	PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. Oncotarget, 2015, 6, 3479-3492.	1.8	146

#	ARTICLE	IF	CITATIONS
1595	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. <i>Oncotarget</i> , 2015, 6, 12297-12309.	1.8	148
1596	Genomic amplification of 9p24.1 targeting <i>JAK2</i> , <i>PD-L1</i> , and <i>PD-L2</i> is enriched in high-risk triple negative breast cancer. <i>Oncotarget</i> , 2015, 6, 26483-26493.	1.8	118
1597	Analysis of SDHD promoter mutations in various types of melanoma. <i>Oncotarget</i> , 2015, 6, 25868-25882.	1.8	9
1598	Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome. <i>Oncotarget</i> , 2015, 6, 33191-33205.	1.8	3
1599	The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. <i>Oncotarget</i> , 2015, 6, 19393-19404.	1.8	61
1600	Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. <i>Oncotarget</i> , 2015, 6, 40836-40849.	1.8	106
1601	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. <i>Oncotarget</i> , 2016, 7, 33350-33362.	1.8	56
1602	Medical management of malignant melanoma. <i>Australian Prescriber</i> , 2015, 38, 74-78.	1.0	24
1603	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. <i>Cancer Biology and Medicine</i> , 2019, 16, 655-670.	3.0	95
1604	Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma. <i>Cancer Biology and Medicine</i> , 2020, 17, 555-568.	3.0	14
1605	The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. <i>Annals of Translational Medicine</i> , 2016, 4, 267-267.	1.7	17
1606	Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?. <i>Annals of Translational Medicine</i> , 2019, 7, S95-S95.	1.7	2
1607	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). <i>Chinese Clinical Oncology</i> , 2016, 5, 57-57.	1.2	46
1608	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	2.8	7
1609	Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2020, 32, 448-466.	2.2	6
1610	Pseudoprogression in patients on immunotherapy. <i>Meditsinskiy Sovet</i> , 2019, , 10-14.	0.5	3
1611	Cancer Immunology and Immunotherapy. <i>Anticancer Research</i> , 2016, 36, 5593-5606.	1.1	69
1612	Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. <i>Anticancer Research</i> , 2019, 39, 781-790.	1.1	25

#	ARTICLE	IF	CITATIONS
1613	Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study. JMIR Formative Research, 2020, 4, e17898.	1.4	17
1614	Update on tumor metabolism and patterns of response to immunotherapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 175-185.	0.7	8
1615	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. Safety and Risk of Pharmacotherapy, 2020, 8, 9-22.	0.2	10
1616	Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World Journal of Gastroenterology, 2019, 25, 1684-1696.	3.3	29
1617	Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncology Reports, 2020, 44, 424-437.	2.6	18
1618	Immunotherapy for synovial sarcoma. AIMS Medical Science, 2019, 6, 191-200.	0.4	1
1619	Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. Journal of Gastrointestinal Oncology, 2015, 6, 561-9.	1.4	61
1620	New therapeutic strategies for BRAF mutant colorectal cancers. Journal of Gastrointestinal Oncology, 2015, 6, 650-9.	1.4	21
1621	A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors. Translational Lung Cancer Research, 2014, 3, 406-7.	2.8	19
1622	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. Translational Lung Cancer Research, 2014, 3, 403-5.	2.8	21
1623	A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736. Translational Lung Cancer Research, 2014, 3, 408-10.	2.8	19
1624	Checkpoint inhibitors in the treatment of cutaneous malignant melanoma. Chinese Clinical Oncology, 2014, 3, 30.	1.2	6
1625	Treatment algorithm of metastatic mucosal melanoma. Chinese Clinical Oncology, 2014, 3, 38.	1.2	16
1626	Immune checkpoint inhibitors: therapeutic advances in melanoma. Annals of Translational Medicine, 2015, 3, 267.	1.7	47
1627	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Annals of Translational Medicine, 2015, 3, 322.	1.7	32
1628	Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors. Journal of Rheumatic Diseases, 2019, 26, 221.	1.1	3
1629	Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens. CytoJournal, 2018, 15, 29.	1.7	14
1630	Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. Journal of Cancer Research and Therapeutics, 2018, 14, 1167-1175.	0.9	51

#	ARTICLE	IF	CITATIONS
1631	Immune cell interplay in colorectal cancer prognosis. World Journal of Gastrointestinal Oncology, 2015, 7, 221.	2.0	27
1632	Cancer immunology â€“ development of novel anti-cancer therapies. Swiss Medical Weekly, 2015, 145, w14066.	1.6	18
1633	Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World Journal of Clinical Oncology, 2017, 8, 230.	2.3	52
1634	Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer. Journal of the Advanced Practitioner in Oncology, 2014, 5, 418-31.	0.4	48
1635	Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma. Journal of the Advanced Practitioner in Oncology, 2017, 8, 58-72.	0.4	7
1636	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 367-402.	4.9	326
1637	Downregulation of Nitric Oxide Collaborated with Radiotherapy to Promote Anti-Tumor Immune Response via Inducing CD8+ T Cell Infiltration. International Journal of Biological Sciences, 2020, 16, 1563-1574.	6.4	16
1638	Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biology and Medicine, 2015, 12, 201-8.	3.0	67
1639	The Association of Radiation Dose-Fractionation and Immunotherapy Use With Overall Survival in Metastatic Melanoma Patients. Cureus, 2020, 12, e8767.	0.5	7
1640	Therapeutic Potential. , 2021, , 465-518.		0
1641	Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis. Current Oncology, 2021, 28, 3978-3986.	2.2	7
1642	Pembrolizumab in endometrial cancer: Where we stand now (Review). Oncology Letters, 2021, 22, 821.	1.8	10
1643	Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma. Frontiers in Immunology, 2021, 12, 740890.	4.8	15
1644	Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. Journal of Clinical Investigation, 2021, 131, .	8.2	40
1645	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell, 2021, 184, 5309-5337.	28.9	588
1646	Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival. Frontiers in Molecular Biosciences, 2021, 8, 745286.	3.5	19
1647	Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. Journal of Clinical Pharmacology, 2022, 62, 532-540.	2.0	14
1648	Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Antiâ€“PD-1/PD-L1 Agents. Cancer Immunology Research, 2021, 9, 1451-1464.	3.4	15

#	ARTICLE	IF	CITATIONS
1649	Cancer and the Immune System. , 2014, , 1-7.		0
1650	Challenges for the Clinical Implementation of Precision Medicine Trials. , 2015, , 133-144.		0
1651	Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies. AIMS Public Health, 2015, 2, 86-114.	2.6	1
1652	The Actual State and Potential of Immunotherapy for Lung Cancer. Japanese Journal of Lung Cancer, 2015, 55, 991-994.	0.1	0
1653	Immune Microenvironment and its Therapeutic Implication in Non-Small Cell Lung Carcinoma: Literature Review. Journal of Clinical & Cellular Immunology, 2015, 05, .	1.5	0
1654	Patient Selection and Monitoring for Immunotherapies: Challenges for Immune Checkpoint Antibody and Cell Therapies. , 2015, , 85-101.		0
1655	Quality of CTL Therapies: A Changing Landscape. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 303-349.	0.1	0
1656	Advanced skin melanoma “systemic treatment. OnCOReview, 2015, 5, 133-138.	0.1	0
1657	Improving of Antitumor Immunity and Therapeutic Efficacy of Cancer Vaccines and Adoptive Immunotherapies Using Monoclonal Antibodies. MOJ Immunology, 2015, 2, .	11.0	0
1658	Immunotherapy in Melanoma. , 2016, , 207-236.		0
1660	Therapeutic Potential. , 2016, , 437-488.		0
1661	Vaccination Against Breast Cancer and its Role in Prevention. , 2016, , 253-278.		1
1662	Mechanisms of Action, Efficacy and Side Effects of Nivolumab and Its Therapeutic Use at Itabashi Hospital, Nihon University School of Medicine. Journal of the Nihon University Medical Association, 2016, 75, 156-160.	0.0	0
1663	New Treatments for Advanced Melanoma. Nishinohon Journal of Dermatology, 2016, 78, 5-12.	0.0	0
1664	Better Together: Immunotherapy as Future Combination Strategy for Breast Cancer. Immunotherapy (Los Angeles, Calif), 2016, 02, .	0.1	0
1665	Monitoring of Immunologic Therapies. , 0, , 1036-1050.		0
1666	Head and Neck Cutaneous Melanoma. , 2016, , 657-663.		0
1667	Preventative and Personalized Approach to the Treatment of Malignant Melanoma: A Case Report.. University of Ottawa Journal of Medicine, 2016, 6, 49-52.	0.0	0

#	ARTICLE	IF	CITATIONS
1668	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.4	3
1669	Malignant Melanoma in the Adolescent and Young Adult (AYA) Population. Pediatric Oncology, 2017, , 231-267.	0.5	0
1671	The Influence of a Poor Prognosis on the Intensity of Treatment and Survival in Advanced Cancer Patients. , 2016, 2, 1-6.		0
1672	Malignes Melanom beim alten und geriatrischen Patienten. , 2017, , 1-8.		0
1673	Altered Signal Transduction Pathways in Melanoma. , 2017, , 177-207.		0
1674	Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure. , 2017, , 427-436.		0
1675	Re-Thinking the Interplay between Tumorigenesis and Immunity. Journal of Cell Signaling, 2017, 01, .	0.3	0
1676	Immune Checkpoint Blockade: Subjugation of the Masses. , 0, , .		0
1677	Immunotherapy related toxicities. Onkologie (Czech Republic), 2017, 11, 83-87.	0.1	3
1678	Immunoth�rapie par anticorps monoclonaux : ing�nierie, indications et perspectives. Bulletin De L'Academie Nationale De Medecine, 2017, 201, 1023-1035.	0.0	0
1679	Malignes Melanom beim alten und geriatrischen Patienten. , 2018, , 527-534.		0
1680	Current Advances in Immuno-oncology for Head and Neck Cancer. International Journal of Head and Neck Surgery, 2018, 9, 78-86.	0.2	0
1681	Eye Symptoms and Toxicities of Systemic Chemotherapy. , 2018, , 563-583.		2
1682	A Case of Lung Adenocarcinoma Complicated with Adrenal Insufficiency Induced by Nivolumab. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 746-752.	0.0	0
1683	ULTRASOUND TUMOR ABLATION: IMMUNE EFFECTS AND PERSPECTIVES OF INTEGRATION IN THE MODERN TREATMENT OF ADVANCED CANCER. Malignant Tumours, 2018, 8, 31-42.	0.5	0
1684	Genomic Applications in Melanoma. , 2019, , 509-540.		0
1685	Managing Checkpoint Inhibitor Symptoms and Toxicity. , 2019, , 1-28.		0
1686	Gastrointestinal side effects of immune checkpoint inhibitors: new topic for gastroncologists. Hematology & Medical Oncology, 2019, 4, .	0.1	0

#	ARTICLE	IF	CITATIONS
1687	A Case of Colon Perforation during the Treatment with an Immune Checkpoint Inhibitor. Nihon Rinsho Gekai Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 1715-1720.	0.0	0
1688	The effects of araneose, cisplatin or paclitaxel in monotherapy and in combination on the expression of Pdâ€‘I1 and Pdâ€‘I2 in melanoma cells. , 2019, 17, 71-80.	0.3	1
1689	Emerging Immune Context. , 2019, , 269-329.		0
1690	Diverse Roles of Heat Shock Proteins in Immune Activation and Tolerance: A Comprehensive Review of Mechanisms and Therapeutic Relevance. Heat Shock Proteins, 2019, , 183-215.	0.2	0
1691	Immunology of Melanoma. , 2019, , 1-32.		0
1692	Malignant melanoma with tumor thrombus in the inferior vena cava secondary to metastatic renal hilar lymph nodes : A case report. Skin Cancer, 2019, 33, 192-195.	0.0	0
1693	Intradural-Extramedullary and Intramedullary Spinal Metastases. , 2019, , 365-379.		1
1694	Anticancer Immunotherapy: Prospects and Challenges. , 2019, , 189-228.		0
1695	Commentary: Small Molecule Inhibition of PD-1 Transcription is an Effective Alternative to Antibody Blockade in Cancer Therapy. Journal of Immunological Sciences, 2019, 3, 9-12.	1.1	1
1696	Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. Journal of the Advanced Practitioner in Oncology, 2019, 10, 37-46.	0.4	5
1698	Principles of Diagnosis and Personalized Treatment of Hereditary Colorectal Cancer. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2019, 74, 118-124.	0.6	2
1699	Common Cutaneous Side Effects ofÂAnti-cancer Agents. , 2020, , 289-306.		0
1700	GI Toxicities from Cancer Therapy. , 2020, , 1-39.		0
1701	Nivolumab in real-life clinical practice. IssledovaniÂ I Praktika V Medicine, 2019, 6, 84-91.	0.5	2
1703	How to manage side effects of immunotherapy. Onkologie (Czech Republic), 2020, 14, 6-12.	0.1	0
1704	Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma. Aging, 2020, 12, 10663-10675.	3.1	7
1705	Immunotherapy in the treatment of non-small cell lung cancer (NSCLC) - analysis of epidemiology and cure - review. Journal of Education, Health and Sport, 2020, 10, 204.	0.1	0
1707	Cemiplimab in advanced cutaneous squamous cell carcinoma. Dermatologic Therapy, 2021, 34, e15184.	1.7	4

#	ARTICLE	IF	CITATIONS
1708	Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU2011). Cancer, 2022, 128, 778-787.	4.1	23
1709	Rescue liver re-transplantation after graft loss due to severe rejection in the setting of pre-transplant nivolumab therapy. Clinical Journal of Gastroenterology, 2021, 14, 1718-1724.	0.8	16
1710	Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy. Cancers, 2021, 13, 5411.	3.7	1
1711	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	1.6	580
1712	Hepatobiliary Adverse Events. Advances in Experimental Medicine and Biology, 2020, 1244, 271-276.	1.6	3
1713	Immunology of Melanoma. , 2020, , 41-72.		0
1715	Melanoma oral metastático: tratamento com radioterapia e nivolumabe. , 2020, 99, 619-625.	0.1	0
1717	The Role of PET/CT in Melanoma Patients: A Surgeon's Perspective. , 2021, , 151-166.		0
1718	Multidimensional indicators of scholarly impact in the skin oncology literature: is there a correlation between bibliometric and altmetric profiles?. Journal of Plastic Surgery and Hand Surgery, 2021, 55, 232-241.	0.8	3
1719	Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrest. Translational Oncology, 2022, 15, 101259.	3.7	2
1720	The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma. Internal Medicine, 2022, 61, 1485-1490.	0.7	3
1721	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2020, , 1215-1241.		0
1723	Cancer Imaging with Radiolabeled Monoclonal Antibodies. , 2020, , 739-760.		5
1725	Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival. World Journal of Gastroenterology, 2021, 27, 7190-7206.	3.3	8
1726	Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples. CytoJournal, 2021, 18, 28.	1.7	1
1727	Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy. BMC Cancer, 2021, 21, 1187.	2.6	6
1728	Comparative Review of Malignant Melanoma and Histologically Well-Differentiated Melanocytic Neoplasm in the Oral Cavity of Dogs. Veterinary Sciences, 2021, 8, 261.	1.7	4
1729	Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy. International Journal of Immunotherapy and Cancer Research, 2020, , 016-018.	0.4	0

#	ARTICLE	IF	CITATIONS
1730	Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.. Journal of Nuclear Medicine, 2021, 62, jnumed.120.254508.	5.0	19
1732	Fractionated radiotherapy combined with PD-1 pathway blockade promotes CD8 T cell-mediated tumor clearance for the treatment of advanced malignancies. Annals of Translational Medicine, 2016, 4, 82.	1.7	6
1733	Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology, 2015, 29, 331-40.	0.5	45
1734	Immune evasion pathways and the design of dendritic cell-based cancer vaccines. Discovery Medicine, 2016, 21, 135-42.	0.5	2
1735	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. Journal of the Advanced Practitioner in Oncology, 2016, 7, 498-509.	0.4	6
1737	Systemic Therapy in Metastatic Melanoma. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2015, 32, 57S-65S.	0.6	1
1739	The role of the immune system in brain metastasis. Current Neurobiology, 2019, 10, 33-48.	1.0	21
1740	T cell recruitment triggered by optimal dose platinum compounds contributes to the therapeutic efficacy of sequential PD-1 blockade in a mouse model of colon cancer. American Journal of Cancer Research, 2020, 10, 473-490.	1.4	11
1743	The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of ⁶⁷ Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 47-55.	1.0	1
1744	Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. Archives of Dermatological Research, 2021, , 1.	1.9	1
1745	Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110565.	2.1	5
1746	Hepatobiliary and Pancreatic Adverse Events. Advances in Experimental Medicine and Biology, 2021, 1342, 339-355.	1.6	6
1747	Pulmonary Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 357-375.	1.6	4
1748	Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy. Advances in Experimental Medicine and Biology, 2021, 1350, 123-143.	1.6	0
1749	Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy. European Journal of Radiology, 2022, 146, 110107.	2.6	8
1750	Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI Insight, 2022, 7, .	5.0	20
1751	Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open, 2022, 7, 100364.	4.5	25
1752	Inhibiting VEGF in cancer immunotherapy. Clinical Immunology Communications, 2022, 2, 12-16.	1.2	3

#	ARTICLE	IF	CITATIONS
1753	Signal pathways of melanoma and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 424.	17.1	115
1754	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. <i>Cancers</i> , 2022, 14, 682.	3.7	6
1755	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. <i>Journal of Hematology and Oncology</i> , 2022, 15, 6.	17.0	17
1756	Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 794615.	2.8	2
1757	Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. <i>Frontiers in Immunology</i> , 2021, 12, 730666.	4.8	31
1758	A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100506.	1.7	4
1759	Preoperative Immune Checkpoint Inhibition and Cryoablation in Early-Stage Breast Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1761	Rational administration sequencing of immunochemotherapy elicits powerful anti-tumor effect. <i>Journal of Controlled Release</i> , 2022, 341, 769-781.	9.9	11
1762	Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. , 2022, 10, e003024.		15
1763	GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models. <i>Nature Communications</i> , 2022, 13, 97.	12.8	15
1764	Emerging strategies for biomaterial-assisted cancer immunotherapy. <i>Korean Journal of Chemical Engineering</i> , 2022, 39, 227-240.	2.7	1
1766	Recent advance in nanomaterials for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2022, 435, 134145.	12.7	16
1768	First experiences with the use of targeted and immunotherapy in the treatment of cutaneous melanoma: A single centre experience. <i>Scripta Medica</i> , 2022, 53, 29-35.	0.1	0
1769	Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours. <i>Cancers</i> , 2022, 14, 978.	3.7	12
1770	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 847350.	2.8	6
1771	An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, 839901.	4.8	1
1772	Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials. <i>Seminars in Cancer Biology</i> , 2022, 86, 909-922.	9.6	26
1773	Re-administration of nivolumab after immune checkpoint inhibitor-induced cholangitis: the first reported case. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 467-474.	0.8	5

#	ARTICLE	IF	CITATIONS
1774	Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma. Cancer Immunology Research, 2022, 10, 612-625.	3.4	12
1775	QUAD SHOT Radiotherapy and Doublet Immunotherapy in the Management of Anal Mucosal Melanoma: A Case Series of Efficacy and Toxicity of a Novel Treatment Approach and a Review of the Literature. Clinical Colorectal Cancer, 2022, , .	2.3	3
1776	Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-“programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemotherapy and Pharmacology, 2022, 89, 515-527.	2.3	7
1777	Discovery of efficacy biomarkers for non-small cell lung cancer with first-line anti-PD-1 immunotherapy by data-independent acquisition mass spectrometry. Clinical and Experimental Immunology, 2022, , .	2.6	1
1778	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. Chemotherapy, 2023, 68, 1-15.	1.6	0
1779	Characterization of aging tumor microenvironment with drawing implications in predicting the prognosis and immunotherapy response in low-grade gliomas. Scientific Reports, 2022, 12, 5457.	3.3	3
1780	Checkpoint Inhibitors and Induction of Celiac Disease-like Condition. Biomedicines, 2022, 10, 609.	3.2	5
1781	PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases. Frontiers in Pharmacology, 2022, 13, 854967.	3.5	10
1782	Melanoma: An update on systemic therapies. Journal of the American Academy of Dermatology, 2022, 86, 515-524.	1.2	26
1783	Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab. Case Reports in Dermatology, 2022, 14, 55-60.	0.8	1
1784	Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment. Frontiers in Immunology, 2022, 13, 864739.	4.8	40
1785	CAR-T Cells for the Treatment of Lung Cancer. Life, 2022, 12, 561.	2.4	8
1786	Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors. Immunotherapy Advances, 2022, 2, .	3.0	5
1787	Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell-“NK cell axis in murine hepatocellular carcinoma model. Journal of Hepatology, 2022, 77, 467-478.	3.7	47
1788	Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma. Surgical Oncology, 2022, 42, 101748.	1.6	2
1789	Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy. Bioactive Materials, 2022, 16, 107-119.	15.6	24
1790	Implementation and Effectiveness of Novel Therapeutic Substances for Advanced Malignant Melanoma in Saxony, Germany, 2010-2020 Cohort Study Based on Administrative Data. Cancers, 2021, 13, 6150.	3.7	3
1791	Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness. Journal of Oncology Pharmacy Practice, 2023, 29, 290-298.	0.9	3

#	ARTICLE	IF	CITATIONS
1792	Molecular pathways, targeted therapies and proteomic investigations of colorectal cancer. Current Molecular Medicine, 2021, 22, .	1.3	1
1793	Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. Nature Communications, 2021, 12, 7297.	12.8	25
1794	Infections in Hospitalized Cancer Patients. World Journal of Oncology, 2021, 12, 195-205.	1.5	3
1795	Clinical Significance of Expression of Immuno-adjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer. Anticancer Research, 2022, 42, 125-136.	1.1	6
1796	Interleukin-8 in Melanoma Pathogenesis, Prognosis and Therapy—An Integrated View into Other Neoplasms and Chemokine Networks. Cells, 2022, 11, 120.	4.1	14
1798	Cancer Therapy Targeting CD47/SIRPα. Cancers, 2021, 13, 6229.	3.7	20
1799	The role of cellular proteostasis in antitumor immunity. Journal of Biological Chemistry, 2022, 298, 101930.	3.4	6
1800	PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. Nature Communications, 2022, 13, 2176.	12.8	18
1821	Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma. Neuro-Oncology, 2022, 24, 2093-2106.	1.2	18
1822	Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review. Advances in Anatomic Pathology, 2022, 29, 183-193.	4.3	5
1824	Checkpoint inhibitors in treatment of metastatic mucosal melanoma. Chinese Clinical Oncology, 2014, 3, 37.	1.2	6
1825	Toxicity of checkpoint inhibitors. Chinese Clinical Oncology, 2014, 3, 31.	1.2	12
1828	Companion Diagnostics: Lessons Learned and the Path Forward From the Programmed Death Ligand-1 Rollout. Archives of Pathology and Laboratory Medicine, 2023, 147, 62-70.	2.5	2
1829	Novel Al ¹⁸ F-NOTA-Conjugated Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptides with Enhanced Melanoma Uptake. Bioconjugate Chemistry, 2022, 33, 982-990.	3.6	1
1830	Novel ⁶⁴ Cu-Labeled NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Enhanced Tumor to Kidney Uptake Ratios. Molecular Pharmaceutics, 2022, 19, 2535-2541.	4.6	6
1831	Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annual Review of Immunology, 2022, 40, 45-74.	21.8	122
1832	Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma. Frontiers in Immunology, 2022, 13, .	4.8	2
1833	Treatment of patients with cancer using PD-1/PD-L1 antibodies: Adverse effects and management strategies (Review). International Journal of Oncology, 2022, 60, .	3.3	9

#	ARTICLE	IF	CITATIONS
1834	Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021. Expert Opinion on Investigational Drugs, 2022, 31, 693-706.	4.1	2
1835	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15
1836	Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells. Cancer Immunology Research, 2022, 10, 885-899.	3.4	7
1837	Overcoming immunotherapeutic resistance in PDAC: SIRPÎ±-CD47 blockade. Pharmacological Research, 2022, 181, 106264.	7.1	4
1838	FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. Seminars in Nuclear Medicine, 2022, 52, 707-719.	4.6	10
1839	Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC). Cancers, 2022, 14, 2695.	3.7	3
1840	Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors. Journal of Geriatric Oncology, 2022, 13, 1003-1010.	1.0	2
1841	Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy. Advanced Drug Delivery Reviews, 2022, 187, 114367.	13.7	15
1842	Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. Clinical Medicine Insights: Oncology, 2022, 16, 117955492210998.	1.3	10
1843	Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. Scientific Reports, 2022, 12, .	3.3	7
1844	Immune Checkpoint Inhibitorâ€™Associated Myositis. Journal of Clinical Rheumatology, 2022, 28, 367-373.	0.9	8
1845	Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. Pharmaceuticals, 2022, 15, 747.	3.8	18
1846	Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course. Frontiers in Oncology, 0, 12, .	2.8	13
1847	Resveratrol in Cancer Treatment with a Focus on Breast Cancer. Current Molecular Pharmacology, 2023, 16, 346-361.	1.5	2
1848	PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells. Frontiers in Immunology, 0, 13, .	4.8	4
1849	Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. Critical Reviews in Oncology/Hematology, 2022, 176, 103746.	4.4	1
1850	Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. Translational Oncology, 2022, 23, 101469.	3.7	6
1851	Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report. Cureus, 2022, , .	0.5	1

#	ARTICLE	IF	CITATIONS
1852	Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	16
1853	TNFRSF9 Suppressed the Progression of Breast Cancer via the p38MAPK/PAX6 Signaling Pathway. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	1.3	1
1854	The Value of Histopathological Characteristics and BRAF and NRAS Mutations for the Diagnosis, Risk Stratification, and Prognosis of Malignant Invasive Melanoma. , 0, , .		0
1855	Immunologic Strategies in Pancreatic Cancer: Making <i>Cold</i> Tumors <i>Hot</i>. <i>Journal of Clinical Oncology</i> , 2022, 40, 2789-2805.	1.6	69
1856	Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma. <i>Cancers</i> , 2022, 14, 3282.	3.7	4
1857	Adverse drug reactions associated with immune checkpoint inhibitors: an exploratory nested case-control study in a historical cohort. <i>Therapie</i> , 2022, , .	1.0	0
1858	The increasing role of abdominal metastasectomy for malignant melanoma in the era of modern therapeutics. <i>Surgical Oncology</i> , 2022, 44, 101808.	1.6	1
1859	Exploring immunotherapy in colorectal cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	17.0	104
1860	The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 834-844.	4.9	11
1861	A case of severe nivolumabâ€induced lichen planus pemphigoides in a child with metastatic spitzoid melanoma. <i>Pediatric Dermatology</i> , 0, , .	0.9	4
1862	Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	1
1863	Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. , 2022, 10, e004879.		14
1864	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologistsâ€™ Perspectives. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 244-253.	0.4	1
1865	Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. <i>Diagnostics</i> , 2022, 12, 1799.	2.6	7
1866	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	32
1867	A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 876-880.	0.8	3
1868	Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	2.5	2
1869	<i>Escherichia coli</i>â€™Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer. <i>Cancer Discovery</i> , 2022, 12, 2280-2307.	9.4	23

#	ARTICLE	IF	CITATIONS
1870	Differential distribution and prognostic value of CD4+ T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
1871	Lipid Nanoparticle Delivery of Fas Plasmid Restores Fas Expression to Suppress Melanoma Growth <i><i>In Vivo</i></i> . <i>ACS Nano</i> , 2022, 16, 12695-12710.	14.6	11
1872	HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	5
1873	A Smart Silkâ€Based Microneedle for Cancer Stem Cell Synergistic Immunity/Hydrogen Therapy. <i>Advanced Functional Materials</i> , 2022, 32, .	14.9	18
1874	Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation. <i>Anticancer Research</i> , 2022, 42, 4589-4595.	1.1	1
1875	Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy. <i>Bioorganic Chemistry</i> , 2022, 128, 106047.	4.1	8
1876	STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 45-56.	2.5	2
1877	Primary lacrimal sac melanoma: a case report describing the novel use of fine needle aspiration cytology (FNAC) for diagnosis, together with literature review and immunotherapy treatment update. <i>Orbit</i> , 2024, 43, 270-279.	0.8	0
1878	Hepatology (Liver and Bile Duct). , 2022, , 119-165.		0
1879	Cancer prognosis and immune system. , 2022, , 75-144.		0
1880	Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1881	Neoantigen vaccine and neoantigenâ€specific cell adoptive transfer therapy in solid tumors: Challenges and future directions. , 2022, 1, 168-182.		1
1882	Disrupting the Interplay between Programmed Cell Death Protein 1 and Programmed Death Ligand 1 with Spherical Nucleic Acids in Treating Cancer. <i>ACS Central Science</i> , 2022, 8, 1299-1305.	11.3	8
1883	Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
1884	Tissue engineered cancer metastases as cancer vaccine to improve cancer immunotherapy. <i>Acta Biomaterialia</i> , 2022, 153, 299-307.	8.3	1
1885	Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?. <i>Biomedicines</i> , 2022, 10, 2424.	3.2	4
1886	ICBatlas: A Comprehensive Resource for Depicting Immune Checkpoint Blockade Therapy Characteristics from Transcriptome Profiles. <i>Cancer Immunology Research</i> , 2022, 10, 1398-1406.	3.4	12
1887	Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	2

#	ARTICLE	IF	CITATIONS
1888	Antifungal immunity mediated by C-type lectin receptors may be a novel target in immunotherapy for urothelial bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	3
1889	Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis. <i>JCI Insight</i> , 2022, 7, .	5.0	7
1892	Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors. <i>Cancer Epidemiology</i> , 2022, 81, 102265.	1.9	2
1893	Epitope Mapping of Therapeutic Antibodies Targeting Human LAG3. <i>Journal of Immunology</i> , 2022, 209, 1586-1594.	0.8	4
1894	Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation. <i>Siberian Journal of Oncology</i> , 2022, 21, 135-141.	0.3	0
1895	Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers. <i>Cancers</i> , 2022, 14, 4985.	3.7	5
1896	Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration. <i>JCI Insight</i> , 2022, 7, .	5.0	2
1898	Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. , 0, 2, .		2
1899	A phase 2 study of firstâ€line nivolumab in patients with locally advanced or metastatic cutaneous squamousâ€cell carcinoma. <i>Cancer</i> , 2022, 128, 4223-4231.	4.1	13
1900	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. <i>Medicina (Lithuania)</i> , 2022, 58, 1572.	2.0	5
1901	Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. <i>International Immunopharmacology</i> , 2022, 113, 109300.	3.8	4
1902	Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion. <i>Biomedicines</i> , 2022, 10, 2809.	3.2	8
1903	Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis. <i>BMC Cancer</i> , 2022, 22, .	2.6	3
1904	Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies. <i>Cancers</i> , 2022, 14, 5858.	3.7	2
1905	Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade. <i>Immuno</i> , 2022, 2, 671-691.	1.5	2
1906	Cutting-Edge Developments in Oncology Research. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2022, 43, 451-457.	0.2	0
1907	Nonsurgical Treatment Strategies for Elderly Head and Neck Cancer Patients: An Emerging Subject Worldwide. <i>Cancers</i> , 2022, 14, 5689.	3.7	0
1908	Effects of BRAF V600E and NRAS mutational status on the progressionâ€free survival and clinicopathological characteristics of patients with melanoma. <i>Oncology Letters</i> , 2022, 25, .	1.8	9

#	ARTICLE	IF	CITATIONS
1909	Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
1910	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. <i>BMC Cancer</i> , 2022, 22, .	2.6	1
1911	Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. <i>Lancet Oncology</i> , The, 2022, 23, e552-e561.	10.7	20
1913	Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society. <i>Endocrinology and Metabolism</i> , 2022, 37, 839-850.	3.0	3
1914	Primary esophageal malignant melanoma without recurrence after surgery and adjuvant therapy with nivolumab. <i>International Cancer Conference Journal</i> , 0, , .	0.5	1
1915	Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. <i>Diagnostics</i> , 2022, 12, 3157.	2.6	6
1916	Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 343-356.	2.5	2
1918	Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial. <i>European Journal of Cancer</i> , 2023, 182, 57-65.	2.8	7
1919	Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response. <i>BMC Medicine</i> , 2023, 21, .	5.5	0
1921	PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells. <i>Journal of Personalized Medicine</i> , 2023, 13, 221.	2.5	8
1922	Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. <i>European Journal of Cancer</i> , 2023, 183, 109-118.	2.8	10
1923	Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	3.3	7
1924	ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors. <i>Cancers</i> , 2023, 15, 878.	3.7	6
1925	High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. <i>JCO Precision Oncology</i> , 2023, , .	3.0	6
1927	Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer. <i>Pathology Research and Practice</i> , 2023, 244, 154338.	2.3	3
1928	Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle. <i>European Medical Journal Oncology</i> , 0, , 70-76.	0.0	1
1929	Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management. <i>Archives of Dermatological Research</i> , 2023, 315, 1697-1703.	1.9	1
1930	Highlights into historical and current immune interventions for cancer. <i>International Immunopharmacology</i> , 2023, 117, 109882.	3.8	2

#	ARTICLE	IF	CITATIONS
1931	Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors. Medical Clinics of North America, 2023, 107, 623-640.	2.5	0
1932	Therapeutic efficacy of plant-produced Nivolumab in transgenic C57BL/6-hPD-1 mouse implanted with MC38 colon cancer. Biotechnology Reports (Amsterdam, Netherlands), 2023, 38, e00794.	4.4	2
1933	Flashback Foreword: Nivolumab in Advanced Melanoma: Survival and Long-Term Safety. Journal of Clinical Oncology, 2023, 41, 941-942.	1.6	0
1934	Cancer immunotherapies: A hope for the incurable?. Frontiers in Molecular Medicine, 0, 3, .	1.9	3
1935	The predictive value of plasma exosomal lncRNAs/mRNAs in NSCLC patients receiving immunotherapy. Advances in Medical Sciences, 2023, 68, 86-93.	2.1	1
1936	Immunotherapy of Cancer: Towards a New Era. European Medical Journal Oncology, 0, , 76-82.	0.0	0
1937	Case series: Immune checkpoint inhibitor-induced transverse myelitis. Frontiers in Neurology, 0, 14, .	2.4	1
1938	Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study. Journal of Clinical Medicine, 2023, 12, 1985.	2.4	7
1939	Discontinuation of Immune Checkpoint Inhibitor due to irAEs in NSCLC Patients With EGFR Mutation. Cancer Diagnosis & Prognosis, 2023, 3, 244-250.	0.7	1
1940	Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer. BMC Cancer, 2023, 23, .	2.6	1
1941	Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. Theranostics, 2023, 13, 1520-1544.	10.0	19
1942	Oral Toxicities in Cancer Patients, Who Receive Immunotherapy: A Case Series of 24 Patients. Oral, 2023, 3, 123-133.	0.6	1
1943	Interactive process mining of cancer treatment sequences with melanoma real-world data. Frontiers in Oncology, 0, 13, .	2.8	0
1944	Low-Dose Immunotherapy: Is It Just an Illusion?. Biomedicines, 2023, 11, 1032.	3.2	1
1945	Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy. Cancer Nanotechnology, 2023, 14, .	3.7	2
1946	Sicca symptoms and sialoadenitis as immune-related adverse events of nivolumab treatment in renal malignancy. MOJ Clinical & Medical Case Reports, 2023, 13, 21-23.	0.0	0
1947	The influence of antibody CD166 on the treatment of tumor and the immunological mechanism in mice bearing oral squamous cell carcinoma. Translational Cancer Research, 2023, .	1.0	0
1948	Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. Healthcare (Switzerland), 2023, 11, 1073.	2.0	0

#	ARTICLE	IF	CITATIONS
1950	Gastrointestinal and Hepatobiliary Immune-related Adverse Events: A Histopathologic Review. <i>Advances in Anatomic Pathology</i> , 2023, 30, 230-240.	4.3	0
1951	Cutaneous manifestations induced by check point inhibitors in 120 melanoma patientsâ€™The European MelSkinTox study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 1606-1615.	2.4	3
1952	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	17.0	14
1953	Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapyâ€™a narrative review. <i>Future Cardiology</i> , 2023, 19, 91-103.	1.2	6
1954	Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival. <i>European Radiology</i> , 2023, 33, 7284-7293.	4.5	1
1955	Association between Fluoxetine Use and Overall Survival among Patients with Cancer Treated with PD-1/L1 Immunotherapy. <i>Pharmaceuticals</i> , 2023, 16, 640.	3.8	2
1956	Predictive impact of prognostic nutritional index in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Nutrition and Cancer</i> , 0, , 1-14.	2.0	0
1957	Challenges presented by complete response to immune checkpoint blockade in patients with dMMR colorectal cancer: A case report. <i>International Journal of Surgery Case Reports</i> , 2023, 106, 108286.	0.6	1
1958	Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	3
1959	Proof of concept nanotechnological approach to in vitro targeting of malignant melanoma for enhanced immune checkpoint inhibition. <i>Scientific Reports</i> , 2023, 13, .	3.3	2
1960	Updates in Glioblastoma Immunotherapy: An Overview of the Current Clinical and Translational Scenario. <i>Biomedicines</i> , 2023, 11, 1520.	3.2	5
1961	Targeting Wnt/ β -catenin signaling using XAV939 nanoparticles in tumor microenvironment-conditioned macrophages promote immunogenicity. <i>Heliyon</i> , 2023, 9, e16688.	3.2	4
1962	Multimodal treatment and immune checkpoint inhibition in sinonasal mucosal melanoma: real-world data of a retrospective, single-center study. <i>European Archives of Oto-Rhino-Laryngology</i> , 2023, 280, 4215-4223.	1.6	1
1963	Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment. <i>Cancer Informatics</i> , 2023, 22, 117693512311785.	1.9	3
1964	Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies. <i>Cancers</i> , 2023, 15, 3126.	3.7	1
1965	A study on melanoma treatment using dendritic cells loaded with antigens purified from melanoma cell lines*. , 2020, 6, 21-25.		0
1966	Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels. <i>Journal of Immunotherapy</i> , 2023, 46, 310-322.	2.4	1
1967	Development and Validation of Blood-Based Predictive Biomarkers for Response to PD-1/PD-L1 Checkpoint Inhibitors: Evidence of a Universal Systemic Core of 3D Immunogenetic Profiling across Multiple Oncological Indications. <i>Cancers</i> , 2023, 15, 2696.	3.7	3

#	ARTICLE	IF	CITATIONS
1968	Anti- PD-1 monoclonal antibody-resistant esophageal squamous cell carcinoma showing the abscopal effect: A case report with T-cell receptor/B-cell receptor repertoire analysis. <i>Cancer Reports</i> , 2023, 6, .	1.4	4
1969	Targeting β -catenin using XAV939 nanoparticle promotes immunogenic cell death and suppresses conjunctival melanoma progression. <i>International Journal of Pharmaceutics</i> , 2023, 640, 123043.	5.2	4
1970	Introduction of a Polyethylene Glycol Linker Improves Uptake of ^{67}Cu -NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide in Melanoma. <i>Cancers</i> , 2023, 15, 2755.	3.7	0
1971	The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics. <i>Chemical Reviews</i> , 2023, 123, 7782-7853.	47.7	13
1972	The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors. <i>Current Oncology</i> , 2023, 30, 5279-5298.	2.2	0
1973	Innovative breakthroughs facilitated by single-cell multi-omics: manipulating natural killer cell functionality correlates with a novel subcategory of melanoma cells. <i>Frontiers in Immunology</i> , 2023, 14, .	4.8	18
1974	Exploration of novel clusters and prognostic value of immune-related signatures and identify HAMP as hub gene in colorectal cancer. <i>Oncology Letters</i> , 2023, 26, .	1.8	1
1975	Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. <i>Journal of Translational Medicine</i> , 2023, 21, .	4.4	12
1976	<i>Lactobacillus</i> in anticancer immunochemotherapy: friend or foe?. , 2023, 0, 2, .		0
1977	Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging. <i>Biomedicines</i> , 2023, 11, 2086.	3.2	2
1978	EXPRESS: Novel Strategies for Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia: Moving Beyond CD19. <i>Journal of Investigative Medicine</i> , 2023, 0, .	1.6	0
1979	Role of enhancement modifications in evaluating tumor response to immunotherapy in metastatic renal cell carcinoma. <i>Tumori</i> , 2023, 0, .	1.1	1
1980	Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective. <i>Viruses</i> , 2023, 15, 1645.	3.3	3
1982	Incidence of Hyper Progressive Disease in Combination Immunotherapy and Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Monotherapy for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2024, 13, 56-69.	7.7	0
1983	Current landscape and challenges ahead of immuno-molecular mechanism and immunotherapy strategy of brain metastases. , 2023, 2, .		0
1984	Trial Design for Cancer Immunotherapy: A Methodological Toolkit. <i>Cancers</i> , 2023, 15, 4669.	3.7	0
1985	BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 3461-3474.	4.2	0
1987	Targeting immune checkpoint pathways in melanoma: triumphs and challenges. <i>Future Drug Discovery</i> , 2023, 5, .	2.1	0

#	ARTICLE	IF	CITATIONS
1988	International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors. International Forum of Allergy and Rhinology, 2024, 14, 149-608.	2.8	6
1989	AZI2 mediates TBK1 activation at unresolved selective autophagy cargo receptor complexes with implications for CD8 T-cell infiltration in breast cancer. Autophagy, 2024, 20, 525-540.	9.1	0
1990	Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy. Frontiers in Immunology, 0, 14, .	4.8	0
1991	The prognostic value of tumor-associated macrophages in glioma patients. Medicine (United States), 2023, 102, e35298.	1.0	1
1992	Systematic analysis reveals a pan-cancer SNHG family signature predicting prognosis and immunotherapy response. IScience, 2023, 26, 108055.	4.1	0
1993	Breaking the "don't eat me" signal: in silico design of CD47-directed peptides for cancer immunotherapy. Molecular Diversity, 0, , .	3.9	0
1994	Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma. Melanoma Research, 0, , .	1.2	0
1995	Toxicités immuno-induites chez les patients avec cancer sous immunothérapie par inhibiteurs des <i>checkpoints</i>. Ce que l'urgentiste doit savoir. Annales Francaises De Medecine D'Urgence, 2023, 13, 241-253.	0.1	1
1996	Identifying endoplasmic reticulum stress-related molecular subtypes and prognostic model for predicting the immune landscape and therapy response in pancreatic cancer. Aging, 2023, 15, 10549-10579.	3.1	1
1997	The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment. Frontiers in Immunology, 0, 14, .	4.8	0
1998	The Predictive Value of CD3+/CD8+ Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer. Current Oncology, 2023, 30, 9647-9659.	2.2	0
1999	Low-dose nivolumab and cabozantinib in recurrent intestinal-type papillary adenocarcinoma of the sinonasal region. BMJ Case Reports, 2023, 16, e255021.	0.5	0
2000	Potential of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy. Frontiers in Immunology, 0, 14, .	4.8	1
2001	Anti-tumor effect of PD-L1-targeting antagonistic aptamer-ASO delivery system with dual inhibitory function in immunotherapy. Cell Chemical Biology, 2023, 30, 1390-1401.e6.	5.2	0
2002	Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy. Journal of Extracellular Vesicles, 2023, 12, .	12.2	0
2003	^{99m} Tc-Labeled Cyclic Peptide Targeting PD-L1 as a Novel Nuclear Imaging Probe. Pharmaceutics, 2023, 15, 2662.	4.5	1
2004	Clinical application of a population-based input function (PBIF) for a shortened dynamic whole-body FDG-PET/CT protocol in patients with metastatic melanoma treated by immunotherapy. EJNMMI Physics, 2023, 10, .	2.7	0
2005	PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade. British Journal of Cancer, 2023, 129, 1409-1416.	6.4	4

#	ARTICLE	IF	CITATIONS
2007	The role of intestinal flora on tumor immunotherapy: recent progress and treatment implications. Heliyon, 2024, 10, e23919.	3.2	0
2008	VerÄnderungen der Mukosa â€“ verschiedene Lokalisationen. , 2023, , 129-177.		0
2009	Targeting Innate Immunity in Glioma Therapy. International Journal of Molecular Sciences, 2024, 25, 947.	4.1	0
2010	Detection and evaluation of signals for immune-related adverse events: a nationwide, population-based study. Frontiers in Oncology, 0, 13, .	2.8	0
2011	Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review. Diagnostics, 2024, 14, 336.	2.6	0
2012	Understanding Cancerâ€™s Defense against Topoisomerase-Active Drugs: A Comprehensive Review. Cancers, 2024, 16, 680.	3.7	0
2013	Generation and Immuno-inflammatory Checkpoints in Oral Cavity Cancers. , 2023, 1, 113-117.		0
2014	Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients. Journal of Translational Medicine, 2024, 22, .	4.4	0
2015	Programmed cell death-1-modified pig developed using electroporation-mediated gene editing for in vitro fertilized zygotes. In Vitro Cellular and Developmental Biology - Animal, 0, , .	1.5	0